# AUTHOR INDEX

*(Page numbers marked with an asterisk refer to abstracts)*


## A

**Abbott, Lynn D., Jr.** See JAMES and ABBOTT *1014

**Abelmann, Walter H.** See CARLETON, LEVINSON and ABELMANN *994

—. See FREINKEL, SANDERS, LEVINSON and ABELMANN *1005

**Abramson, David I., Tuck, Samuel, Jr., Bell, Yvonne, Burnett, Carolyn,** and **Rejal, Habib.** Relationship between a range of tissue temperature and local oxygen uptake in the human forearm. III. Changes observed after anaerobic work, in the postexercise period 1126

**Adam, Avinoam.** See RAMOT, SZEINBERG, ADAM, SHEBA and GAFNI 1659

—. See RAMOT, FISHER, SZEINBERG, ADAM, SHEBA and GAFNI 2234

**Adams, Reuben.** See MADISON, COMBES, STRICKLAND and ADAMS *1023

**Ahrens, E. H., Jr.** See INSULL, HIRSCH, JAMES and AHRENS 443

**Aisenberg, Alan C.** Studies on the mechanism of the lupus erythematosus (L.E.) phenomenon 325

**Albright, Edwin C., Tomita, Kenkichi,** and **Larson, Frank C.** Metabolism of L-triiodothyronine by human mitochondria *984

—, and **Larson, Frank C.** Metabolism of L-thyroxine by human tissue slices 1899

**Alkjaersig, Norma.** See SHERRY, LINDENMEYER, FLETCHER and ALKJAERSIG 810

—. See FLETCHER, ALKJAERSIG and SHERRY *1005

—, **Fletcher, Anthony P.,** and **Sherry, Sol.** The mechanism of clot dissolution by plasmin 1086

—. See FLETCHER, ALKJAERSIG and SHERRY 1096

—. See FLETCHER, SHERRY, ALKJAERSIG, SMYRNIOTIS and JICK 1111

**Allen, David W.** See JANDL, INMAN, SIMMONS and ALLEN 161

**Almy, Thomas P.** See PERT, DAVIDSON, ALMY and SLEISENGER 397

**Alvarez, Hermogenes.** See HUTCHINSON, GRAY, PLENTL, ALVAREZ, CALDEYRO-BARCIA, KAPLAN and LIND 971

**Antonowicz, Irena.** See METCOFF, FRENK and ANTONOWICZ *1025

**Arabehety, Julian.** See DONALDSON, ARABEHETY and GRAY 933

**Ashenbrucker, Helen.** See MAUER, ATHENS, ASHENBRUCKER and CARTWRIGHT *1025

**Athans, J. C.** See ROSENBERG, ATHANS and BEHAR *1036

**Athens, John W.** See MAUER, ATHENS, ASHENBRUCKER and CARTWRIGHT *1025

**Au, William Y. W.** See RAISZ, AU and SCHEER 8

—. See RAISZ, AU and SCHEER 1725

**Auditore, Joseph V., Hartmann, Robert C.,** and **Cole, Edward F.** Potassium transport in the acetylcholinesterase-deficient erythrocytes of paroxysmal nocturnal hemoglobinuria (PNH) 702

—. See HARTMANN and AUDITORE *1009

**August, J. Thomas,** and **Nelson, Don H.** Adjustment to aldosterone or desoxycorticosterone acetate induced sodium retention in patients with Addison's disease 1964

**Austen, Frank K.** Differentiation of a chloroform-induced esterase of human serum from plasmin and its possible identity with the first component of complement *984

**Avery, Mary Ellen, Frank, N. Robert,** and **Gribetz, Irwin.** The inflationary force produced by pulmonary vascular distention in excised lungs. The possible relation of this force to that needed to inflate the lungs at birth 456

—. See GRIBETZ, FRANK and AVERY 2168

**Azarnoff, Daniel L.** See CURRAN, AZARNOFF and BOLINGER 1251

## B

**Bacaner, Marvin, Connelly, John,** and **Bruns, David.** Veno-arterial perfusion as therapy for the failing heart *984

**Bacchus, Habeeb.** See TSCHUDY, BACCHUS, WEISSMAN, WATKIN, EUBANKS and WHITE 892

**Bacos, James M.** See MCINTOSH, GLEASON, MILLER and BACOS *1023

**Baertl, Juan M.** See RUSZKOWSKI, BAERTL and GABUZDA *1038

**Baker, Faith A.** See SMITH and BAKER 798

—. See SMITH and BAKER *1044

**Baker, Katherine J.** See JAVITT, WHEELER, BAKER and RAMOS *1015

**Baker, Orland.** See CHAPMAN, BAKER and MITCHELL 1202

**Baldini, Mario, Costea, Nicholas,** and **Small, Walter.** Platelet survival and viability of stored platelets *985

**Baldwin, David S., Hulet, William H., Gombos, Ervin A.,** and **Biggs, Albert W.** Functional disparity between the two kidneys in essential hypertension *985

**Balis, M. Earl.** See KRAKOFF and BALIS 907

—. See KRAKOFF and BALIS *1019

**Baltch, A. L., Osborne, W., Bunn, P., Canarile, L.,** and **Hassirdjian, A.** Serum properdin and complement levels in normal dogs and in dogs with staphylococcal bacteremia *985

**Bancroft, W. H., Jr.** See JONES, HEFNER, BANCROFT and KLIP 2087

**Bank, Norman.** See SCHWARTZ, BANK and CUTLER 347

**Barker, Earl S.,** and **Clark, John K.** Factors influencing the renal excretion of magnesium in man *986

—, **Elkinton, J. Russell,** and **Clark, John K.** Studies of the renal excretion of magnesium in man 1733

**Barnett, Jack A.** See SANFORD, BARNETT and GOTT *1039

**Barron, Donald.** See HELLEGERS, METCALFE, HUCKABEE, MESCHIA, PRYSTOWSKY and BARRON *1010

**Bartlett, Grant R.** See SHAFER and BARTLETT *1043

**Bartter, Frederic C.** See PECHET, BOWERS and BARTTER 681

—, **Mills, Ivor H.,** and **Gann, Donald S.** Increase of aldosterone secretion by carotid artery constriction and its prevention by thyro-carotid arterial junction denervation *986

—. See Pechet, Bowers and Bartter 691
**Baxter, James H., Goodman, Howard C.,** and **Shafrir, Eleazar.** Effects of glucose infusions on serum lipids and lipoproteins in nephrosis *986
**Bean, William B.** See Hodges, Bean, Ohlson and Bleiler 1421
**Beck, David.** See Epstein, Beck, Carone, Levitin and Manitius 1214
**Beck, J. C.** See Fishman, McGarry and Beck *1004
**Beck, Walter.** See Swan, Beck and Burchell *1047
**Behar, A.** See Rosenberg, Athans and Behar *1036
**Beierwaltes, William H.,** and **Bollet, Alfred Jay.** Mucopolysaccharide content of skin in patients with pretibial myxedema 945
—. See Bollet, Knopf and Beierwaltes *989
—, and **Robbins, Jacob.** Familial increase in the thyroxine-binding sites in serum alpha globulin 1683
**Beigelman, Paul M.** Insulin-like activity of human serum fractions obtained by preparative electrophoresis *987
**Bell, Virginia M.** See Dawson, Bell and Isselbacher *999
**Bell, Yvonne.** See Abramson, Tuck, Bell, Burnett and Rejal 1126
**Bennett, L. R.** See Brown and Bennett *993
—. See Mena, Bennett and Mellinkoff *1025
**Bennhold, Hermann,** and **Kallee, Ekkehard.** Comparative studies on the half-life of $I^{131}$-labeled albumins and nonradioactive human serum albumin in a case of analbuminemia 863
**Berger, Eugene Y.** The effect of desoxycorticosterone on the unidirectional transfers of sodium and potassium into and out of the dog intestine *987
**Berger, Lawrence.** See Gutman, Yü and Berger 1789
**Bering, Edgar A., Jr.** See Uzman, Bering and Morris 1756
**Bernhard, Gerson C.,** and **Stollerman, Gene H.** Serum inhibition of streptococcal diphosphopyridine nucleotides in uncomplicated streptococcal pharyngitis and in rheumatic fever 1942
—. See Levinsky, Davidson and Berliner 730
—. See Levinsky and Berliner 741
**Berman, Mones.** See Lewallen, Berman and Rall 66
—. See Lewallen, Rall and Berman 88
**Bernstein, Donald.** See Kleeman, Bernstein, Dowling, Koplowitz and Maxwell *1018
**Bernstein, Ralph E.** Alterations in metabolic energetics and cation transport during aging of red cells 1572
**Bernstein, Stanley H.** Serum protein patterns in acute poststreptococcal glomerulonephritis *987
**Berry, Helen K.** See Glueck, Goldsmith, Wayne and Berry *1006
**Berson, Solomon A.,** and **Yalow, Rosalyn S.** Quantitative aspects of the reaction between insulin and insulin-binding antibody 1996
—, and **Yalow, Rosalyn S.** Species-specificity of human anti-beef, pork insulin serum 2017
**Bertrand, Jean.** See Migeon, Wall and Bertrand 619
**Bessman, Samuel P.** See Borges, Merlis and Bessman 715
**Beutler, Ernest.** See Necheles and Beutler 788
—. Iron enzymes in iron deficiency. VI. Aconitase activity and citrate metabolism 1605
**Biederman, Oliver.** See Daughaday, Kozak and Biederman *998
**Bierman, Edwin L.** See Rich, Bierman and Schwartz 275
**Bierman, H. R., Kelly, K. H., Marshall, G. J.,** and **Byron, R. L., Jr.** Large dose chemotherapy of advanced neoplastic diseases preceded by hematopoietic stimulation *988
**Biggs, Albert W.** See Baldwin, Hulet, Gombos and Biggs *985
**Bills, Charles E.** See Thomas, Morgan, Connor, Haddock, Bills and Howard 1078
**Binak, Kenan.** See Regan, Binak, Gordon, DeFazio and Hellems *1033
—. See Regan, DeFazio, Binak, Kenan and Hellems 1564
**Bishop, Jonathan S.,** and **Marks, Paul A.** Studies on carbohydrate metabolism in patients with neoplastic disease. II. Response to insulin administration 668
**Blankenhorn, David H.** See Wyman, Weil and Blankenhorn *1056
**Bleiler, Roberta.** See Hodges, Bean, Ohlson and Bleiler 1421
**Blizzard, Robert M., Liddle, Grant W., Migeon, Claude J.,** and **Wilkins, Lawson.** Aldosterone excretion in virilizing adrenal hyperplasia 1442
**Block, Jerome B., Graham, Dorothy E.,** and **Burrows, Belton A.** The influence of protein binding on $I^{131}$-diodrast excretion *988
**Blount, S. Gilbert, Jr.** See Reeves, Roberts, Grover, Filley and Blount *1033
**Bluemle, L. W., Jr.** See Seligson, Bluemle, Webster and Senesky *1042
**Blumberg, B. S.,** and **Robbins, J.** Polymorphism in thyroxine-binding serum proteins of man and other mammals *988
**Blumenfeld, Herbert L., Kilbourne, Edwin D., Louria, Donald B.,** and **Rogers, David E.** Studies on influenza in the pandemic of 1957–1958. I. An epidemiologic, clinical and serologic investigation of an intrahospital epidemic, with a note on vaccination efficacy 199
—. See Louria, Blumenfeld, Ellis, Kilbourne and Rogers 213
**Bodenlos, Leonard J.** See Walser and Bodenlos 1617
**Bogdonoff, Morton D., Weissler, Arnold M., Merritt, Francis L., Jr., Harlan, William R.,** and **Estes, E. Harvey, Jr.** The role of the autonomic nervous system in human lipid metabolism *989
—. See Estes, Bogdonoff, Friedberg, Harlan and Trout 2131
**Bolinger, Robert E.** See Curran, Azarnoff and Bolinger 1251
**Bollet, Alfred Jay.** See Beierwaltes and Bollet 945
—, **Goodwin, Jesse F.,** and **Brown, Audrey K.** Metabolism of mucopolysaccharides in connective tissue. I. Studies of enzymes involved in glucuronide metabolism 451
—, **Knopf, Ralph F.,** and **Beierwaltes, William H.** Extraocular and neck muscle, and thyroid gland mucopolysaccharide response to thyroid stimulating hormone *989
**Bond, Victor P.** See Jackson, Sorensen, Cronkite, Bond and Fliedner 1689
**Bondy, Philip K.** The American Society for Clinical Investigation, 1909–1959 and the Journal of Clinical Investigation, 1924–1959. Introduction 1783
—. History of the Journal of Clinical Investigation, 1924–1959. II. Scientific contents 1873
**Bonting, Sjoerd L.** See Muehrcke, Pollak and Bonting *1027

**Borges, Francis J., Merlis, Jerome K.,** and **Bessman, Samuel P.** Serotonin metabolism in liver disease 715
**Borrelli, Jennie.** See ZUCKER and BORRELLI 148
**Boshell, Buris R.** See ROBIN, TRAVIS, JULIAN and BOSHELL 2229
**Bove, Joseph R.** Separation and characterization of aging red cell populations *989
**Bowers, Blair.** See PECHET, BOWERS and BARTTER 681
—. See PECHET, BOWERS and BARTTER 691
**Boyce, William H.,** and **King, Stanton J., Jr.** Total nondialyzable solids (TNDS) in human urine. IV. Electrophoretic properties of RS-1 subfraction 1525
—. See KING and BOYCE 1927
**Brachfeld, Norman.** See GORLIN, BRACHFELD, TURNER and MESSER *1007
—. See GORLIN, BRACHFELD, TURNER, MESSER and SALAZAR 2144
**Bradbury, James T.** See HODGES, EVANS, BRADBURY and KEETTEL *1012
**Bradley, B.** See WENNESLAND, BROWN, HOPPER, HODGES, GUTTENTAG, SCOTT, TUCKER and BRADLEY 1065
**Bradlow, H. Leon.** See HELLMAN, BRADLOW, ZUMOFF, FUKUSHIMA and GALLAGHER *1010
**Brainard, Ellen R.** History of the American Society for Clinical Investigation, 1909–1959 1784
—. History of the Journal of Clinical Investigation. I. Personnel and policies 1865
**Brandfonbrener, M.** See TURINO, BRANDFONBRENER and FISHMAN 1186
**Braude, Abraham I.** Catalase activity of infected urine *990
—. See SHAPIRO, BRAUDE and SIEMIENSKI 1228
**Brauer, Ralph W., Shill, Otto S.,** and **Krebs, John S.** Studies concerning functional differences between liver regions supplied by the hepatic artery and by the portal vein 2202
**Braunwald, Eugene, Long, Robert T. L.,** and **Morrow, Andrew G.** Injections of radioactive krypton ($Kr^{85}$) solutions in the detection and localization of cardiac shunts *990
**Breall, William.** See ROSENMAN, BREALL, BYERS and RABIN 1434
**Bricker, Neal S., Dewey, Richard R., Lubowitz, Herbert, Stokes, James,** and **Kirkensgaard, Tove.** Observations on the concentrating and diluting mechanisms of the diseased kidney 516
—, **Morrin, Peter A. F., Kime, S. Wesley, Jr., Schultze, Raymond G.,** and **Klein, Claire.** An analysis of the intrarenal mechanisms for sodium excretion in the diseased kidney employing an experimental model with one normal and one diseased kidney *990
**Briller, Stanley A.,** and **Okada, Robert H.** Synthesis of precordial leads: A clinical study of the dipole hypothesis of electrocardiography *991
**Brockman, Stanley K.** See COOPERSTEIN and BROCKMAN 435
**Brody, Daniel A.** A unified concept of the electrocardiographic image torso *991
**Brody, Jerome I.,** and **Finch, Stuart C.** *Candida* reacting antibody in the serum of patients with lymphomas and related disorders *992
**Brodsky, William A., Kaim, John T.,** and **Carrasquer, Gaspar.** The nature of urinary acidification process during transient obstruction of renal artery and ureter *991
**Bromberg, Philip A.** See ROBIN, BROMBERG and FORKNER *1035
**Brooke, Marcus S.** See PIOMELLI and BROOKE *1030
**Brotmacher, Leon, Marshall, Hiram W., Cheesman, Richard J.,** and **Donald, David E.** Detection and measurement of experimentally produced aortic regurgitation *992
**Browder, Ann A.** See WALSER and BROWDER 1404
**Brown, Audrey K.** See BOLLET, GOODWIN and BROWN 451
**Brown, E.** See HODES, FAILEY and BROWN *1011
**Brown, Ellen.** See WENNESLAND, BROWN, HOPPER, HODGES, GUTTENTAG, SCOTT, TUCKER and BRADLEY 1065
**Brown, Josiah,** and **Bennett, L. R.** Control of fat metabolism by growth hormone in humans *993
**Brown, R. H.** See LYNN and BROWN *1022
**Bruce, Robert A.** See COBB, BRUCE and MORLEDGE *995
**Bruns, David.** See BACANER, CONNELLY and BRUNS *984
**Brunton, Lauder.** See LOWENSTEIN, COOPER, BRUNTON and GARTHA *1022
**Bryant, John H.** Metabolic studies on cortisone sensitivity and resistance in a lymphocytic neoplasm *993
**Bunn, P.** See BALTCH, OSBORNE, BUNN, CANARILE and HASSIRDJIAN *985
**Burchell, Howard B.** See SWAN, BECK and BURCHELL *1047
**Burnett, Carolyn.** See ABRAMSON, TUCK, BELL, BURNETT and REJAL 1126
**Burrows, Belton A.** See BLOCK, GRAHAM and BURROWS *988
**Butler, Thomas C.** See WADDELL and BUTLER 720
**Byers, Sanford O.** See FRIEDMAN, BYERS, FELTON and CADY 539
—. See ROSENMAN and BYERS *1036
—. See FRIEDMAN AND BYERS 1328
—. See ROSENMAN, BREALL, BYERS and RABIN 1434
**Byron, R. L., Jr.** See BIERMAN, KELLY, MARSHALL and BYRON *988

## C

**Cade, Robert.** See PORTWOOD, SELDIN, RECTOR and CADE 770
—. See SELDIN, PORTWOOD, RECTOR and CADE 1663
**Cady, Paxton.** See FRIEDMAN, BYERS, FELTON and CADY 539
**Calabresi, Massimo.** See DALY, CALABRESI, NIMS and GRAY *998
**Calabresi, Paul, Edwards, Earl A.,** and **Schilling, Robert F.** Fluorescent antiglobulin studies in leukopenic and related disorders 2091
**Caldeyro-Barcia, Roberto.** See HUTCHINSON, GRAY, PLENTL, ALVAREZ, CALDEYRO-BARCIA, KAPLAN and LIND 971
**Calkins, Evan,** and **Cohen, Alan S.** Similarity of serum protein changes in primary and secondary amyloidosis *993
**Campbell, James A.** See GRAETTINGER, MUENSTER, SELVERSTONE and CAMPBELL 1316
**Canarile, L.** See BALTCH, OSBORNE, BUNN, CANARILE and HASSIRDJIAN *985
**Canary, John J.,** and **Kyle, Laurence H.** The hypercalciuria of hyperparathyroidism in man *994
—. See KYLE, WERDEIN, CANARY and PACHUTA 1475
**Cannon, Joe H.** See THOMAS, LOCHTE, CANNON, SAHLER and FERREBEE 1709

**Carbone, John V., Grodsky, G. M.,** and **Fanska, R.** Chemical and clinical studies of bromsulfalein (BSP) metabolites *994
—. See GRODSKY, CARBONE and FANSKA 1981
—, **Grodsky, Gerold M.,** and **Hjelte, Virginia.** Effect of hepatic dysfunction on circulating levels of sulfobromophthalein and its metabolites 1989
**Carey, T. Nelson.** See CONNOR, CAREY, DAVIS and LOVICE *997
**Carleton, Richard A., Levinson, Gilbert E.,** and **Abelmann, Walter H.** Measurement of mitral regurgitant flow: A modification of the variance method based on physiologic principles *994
**Carlson, Lars A.,** and **Olhagen, Börje.** Studies on a case of essential hyperlipemia. Blood lipids, with special reference to the composition and metabolism of the serum glycerides before, during and after the course of a viral hepatitis 854
**Carone, Frank A.** See EPSTEIN, BECK, CARONE, LEVITIN and MANITIUS 1214
**Carrasquer, Gaspar.** See BRODSKY, KAIM and CARRASQUER *991
**Carroll, Evelyn L.** See PECHET and CARROLL *1029
**Carson, John C.** See KUO and CARSON *1019
—. See KUO and CARSON 1384
**Carson, Paul E.** See KELLERMEYER, TARLOV, SCHRIER and CARSON *1016
**Carter, Anne C.** See WALLACH and CARTER *1052
**Carter, Norman W., Seldin, Donald W.,** and **Teng, H. C.** Tissue and renal response to chronic respiratory acidosis 949
**Cartwright, George E.** See MAUER, ATHENS, ASHENBRUCKER and CARTWRIGHT *1025
**Cass, Rosemary.** See MITCHELL and CASS 595
**Cassidy, Carl.** See VANDERLAAN and CASSIDY *1051
**Castillo, Cesar A.** See ROWE, MAXWELL, CASTILLO and CRUMPTON *1037
—. See ROWE, MAXWELL, CASTILLO, FREEMAN and CRUMPTON 2154
**Chalmers, Thomas C.** See SEKI, FIELD and CHALMERS *1042
—. See MOORE, MITCHELL and CHALMERS 1222
**Chapman, Carleton B., Baker, Orland,** and **Mitchell, Jere H.** Left ventricular function at rest and during exercise 1202
**Cheesman, Richard J.** See BROTMACHER, MARSHALL, CHEESMAN and DONALD *992
**Cherniack, Reuben M.** The oxygen consumption and efficiency of the respiratory muscles in health and emphysema 494
—. See KAUFMAN, FERGUSON and CHERNIACK 500
**Cherniak, Morris.** See SASS-KORTSAK, CHERNIAK, GEIGER and SLATER 1672
**Chobanian, Aram V.** See HOLLANDER and CHOBANIAN *1013
**Chodos, Robert B.** See JACOBSON, CHODOS, HIBBS and FALOON *1014
**Christensen, Raymond C.** See REGAN, CHRISTENSEN, WADA, TALMERS and HELLEMS 306
**Christy, Nicholas P., Wallace, Eleanor Z., Gordon, Wilfred E. L.,** and **Jailer, Joseph W.** On the rate of hydrocortisone clearance from plasma in pregnant women and in patients with Laennec's cirrhosis 299
—. See JAILER, VANDE WIELE, CHRISTY and LIEBERMAN 357
—. Inhibitory effect of canine and human plasma upon enzymatic hydrolysis of steroid glucuronides *995
**Cich, John.** See TOBIAN, CICH and SEVERSEIKE *1048
**Cintron, Jose.** See SPAET and CINTRON *1044
**Clark, John K.** See BARKER and CLARK *986
—. See BARKER, ELKINTON and CLARK 1733
**Clarkson, Bayard.** See SLEISENGER, RICHARD, KOWLESSAR, CLARKSON, THOMPSON and PETERSON *1043
**Clements, John A., Sharp, John T., Johnson, Rudolph P.,** and **Elam, James O.** Estimation of pulmonary resistance by repetitive interruption of airflow 1262
**Cobb, Leonard A., Bruce, Robert A.,** and **Morledge, John H.** Circulatory effects and use of isoproterenol in differentiating patients with pulmonary venous hypertension *995
**Cohen, Alan S.** See CALKINS and COHEN *993
**Cohen, Gerald.** See GOLDRING, TURINO, COHEN, JAMESON and FISHMAN *1007
—, **Holland, Bernard, Sha, Joanne,** and **Goldenberg, Marcel.** Plasma concentrations of epinephrine and norepinephrine during intravenous infusions in man 1935
**Cohen, Phin,** and **Gardner, Frank H.** Canine platelet lifespan after freezing with glycerin-plasma solutions *995
**Cohn, George L.** See MULROW and COHN *1028
**Cohn, Maurice L., Middlebrook, Gardner,** and **Russell, William F., Jr.** Combined drug treatment of tuberculosis. I. Prevention of emergence of mutant populations of tubercle bacilli resistant to both streptomycin and isoniazid *in vitro* 1349
**Cohn, Zanvil A.,** and **Morse, Stephen I.** The fate of staphylococci in suspensions of polymorphonuclear leukocytes *996
**Cole, Edward F.** See AUDITORE, HARTMANN and COLE 702
**Cole, Leon R., Henderson, Ruth W.,** and **West, Ann F.** Demonstration of circulating antibody to Ehrlich ascites tumor in mice *996
**Colle, E.** See ULSTROM and COLLE *1050
**Combes, Burton.** The excretion of bromsulphalein in bile as a conjugate of glycine and glutamic acid *997
—. See MADISON, COMBES, STRICKLAND and ADAMS *1023
—. The biliary excretion of sulfobromophthalein sodium (BSP) in the rat as a conjugate of glycine and glutamic acid 1426
**Connelly, John.** See BACANER, CONNELLY and BRUNS *984
**Connor, Thomas B., Carey, T. Nelson, Davis, Thomas,** and **Lovice, Harris.** Observations on the uricosuric effects of zoxazolamine in gout *997
—. See THOMAS, MORGAN, CONNOR, HADDOCK, BILLS and HOWARD 1078
**Connor, William E.,** and **Eckstein, John W.** The removal of lipoprotein lipase from the blood by the normal and diseased liver 1746
**Constantine, Herbert.** See STANFIELD, PERKINS, CONSTANTINE, LURIA, FINLAYSON, LOVEJOY and YU *1045
**Cooper, Bernard A.** See LOWENSTEIN, COOPER, BRUNTON and GARTHA *1022
**Cooperstein, I. L.,** and **Brockman, Stanley K.** The electrical potential difference generated by the large intestine: Its relation to electrolyte and water transfer 435

**Coppage, William S., Jr., Island, Donald, Smith, Maureen,** and **Liddle, Grant W.** Inhibition of aldosterone secretion and modification of electrolyte excretion in man by a chemical inhibitor of 11β-hydroxylation 2101
**Costea, Nicholas.** See BALDINI, COSTEA and SMALL *985
**Cournand, A.** See FRITTS, FILLER, FISHMAN and COURNAND 1339
**Cronkite, Eugene P.** See JACKSON, SORENSEN, CRONKITE, BOND and FLIEDNER 1689
**Crosby, William H.** Evidence of the recycling of siderocyte iron *997
**Crumpton, Charles W.** See ROWE, MAXWELL, CASTILLO and CRUMPTON *1037
—. See ROWE, MAXWELL, CASTILLO, FREEMAN and CRUMPTON 2154
**Curran, George L., Azarnoff, Daniel L.,** and **Bolinger, Robert E.** Effect of cholesterol synthesis inhibition in normocholesteremic young men 1251
**Cutler, Robert W. P.** See SCHWARTZ, BANK and CUTLER 347

D

**Daly, Jerome J., Calabresi, Massimo, Nims, Robert G.,** and **Gray, Frank D., Jr.** Respiratory variations in pulmonary vascular net pressures *998
**Dameshek, William.** See SCHWARTZ, EISNER and DAMESHEK 1394
**Daughaday, William H., Kozak, Ida,** and **Biederman, Oliver.** Corticosteroid binding globulin activity in body fluids and in fetal and maternal plasma *998
**Davidson, Douglas G.** See ORLOFF and DAVIDSON 21
—. See LEVINSKY, DAVIDSON and BERLINER 730
**Davidson, Murray.** See PERT, DAVIDSON, ALMY and SLEISENGER 397
**Davis, A. L.** See ROTHSCHILD, DAVIS, ORATZ and SCHREIBER 2224
**Davis, James O.** See YANKOPOULOS, DAVIS, KLIMAN and PETERSON 1278
**Davis, Neil C.** See MIRSKY, PERISUTTI and DAVIS 14
**Davis, Thomas.** See CONNOR, CAREY, DAVIS and LOVICE *997
**Dawson, Anthony M., Bell, Virginia M.,** and **Isselbacher, Kurt J.** The transport and synthesis of lipid by the small intestine *999
**Deeney, J. M.** See GREER and DEENEY 1465
**DeFazio, Valentino.** See REGAN, BINAK, GORDON, DEFAZIO and HELLEMS *1033
—. See REGAN, DEFAZIO, BINAK, KENAN and HELLEMS 1564
**Deicher, Helmuth R. G.** See HOLMAN, DEICHER and KUNKEL *1013
—. See HOLMAN and DEICHER 2059
**Deiss, William P., O'Shaughnessy, Patrick J.,** and **Wynn, James O.** Early effects of thyrotropin on protein-bound iodine$^{131}$ and plasma iodide$^{131}$ 334
—, and **Holmes, Leila B.** *In vitro* calcium-mobilizing activity of parathyroid extract (PTE) *999
**Denst, John.** See HEATON, RUSSELL, DENST and MIDDLEBROOK 1376
**Dewey, Richard R.** See BRICKER, DEWEY, LUBOWITZ, STOKES and KIRKENSGAARD 516
**Dingman, Joseph F., Gaitan, Eduardo,** and **Staub, Max C.** Effects of vasopressin on electrolyte and water metabolism in primary aldosteronism *999
**Dixon, Frank J.** See FARR and DIXON *1003
**Dole, V. P., James, A. T., Webb, J. P. W., Rizack, M. A.,** and **Sturman, M. F.** The fatty acid patterns of plasma lipids during alimentary lipemia 1544
**Donald, David E.** See BROTMACHER, MARSHALL, CHEESMAN and DONALD *992
**Donaldson, Robert M., Jr., Arabehety, Julian,** and **Gray, Seymour J.** *In vivo* studies of 5-hydroxyindole metabolism in patients with hepatic cirrhosis and in rats 933
**Doray, B. H.** See LOWE, SOKAL, DORAY and SARCIONE *1021
**Dornbush, A. C.** See KUNIN, DORNBUSH and FINLAND 1950
**Dowling, Harry F.** See JACKSON and DOWLING 762
—. See JACKSON, DOWLING and MOGABGAB *1014
**Dowling, J. Thomas.** See KLEEMAN, BERNSTEIN, DOWLING, KOPLOWITZ and MAXWELL *1018
—. See RICHARDS, DOWLING and INGBAR *1035
**Doyle, Joseph T., Richardson, David W.,** and **Hardie, Edith L.** The circulation in induced acute head injury *1000
**Dressler, Sidney H.** See RUSSELL, KASS, HEATON, DRESSLER and MIDDLEBROOK 1366
**Durand, Jacques.** See FRITTS, HARDEWIG, ROCHESTER and DURAND *1006

E

**Earle, David P., Hutt, Martin P., Schmid, Karl,** and **Gitlin, David.** Observations on double albumin: A genetically transmitted serum protein anomaly 1412
**Earley, Laurence E.,** and **Sanders, Charles A.** The effect of changing serum osmolality on the release of antidiuretic hormone in certain patients with decompensated cirrhosis of the liver and low serum osmolality 545
—. Water diuresis following the ingestion of large volumes of slightly hypertonic urea solution by hydropenic subjects *1000
**Ebert, Richard V.** See ROSS and EBERT 155
**Eckstein, John W.,** and **Hamilton, William K.** Effects of isoproterenol on peripheral venous tone and transmural right atrial pressure in man 342
—, and **Horsley, A. W.** Hemodynamic effects of epinephrine in the presence of ganglionic blockade in conscious dogs *1000
—. See CONNOR and ECKSTEIN 1746
**Edelman, I. S.** See LEIBMAN and EDELMAN 2176
**Edwards, Earl A.** See CALABRESI, EDWARDS and SCHILLING 2091
**Egdahl, R. H.** See HUME, JACKSON, KUPFER, HAM and EGDAHL *1013
—. The differential response of the adrenal cortex and medulla to bacterial endotoxin 1120
**Eich, Robert H., Staib, Ingolf,** and **Enerson, Daniel.** An experimental evaluation of the indicator dilution technique for the measurement of mitral regurgitation 2035
**Eichna, Ludwig W.** See SOBOL, KESSLER, RADER and EICHNA 557
**Eisner, Anna.** See SCHWARTZ, EISNER and DAMESHEK 1394
**Elam, James O.** See CLEMENTS, SHARP, JOHNSON and ELAM 1262

**Elder, T. David,** and **Wyngaarden, James B.** The synthesis and turnover of oxalic acid in normal and hyperoxaluric subjects *1001
**Eliasch, Harald.** See SCHNABEL, ELIASCH, THOMASSON and WERKÖ 117
**Elkinton, J. R.** See HUTH, SQUIRES and ELKINTON 1149
—. See BARKER, ELKINTON and CLARK 1733
**Ellis, John T.** See LOURIA, BLUMENFELD, ELLIS, KILBOURNE and ROGERS 213
**Enerson, Daniel.** See EICH, STAIB and ENERSON 2035
**Epstein, Franklin H.,** and **Levitin, Howard.** "Cerebral salt-wasting": An example of sustained inappropriate release of antidiuretic hormone *1001
—, **Beck, David, Carone, Frank A., Levitin, Howard,** and **Manitius, Andrzej.** Changes in renal concentrating ability produced by parathyroid extract 1214
**Erslev, Allan J.,** and **Hughes, James R.** Maturation and multiplication of nucleated red cells *in vitro* *1001
**Estes, E. Harvey, Jr.** See BOGDONOFF, WEISSLER, MERRITT, HARLAN and ESTES *989
—, **Bogdonoff, M. D., Friedberg, S. J., Harlan, W. R., Jr.,** and **Trout, D. L.** The effect of insulin on nonesterified fatty acid release from the human leg 2131
**Eubanks, Marjoria.** See TSCHUDY, BACCHUS, WEISSMAN, WATKIN, EUBANKS and WHITE 892
**Evans, David A. Price.** Fucose and blood group substances in the salivas of duodenal ulcer subjects *1002
**Evans, Titus C.** See HODGES, EVANS, BRADBURY and KEETTEL *1012
**Ezrin, Calvin,** and **Moloney, Peter J.** The antigenicity of insulin *1002

F

**Failey, R. B., Jr.** See HODES, FAILEY and BROWN *1011
**Falbriard, Adrien.** See SCHWARTZ, FALBRIARD and LEMIEUX 939
—. See SCHWARTZ, LEMIEUX and FALBRIARD *1042
—. See SCHWARTZ, LEMIEUX and FALBRIARD 2197
**Falcone, A. B.** Studies on the mechanism of action of salicylates; effects on oxidative phosphorylation *1002
**Faloon, William W.** See JACOBSON, CHODOS, HIBBS and FALOON *1014
**Fanska, R.** See CARBONE, GRODSKY and FANSKA *994
—. See GRODSKY, CARBONE and FANSKA 1981
**Farquhar, John W.** See HIRSCH, FARQUHAR, PETERSON and STOFFEL *1011
**Farr, Richard S.,** and **Dixon, Frank J.** The effect of antigen concentration on the initiation of antibody synthesis in rabbits *1003
**Farrar, John T.,** and **Groisser, Victor W.** The effect of organomercurials on the absorption of $Na^{24}$ from the human small intestine *1003
**Felton, Leland.** See FRIEDMAN, BYERS, FELTON and CADY 539
**Ferguson, M. H.** See KAUFMAN, FERGUSON and CHERNIACK 500
**Ferrebee, Joseph W.** See THOMAS, LOCHTE, CANNON, SAHLER and FERREBEE 1709
**Field, James B.** Studies on the circulating insulin inhibitor found in some diabetic patients exhibiting chronic insulin resistance 551
—, **Weinberg, Arnold, Johnson, Phyllis,** and **Spoont, Stanley.** An unusual case of diabetes mellitus with increased pancreatic production of insulin *1003
**Field, Michael.** See SEKI, FIELD and CHALMERS *1042
**Field, Morton H.,** and **Reiss, Eric.** "Vitamin D-resistant rickets": A disease associated with normal renal transport of phosphate *1004
**Filler, J.** See FRITTS, FILLER, FISHMAN and COURNAND 1339
**Filley, Giles F.** See REEVES, ROBERTS, GROVER, FILLEY and BLOUNT *1033
**Finch, Clement A.** Body iron exchange in man 392
**Finch, Stuart C.** See BRODY and FINCH *992
**Fine, J.** See SCHWEINBURG, SMIDDY and FINE 673
**Finegold, Sydney.** See GUZE, GOLDNER, FINEGOLD and HEWITT *1009
**Finland, Maxwell.** See KUNIN, REES, MERRILL and FINLAND 1487
—. See KUNIN and FINLAND 1509
—. See KUNIN, DORNBUSH and FINLAND 1950
**Finlayson, James.** See STANFIELD, PERKINS, CONSTANTINE, LURIA, FINLAYSON, LOVEJOY and YU *1045
**Fisher, Sharon.** See RAMOT, FISHER, SZEINBERG, ADAM, SHEBA and GAFNI 2234
**Fishman, Alfred P.** See GOLDRING, TURINO, COHEN, JAMESON and FISHMAN *1007
—. See TURINO, BRANDFONBRENER and FISHMAN 1186
—. See FRITTS, FILLER, FISHMAN and COURNAND 1339
**Fishman, J., McGarry, Eleanor,** and **Beck, J. C.** Studies using anterior pituitary hormones as antigens *1004
**Fishman, Robert A.** Factors influencing the exchange of sodium between plasma and cerebrospinal fluid 1698
**Fleshler, Bertram, Hendrix, Thomas R., Kramer, Philip,** and **Ingelfinger, Franz J.** The characteristics and similarity of primary and secondary peristalsis in the esophagus 110
**Fletcher, Anthony P.** See SHERRY, LINDEMEYER, FLETCHER and ALKJAERSIG 810
—, **Alkjaersig, Norma,** and **Sherry, Sol.** Pathogenesis of the hemorrhagic diathesis developing during "fibrinolytic" states: The significance of defective fibrin polymerization *1005
—. See ALKJAERSIG, FLETCHER and SHERRY 1086
—, **Alkjaersig, Norma,** and **Sherry, Sol.** The maintenance of a sustained thrombolytic state in man. I. Induction and effects 1096
—, **Sherry, Sol, Alkjaersig, Norma, Smyrniotis, Fotios E.,** and **Jick, Sidney.** The maintenance of a sustained thrombolytic state in man. II. Clinical observations on patients with myocardial infarction and other thromboembolic disorders 1111
**Fliedner, Theodore M.** See JACKSON, SORENSEN, CRONKITE, BOND and FLIEDNER 1689
**Foley, Joseph B.** See SEGAL and FOLEY 407
**Fong, Conrad T. O.** See SCHWARTZ, FONG, POPENOE, SILVER and SCHOESSLER *1041
**Fordham, Christopher C., III.** See WILLIAMS, FORDHAM, HOLLANDER and WELT 1587
**Forkner, Claude E., Jr.** See ROBIN, BROMBERG and FORKNER *1035
**Fowler, Ward S.** See LILLINGTON, FOWLER, MILLER and HELMHOLZ 2026
**Frank, N. Robert.** See AVERY, FRANK and GRIBETZ 456

—. See GRIBETZ, FRANK and AVERY 2168
**Franklin, E. C.** See KUNKEL, FRANKLIN and MULLER-EBERHARD 424
—. Physicochemical and immunologic studies of gamma globulins of normal human urine 2159
**Franklin, Stanley S., Niall, John F.,** and **Merrill, John P.** The influence of solute load on the isosthenuria of renal disease *1005
**Frayser, Regina.** See ROSS, FRAYSER and HICKAM 916
—. See ROSS, HICKAM and FRAYSER *1036
**Freeman, D. J.** See ROWE, MAXWELL, CASTILLO, FREEMAN and CRUMPTON 2154
**Freinkel, Norbert, Sanders, Charles A., Levinson, Gilbert E.,** and **Abelmann, Walter H.** The utilization of glucose and metabolism of insulin in the exercised extremity of man *1005
**Freis, Edward D.** See PIPBERGER, TABACK, MARDEN, MASON and FREIS *1031
**Frenk, Silvestre.** See METCOFF, FRENK and ANTONOWICZ *1025
**Friedberg, S. J.** See ESTES, BOGDONOFF, FRIEDBERG, HARLAN and TROUT 2131
**Friedman, Emanuel A., Gray, Mary Jane, Hutchinson, Donald L.,** and **Plentl, Albert A.** The role of the monkey fetus in the exchange of the water and sodium of the amniotic fluid 961
**Friedman, Meyer, Byers, Sanford O., Felton, Leland,** and **Cady, Paxton.** Localization and retention of $I^{131}$ from fed triolein in the atherosclerotic infiltration of rabbit aortas 539
—, and **Byers, Sanford O.** Evaluation of nicotinic acid as an hypocholesteremic and antiatherogenic substance 1328
**Fritts, Harry W., Jr., Hardewig, Alfred, Rochester, Dudley,** and **Durand, Jacques.** Detection of pulmonary arteriovenous shunts using intravenous injections of $Kr^{85}$ and T-1824 dye *1006
—, **Filler, J., Fishman, A. P.,** and **Cournand, A.** The efficiency of ventilation during voluntary hyperpnea: Studies in normal subjects and in dyspneic patients with either chronic pulmonary emphysema or obesity 1339
**Fukushima, David K.** See HELLMAN, BRADLOW, ZUMOFF, FUKUSHIMA and GALLAGHER *1010

## G

**Gabuzda, George J.** See RUSZKOWSKI, BAERTL and GABUZDA *1038
**Gafni, Dora.** See RAMOT, SZEINBERG, ADAM, SHEBA and GAFNI 1659
—. See RAMOT, FISHER, SZEINBERG, ADAM, SHEBA and GAFNI 2234
**Gaitan, Eduardo.** See DINGMAN, GAITIN and STAUB *999
**Gallagher, T. F.** See HELLMAN, BRADLOW, ZUMOFF, FUKUSHIMA and GALLAGHER *1010
**Gann, Donald S.** See BARTTER, MILLS and GANN *986
**Garby, Lars,** and **Noyes, Ward D.** Studies on hemoglobin metabolism. I. The kinetic properties of the plasma hemoglobin pool in normal man 1479
**Gardner, Frank H.** See COHEN and GARDNER *995
**Garrow, J. S.** The effect of protein depletion on the distribution of protein synthesis in the dog 1241
**Gartha, Susan.** See LOWENSTEIN, COOPER, BRUNTON and GARTHA *1022
**Geiger, Douglas W.** See SASS-KORTSAK, CHERNIAK, GEIGER and SLATER 1672
**Gerst, Paul H., Rattenborg, Christen,** and **Holaday, Duncan A.** The effects of hemorrhage on pulmonary circulation and respiratory gas exchange 524
**Giebisch, Gerhard,** and **Lozano, Rodolfo.** The effects of adrenal steroids and potassium depletion on the elaboration of an osmotically concentrated urine 843
**Gilbertsen, A. Sigrid, Lowry, Paul T., Hawkinson, Violet,** and **Watson, C. J.** Studies of the dipyrrylmethene ("fuscin") pigments. I. The anabolic significance of the fecal mesobilifuscin 1166
—, **Hawkinson, Violet,** and **Watson, C. J.** Studies of the dipyrrylmethene ("fuscin") pigments. II. The contrasting ratios and significance of the fecal urobilinogen and mesobilifuscin in certain anemias 1175
**Gitlin, David.** See EARLE, HUTT, SCHMID and GITLIN 1412
**Gleason, William L.** See MCINTOSH, GLEASON, MILLER and BACOS *1023
**Glueck, Helen I., Goldsmith, Richard E., Wayne, Leo,** and **Berry, Helen K.** Abnormal calcium binding associated with hyperglobulinemia, clotting defects and osteoporosis: A study of this relationship *1006
**Gold, Norman I., Smith, Louis L.,** and **Moore, Francis D.** Cortisol metabolism in man: Observations of pathways, pool sizes of metabolites and rates of formation of metabolites 2238
**Goldenberg, Marcel.** See COHEN, HOLLAND, SHA and GOLDENBERG 1935
**Goldfien, Alan,** and **Havel, Richard J.** The effects of norepinephrine and epinephrine on unesterified fatty acid metabolism *1007
**Goldner, Bernard H.** See GUZE, GOLDNER, FINEGOLD and HEWITT *1009
**Goldring, Roberta M., Turino, Gerard M., Cohen, Gerald, Jameson, A. Gregory,** and **Fishman, Alfred P.** Catechol amines in the pulmonary pressor response to acute hypoxia *1007
**Goldsmith, Richard E.** See GLUECK, GOLDSMITH, WAYNE and BERRY *1006
**Gombos, Ervin A.** See BALDWIN, HULET, GOMBOS and BIGGS *985
**Good, Robert A.** See ZAK and GOOD 579
**Goodall, McC., Kirshner, N.,** and **Rosen, Lawrence.** Metabolism of noradrenaline in the human 707
**Goodman, Howard C.** See BAXTER, GOODMAN and SHAFRIR *986
**Goodwin, Jesse F.** See BOLLET, GOODWIN and BROWN 451
**Gordan, G. S.** See LOKEN and GORDAN *1021
**Gordon, Seymour.** See REGAN, BINAK, GORDON, DEFAZIO and HELLEMS *1033
**Gordon, Wilfred E. L.** See CHRISTY, WALLACE, GORDON and JAILER 299
**Gorlin, Richard, Brachfeld, Norman, Turner, John D.,** and **Messer, Joseph V.** Hyperhemorrhea of unknown cause: A possible physiologic-clinical entity *1007
—, **Brachfeld, Norman, Turner, John D., Messer, Joseph V.,** and **Salazar, Eduardo.** The idiopathic high cardiac output state 2144
**Gott, Cora.** See SANFORD, BARNETT and GOTT *1039
**Graettinger, John S., Muenster, Joseph J., Selverstone, Louis A.,** and **Campbell, James A.** A cor-

relation of clinical and hemodynamic studies in patients with hyperthyroidism with and without congestive heart failure 1316
**Graham, Dorothy E.** See BLOCK, GRAHAM and BURROWS *988
**Gray, Frank D., Jr.** See DALY, CALABRESI, NIMS and GRAY *998
**Gray, Mary Jane.** See FRIEDMAN, GRAY, HUTCHINSON and PLENTL 961
—. See HUTCHINSON, GRAY, PLENTL, ALVAREZ, CALDEYRO-BARCIA, KAPLAN and LIND 971
**Gray, Seymour J.** See DONALDSON, ARABEHETY and GRAY 933
**Grayzel, Arthur I.,** and **Seegmiller, J. E.** Suppression of uric acid synthesis in the gouty human by the use of 6-diazo-5-oxo-L-norleucine (DON) *1008
**Greer, Monte A.,** and **Deeney, J. M.** Antithyroid activity elicited by the ingestion of pure progoitrin, a naturally occurring thioglycoside of the turnip family 1465
**Greisman, Sheldon E.** Studies on the collapse of endotoxin defenses following hemorrhagic shock *1008
**Gribetz, Irwin.** See AVERY, FRANK and GRIBETZ 456
—, **Frank, N. R.,** and **Avery, Mary Ellen.** Static volume-pressure relations of excised lungs of infants with hyaline membrane disease, newborn and stillborn infants 2168
**Grodsky, G. M.** See CARBONE, GRODSKY and FANSKA *994
—, **Carbone, J. V.,** and **Fanska, R.** Identification of metabolites of sulfobromophthalein 1981
—. See CARBONE, GRODSKY and HJELTE 1989
**Groisser, Victor W.** See FARRAR and GROISSER *1003
**Grollman, Arthur.** See GROLLMAN and GROLLMAN 749
**Grollman, Evelyn Frances,** and **Grollman, Arthur.** Toxicity of urea and its role in the pathogenesis of uremia 749
**Gross, Ruth T.** See MARKS and GROSS *1023
—. See MARKS and GROSS 2253
**Grover, Robert F.** See REEVES, ROBERTS, GROVER, FILLEY and BLOUNT *1033
**Guest, M. Joanne.** See SIPERSTEIN and GUEST *1043
**Gursey, Deha, Vester, John W.,** and **Olson, Robert E.** Effect of ethanol administration upon serotonin and norepinephrine levels in rabbit brain *1008
**Gutman, Alexander B.** See YÜ and GUTMAN 1298
—, **Yü, T'sai Fan,** and **Berger, Lawrence.** Tubular secretion of urate in man 1789
**Guttentag, O. E.** See WENNESLAND, BROWN, HOPPER, HODGES, GUTTENTAG, SCOTT, TUCKER and BRADLEY 1065
**Guze, Lucien B., Goldner, Bernard H., Finegold, Sydney,** and **Hewitt, William.** Observations on the course of chronic nonobstructed pyelonephritis in the rat *1009

## H

**Haddock, Lillian.** See THOMAS, MORGAN, CONNOR, HADDOCK, BILLS and HOWARD 1078
**Haddy, Francis J.** See SWEANY, MOSS and HADDY 587
**Hall, Philip W., 3rd.** See SCHWARTZ, HALL, HAYS and RELMAN 39
**Ham, W. T.** See HUME, JACKSON, KUPFER, HAM and EGDAHL *1013
**Hamilton, William K.** See ECKSTEIN and HAMILTON 342
**Hammond, John D. S.** See ROSS and HAMMOND *1037
**Hardewig, Alfred.** See FRITTS, HARDEWIG, ROCHESTER and DURAND *1006
**Hardie, Edith L.** See DOYLE, RICHARDSON and HARDIE *1000
**Harlan, William R.** See BOGDONOFF, WEISSLER, MERRITT, HARLAN and ESTES *989
—. See ESTES, BOGDONOFF, FRIEDBERG, HARLAN and TROUT 2131
**Hartmann, Robert C.** See AUDITORE, HARTMANN and COLE 702
—, and **Auditore, Joseph V.** Erythrocyte enzymes in paroxysmal nocturnal hemoglobinuria *1009
**Hassirdjian, A.** See BALTCH, OSBORNE, BUNN, CANARILE and HASSIRDJIAN *985
**Haurani, Farid.** See STOLOFF, HAURANI and REPPLINGER *1046
**Havel, Richard J.** See GOLDFIEN and HAVEL *1007
**Hawkinson, Violet.** See GILBERTSEN, LOWRY, HAWKINSON and WATSON 1166
—. See GILBERTSEN, HAWKINSON and WATSON 1175
**Hayford-Welsing, Ernest J.** See LEWIS, LINN, NOE and HAYFORD-WELSING 2073
**Hays, Richard M.** See SCHWARTZ, HALL, HAYS and RELMAN 39
—. See LAMDIN, MAFFLY, HAYS and LEAF *1019
**Heaton, Angeline D.** See MANDEL, HEATON, RUSSELL and MIDDLEBROOK 1356
—. See RUSSELL, KASS, HEATON, DRESSLER and MIDDLEBROOK 1366
—, **Russell, William F., Jr., Denst, John,** and **Middlebrook, Gardner.** Combined drug treatment of tuberculosis. IV. Bacteriologic studies on the sputum and resected pulmonary lesions of tuberculous patients 1376
**Hefley, Bill F.,** and **Pierce, John A.** The influence of elastin removal on the elastic properties of lung preparation *1009
**Hefner, Lloyd.** See REEVES, SHOURIE, HEFNER and TAYLOR *1033
—. See JONES, HEFNER, BANCROFT and KLIP 2087
**Hellegers, Andre, Metcalfe, James, Huckabee, William, Meschia, Giacomo, Prystowsky, Harry,** and **Barron, Donald.** The alveolar $pCO_2$ and $pO_2$ in pregnant and nonpregnant women at altitude *1010
**Hellems, Harper K.** See REGAN, CHRISTENSEN, WADA, TALMERS and HELLEMS 306
—. See REGAN, BINAK, GORDON, DEFAZIO and HELLEMS *1033
—. See REGAN, DEFAZIO, BINAK, KENAN and HELLEMS 1564
**Heller, Paul, Yakulis, Vincent,** and **Zimmerman, Hyman J.** The antigenicity of connective tissue *1010
**Hellman, Leon, Bradlow, H. Leon, Zumoff, Barnett, Fukushima, David K.,** and **Gallagher, T. F.** The hypocholesteremic effect of androsterone *1010
—. See ROSENFELD and HELLMAN 1334
**Helmholz, H. Frederic, Jr.** See LILLINGTON, FOWLER, MILLER and HELMHOLZ 2026
**Hemmerly, Thomas.** See KNIGHT, HEMMERLY, MARTIN and WHITE *1018
**Henderson, Ruth W.** See COLE, HENDERSON and WEST *996
**Hendrix, Thomas R.** See FLESHLER, HENDRIX, KRAMER and INGELFINGER 110
**Herbert, Victor.** Mechanism of intrinsic factor action in everted sacs of rat small intestine 102

**Hewitt, William.** See GUZE, GOLDNER, FINEGOLD and HEWITT *1009
**Heyman, A.** See KARP, WEISSLER and HEYMAN *1016
**Heymann, Walter,** and **Wilson, S. G. F.** Hyperlipemia in early stages of acute glomerular nephritis 186
**Hibbs, Susan.** See JACOBSON, CHODOS, HIBBS and FALOON *1014
**Hickam, John B.** See ROSS, FRAYSER and HICKAM 916
—. See ROSS, HICKAM and FRAYSER *1036
**Hickler, Roger B.** See WELLS, WALKER and HICKLER *1053
**Hill, R. L.** See PERKOFF, SCHWARTZ, HILL and TYLER *1029
**Hills, A. Gorman, Parsons, David W., Rosenthal, Otto,** and **Kiem, Iris.** Excessive renal tubular reabsorption of filtered urea in human adrenal insufficiency *1011
**Hirsch, J.** See INSULL, HIRSCH, JAMES and AHRENS 443
—, **Farquhar, John W., Peterson, Malcolm L.,** and **Stoffel, Wilhelm.** The fatty acid composition of adipose tissue in man *1011
**Hjelte, Virginia.** See CARBONE, GRODSKY and HJELTE 1989
**Hodes, M. E., Failey, R. B., Jr.,** and **Brown, E.** Studies of the effect of L-triiodothyronine upon bile acid formation in man *1011
**Hodges, J. L., Jr.** See WENNESLAND, BROWN, HOPPER, HODGES, GUTTENTAG, SCOTT, TUCKER and BRADLEY 1065
**Hodges, Robert E., Evans, Titus C., Bradbury, James T.,** and **Keettel, William C.** Measurements of the amount of irradiation of human ovaries incident to administration of radioactive iodine ($I^{131}$) *1012
—, **Bean, William B., Ohlson, Margaret A.,** and **Bleiler, Roberta.** Human pantothenic acid deficiency produced by omega-methyl pantothenic acid 1421
**Hoffman, J. I. E.,** and **Rowe, George G.** Some factors affecting indicator dilution curves in the presence and absence of valvular incompetence 138
—, **Rudolph, Abraham M.,** and **Nadas, Alexander S.** Nine patients with pulmonic stenosis, right-to-left shunt through a ventricular septal defect, and right ventricular pressure above systemic pressure *1012
**Holaday, Duncan A.** See GERST, RATTENBORG and HOLADAY 524
**Holland, Bernard.** See COHEN, HOLLAND, SHA and GOLDENBERG 1935
**Hollander, Vincent P.** Studies on estradiol mediated pyridine nucleotide transhydrogenase in human breast cancer *1012
**Hollander, Walter, Jr.** See WOODS, WELT, HOLLANDER and NEWTON *1056
—. See WILLIAMS, FORDHAM, HOLLANDER and WELT 1587
**Hollander, William,** and **Chobanian, Aram V.** The cholesterol lowering effect of 1-*p*-[-(β-diethylaminoethyoxy)-phenyl]-1-(*p*-tolyl)-2-(*p*-chlorophenyl) ethanol in hypertensive man *1013
**Hollenberg, C. H.** See RABEN and HOLLENBERG 484
—. See RABEN and HOLLENBERG *1032
**Holman, Halsted R., Deicher, Helmuth R. G.,** and **Kunkel, Henry G.** Multiple "antibodies" to cell constituents in systemic lupus erythematosus (S.L.E.) and related disorders *1013
—, and **Deicher, Helmuth R.** The reaction of the lupus erythematosus (L.E.) cell factor with deoxyribonucleoprotein of the cell nucleus 2059
**Holmes, Leila B.** See DEISS and HOLMES *999
**Holtzman, Charles M.** See KURTZ, HOLTZMAN and MEILMAN 902
**Holub, Donald A., Kitay, Julian I.,** and **Jailer, Joseph W.** Effects of exogenous adrenocorticotropic hormone (ACTH) upon pituitary ACTH concentration after prolonged cortisone treatment and stress 291
**Hopper, J., Jr.** See WENNESLAND, BROWN, HOPPER, HODGES, GUTTENTAG, SCOTT, TUCKER and BRADLEY 1065
**Horsley, A. W.** See ECKSTEIN and HORSLEY *1000
**Howard, John E.** See THOMAS, MORGAN, CONNOR, HADDOCK, BILLS and HOWARD 1078
**Hsu, Konrad C.** See KAYDEN, SEEGAL and HSU *1016
**Huckabee, William.** See HELLEGERS, METCALFE, HUCKABEE, MESCHIA, PRYSTOWSKY and BARRON *1010
**Hughes, James R.** See ERSLEV and HUGHES *1001
**Hulet, William H.** See BALDWIN, HULET, GOMBOS and BIGGS *985
—, and **Smith, Homer W.** Negative pressure respiration, water diuresis and natriuresis in normotensive, hypertensive and prehydrated normotensive subjects 1972
**Hume, D. M., Jackson, B. T., Kupfer, H. G., Ham, W. T.,** and **Egdahl, R. H.** Fetal hematopoietic tissue transplantation following lethal whole body irradiation in dogs, and a consideration of its clinical use *1013
**Hutchinson, Donald L.** See FRIEDMAN, GRAY, HUTCHINSON and PLENTL 961
—, **Gray, Mary Jane, Plentl, Albert A., Alvarez, Hermogenes, Caldeyro-Barcia, Roberto, Kaplan, Bruno,** and **Lind, John.** The role of the fetus in the water exchange of the amniotic fluid of normal and hydramniotic patients 971
**Huth, E. J.** See WEBSTER and HUTH *1053
—. See SQUIRES and HUTH 1134
—, **Squires, R. D.,** and **Elkinton, J. R.** Experimental potassium depletion in normal human subjects. II. Renal and hormonal factors in the development of extracellular alkalosis during depletion 1149
**Hutt, Martin P.** See EARLE, HUTT, SCHMID and GITLIN 1412

## I

**Ingbar, Sidney H.** See RICHARDS, DOWLING and INGBAR *1035
**Ingelfinger, Franz J.** See FLESHLER, HENDRIX, KRAMER and INGELFINGER 111
**Inman, John K.** See JANDL, INMAN, SIMMONS and ALLEN 161
**Insull, W., Jr., Hirsch, J., James, A. T.,** and **Ahrens, E. H., Jr.** The fatty acids of human milk. II. Alterations produced by manipulation of caloric balance and exchange of dietary fats 443
**Isacson, Peter.** See MCCOLLUM and ISACSON *1022
**Island, Donald.** See COPPAGE, ISLAND, SMITH and LIDDLE 2101
**Isselbacher, Kurt J.,** and **McCarthy, Elizabeth A.** Studies on bilirubin sulfate and other nonglucuronide conjugates of bilirubin 645
—. See DAWSON, BELL and ISSELBACHER *999

J

**Jackson, B. T.** See HUME, JACKSON, KUPFER, HAM and EGDAHL *1013

**Jackson, Dudley P., Sorensen, Dale K., Cronkite, Eugene P., Bond, Victor P., and Fliedner, Theodore, M.** Effectiveness of transfusions of fresh and lyophilized platelets in controlling bleeding due to thrombocytopenia 1689

**Jackson, George Gee, and Dowling, Harry F.** Transmission of the common cold to volunteers under controlled conditions. IV. Specific immunity to the common cold 762

—, **Dowling, Harry F., and Mogabgab, William J.** The infectivity and interrelationships of 2060 and J. H. viruses among volunteers *1014

**Jacobson, Eugene D., Chodos, Robert B., Hibbs, Susan, and Faloon, William W.** Effect of gluten and of cortisone upon experimental malabsorption induced by neomycin *1014

**Jaffé, Ernst R.** The reduction of methemoglobin in human erythrocytes incubated with purine nucleosides 1555

**Jailer, Joseph W.** See HOLUB, KITAY and JAILER 291

—. See CHRISTY, WALLACE, GORDON and JAILER 299

—, **Vande Wiele, Raymond, Christy, Nicholas P., and Lieberman, Seymour.** Studies in Cushing's syndrome. III. Urinary 17-ketosteroids in patients with bilateral adrenal cortical hyperplasia 357

**James, A. T.** See INSULL, HIRSCH, JAMES and AHRENS 443

—. See DOLE, JAMES, WEBB, RIZACK and STURMAN 1544

**James, G. Watson, III, and Abbott, Lynn D., Jr.** Abnormal patterns of stercobilin formation in dyserythropoiesis *1014

**Jameson, A. Gregory.** See GOLDRING, TURINO, COHEN, JAMESON and FISHMAN *1007

**Jandl, James, Inman, John K., Simmons, Richard L., and Allen, David W.** Transfer of iron from serum iron-binding protein to human reticulocytes 161

—. See MARTIN and JANDL *1024

**Janecek, Jeannette.** See TOBIAN, TOMBOULIAN and JANECEK 605

**Javitt, Norman B., Wheeler, Henry O., Baker, Katherine J., and Ramos, Oswaldo.** Intrahepatic conjugation of bromsulphalein and glutathione *1015

**Jensen, Roderick E.** See PETERSON and JENSEN *1030

**Jensen, Wallace N.** See WESTERMAN, PIERCE and JENSEN *1054

**Jick, Sidney.** See FLETCHER, SHERRY, ALKJAERSIG, SMYRNIOTIS and JICK 1111

**Johns, Richard J.** See WRIGHT and JOHNS *1056

**Johnson, Alan J., and McCarty, W. Ross.** The lysis of artificially induced intravascular clots in man by intravenous infusions of streptokinase 1627

**Johnson, Ben B., and Roberts, Kathleen E.** Effects of intravenous hypertonic saline in patients with hyponatremia and edema *1015

**Johnson, P. C.** Vitamin B-12 binding and human intrinsic factor activity *1015

**Johnson, Phyllis.** See FIELD, WEINBERG, JOHNSON and SPOONT *1003

**Johnson, Rudolph P.** See CLEMENTS, SHARP, JOHNSON and ELAM 1262

**Jones, Frances.** See MUIRHEAD, STIRMAN and JONES *1027

**Jones, William B., Hefner, Lloyd L., Bancroft, W. H., Jr., and Klip, Willem.** Velocity of blood flow and stroke volume obtained from the pressure pulse 2087

**Jose, Anthony D., and Milnor, William R.** The demonstration of pulmonary arteriovenous shunts in normal human subjects, and their increase in certain disease states 1915

**Julian, Desmond G.** See ROBIN, TRAVIS, JULIAN and BOSHELL 2229

K

**Kaim, John T.** See BRODSKY, KAIM and CARRASQUER *991

**Kalant, Norman.** See SAFFRAN and KALANT 1717

**Kallee, Ekkehard.** See BENNHOLD and KALLEE 863

**Kaplan, Bruno.** See HUTCHINSON, GRAY, PLENTL, ALVAREZ, CALDEYRO-BARCIA, KAPLAN and LIND 971

**Karp, H. R., Weissler, A. M., and Heyman, A.** Circulatory and electroencephalographic changes associated with loss of consciousness in vasodepressor syncope *1016

**Kass, Irving.** See RUSSELL, KASS, HEATON, DRESSLER and MIDDLEBROOK 1366

**Kaufman, B. J., Ferguson, M. H., and Cherniack, R. M.** Hypoventilation in obesity 500

**Kayden, Herbert J., Seegal, Beatric C., and Hsu, Konrad C.** Biochemical and immunochemical studies on the low density lipoproteins of human serum and aortic wall *1016

**Keettel, William C.** See HODGES, EVANS, BRADBURY and KEETTEL *1012

**Kellermeyer, Robert W., Tarlov, Alvin R., Schrier, Stanley L., and Carson, Paul E.** Dosage-response studies during the resistant phase in primaquine-sensitive hemolytic anemia *1016

**Kelly, K. H.** See BIERMAN, KELLY, MARSHALL and BYRON *988

**Kempthorne, Oscar.** See PETERSON, O'TOOLE, KIRKENDALL and KEMPTHORNE 1644

**Kenney, Francis T., and Kretchmer, Norman.** Hepatic metabolism of phenylalanine during development 2189

**Kerby, Grace P., and Taylor, S. M.** The acid mucopolysaccharide and 5-hydroxytryptamine content of human thrombocytes in rheumatoid arthritic and nonarthritic individuals 1059

**Kessler, Richard H.** See SOBOL, KESSLER, RADER and EICHNA 557

**Kiem, Iris.** See HILLS, PARSONS, ROSENTHAL and KIEM *1011

**Kilbourne, Edwin D.** See BLUMENFELD, KILBOURNE, LOURIA and ROGERS 199

—. See LOURIA, BLUMENFELD, ELLIS, KILBOURNE and ROGERS 213

—. Studies on influenza in the pandemic of 1957–1958. III. Isolation of influenza A (Asian strain) viruses from influenza patients with pulmonary complications. Details of virus isolation and characterization of isolates, with quantitative comparison of isolation methods 266

**Kime, S. Wesley, Jr.** See BRICKER, MORRIN, KIME, SCHULTZE and KLEIN *990

**King, Stanton J., Jr.** See BOYCE and KING 1525

—, and **Boyce, William H.** Total nondialyzable solids (TNDS) in human urine. V. Subfractionation of the ultrafiltrate (UF–O) fraction 1927

**Kinney, John, Zarem, Harvey,** and **Rogers, Richard.** Energy expenditure and utilization of carbohydrate, fat and protein in hospitalized patients *1017
**Kipnis, David M.** The regulation of glucose uptake by muscle: Significance of cellular permeability and hexokinase activity *1017
**Kirkendall, Walter M.** See PETERSON, O'TOOLE, KIRKENDALL and KEMPTHORNE 1644
**Kirkensgaard, Tove.** See BRICKER, DEWEY, LUBOWITZ, STOKES and KIRKENSGAARD 516
**Kirshner, N.** See GOODALL, KIRSHNER and ROSEN 707
**Kitay, Julian I.** See HOLUB, KITAY and JAILER 291
**Kleeman, Charles R., Bernstein, Donald, Dowling, J. Thomas, Koplowitz, Jerry M.,** and **Maxwell, Morton H.** The combined influence of the adrenal and parathyroid glands in the regulation of serum calcium *1018
**Klein, Claire.** See BRICKER, MORRIN, KIME, SCHULTZE and KLEIN *990
**Kliman, Bernard.** See YANKOPOLOUS, DAVIS, KLIMAN and PETERSON 1278
**Klip, Willem.** See JONES, HEFNER, BANCROFT and KLIP 2087
**Knight, Vernon, Hemmerly, Thomas, Martin, Margaret P.,** and **White, Arthur.** Reproduction of the historical sequence of development of resistant staphylococci in hospitals *1018
**Knopf, Ralph F.** See BOLLET, KNOPF and BEIERWALTES *989
**Kono, Paul.** See RANNEY and KONO 508
**Koplowitz, Jerry M.** See KLEEMAN, BERNSTEIN, DOWLING, KOPLOWITZ and MAXWELL *1018
**Korman, Samuel.** Studies on the pathogenesis of anemia with an iron chelate *1018
**Kowlessar, O. Dhodanand.** See SLEISENGER, RICHARD, KOWLESSAR, CLARKSON, THOMPSON and PETERSON *1043
**Kozak, Ida.** See DAUGHADAY, KOZAK and BIEDERMAN *998
**Krakoff, Irwin H.,** and **Balis, M. Earl.** Studies of the uricogenic effect of 2-substituted thiadiazoles in man 907
—, and **Balis, M. Earl.** Effect of 2-substituted thiadiazoles on uric acid synthesis in man *1019
**Kramer, Philip.** See FLESHLER, HENDRIX, KRAMER and INGELFINGER 110
**Krebs, John S.** See BRAUER, SHILL and KREBS 2202
**Kretchmer, Norman.** See KENNEY and KRETCHMER 2189
**Kuida, Hiroshi.** See LANGE and KUIDA *1020
**Kunin, Calvin M., Rees, Searle B., Merrill, John P.,** and **Finland, Maxwell.** Persistence of antibiotics in blood of patients with acute renal failure. I. Tetracycline and chlortetracycline 1487
—, and **Finland, Maxwell.** Persistence of antibiotics in blood of patients with acute renal failure. III. Penicillin, streptomycin, erythromycin and kanamycin 1509
—, **Dornbush, A. C.,** and **Finland, Maxwell.** Distribution and excretion of four tetracycline analogues in normal young men 1950
**Kunkel, H. G., Franklin, E. C.,** and **Muller-Eberhard, H. J.** Studies on the isolation and characterization of the "rheumatoid factor" 424
—. See HOLMAN, DEICHER and KUNKEL *1013
**Kuo, Peter T.,** and **Carson, John C.** The effect of diet upon the diurnal serum triglycerides of patients having hyperlipidemia, cystic fibrosis of the pancreas and of healthy subjects *1019
—, and **Carson, John C.** Dietary fats and the diurnal serum triglyceride levels in man 1384
**Kupfer, H. G.** See HUME, JACKSON, KUPFER, HAM and EGDAHL *1013
**Kurtz, Martin, Holtzman, Charles M.,** and **Meilman, Edward.** Tolbutamide hypoglycemia in acutely depancreatized dogs 902
**Kyle, Laurence H.** See CANARY and KYLE *994
—, **Werdein, Edward J., Canary, John J.,** and **Pachuta, Bernice.** Measurement of change in total body fat 1475

L

**Lambie, Anne T., Relman, Arnold S.,** and **Schwartz, William B.** Electrolyte and acid-base balance during acute loading with rubidium chloride 1538
**Lamdin, Ezra, Maffly, Roy H., Hays, Richard M.,** and **Leaf, Alexander.** Some actions of neurohypophyseal hormones on a living membrane *1019
**Lange, Ramon,** and **Kuida, Hiroshi.** Multiple site indicator dilution curves in dogs with and without metered left heart regurgitation *1020
**Lanman, Hilda.** See REYNOLDS, LANMAN and TUPIKOVA *1034
**Lanz, Henry.** See UNGER, MADISON, MCCALL and LANZ *1050
**Larson, Frank C.** See ALBRIGHT, TOMITA and LARSON *984
—. See ALBRIGHT and LARSON 1899
**Lassiter, William E.,** and **Stanbury, John B.** The renal clearances of iodide and L-diiodotyrosine measured simultaneously 784
**Lathem, Willoughby,** and **Worley, William E.** The distribution of extracorpuscular hemoglobin in circulating plasma 474
—. The renal excretion of hemoglobin: Regulatory mechanisms and the differential excretion of free and protein-bound hemoglobin 652
—. The binding of myoglobin by plasma protein *1020
**Law, David H.** See SLEISENGER, LAW, SMITH, PERT and LEWIS 2119
**Lawrence, Walter, Jr.** See VANAMEE, LAWRENCE, LEVIN, PETERSON and RANDALL *1051
**Lazar, Harold P.** See TEXTER, LAZAR, PULETTI and VANTRAPPEN *1048
**Leaf, Alexander.** See LAMDIN, MAFFLY, HAYS and LEAF *1019
**Leeper, Lemuel C.** See SJOERDSMA, LEEPER, TERRY and UDENFRIEND 31
**Lefèvre, André.** See LIEBER and LEFÈVRE 1271
**Lefkowitz, M.** See VIGNOS and LEFKOWITZ 873
**Leibman, J.,** and **Edelman, I. S.** Interrelations of plasma potassium concentration, plasma sodium concentration, arterial pH and total exchangeable potassium 2176
**Leight, Leonard.** See ROSTON and LEIGHT 777
**Lemann, Jacob, Jr.** See RELMAN and LEMANN *1034
—, and **Relman, Arnold S.** The relation of sulfur metabolism to acid-base balance and electrolyte excretion: The effects of DL-methionine in normal man 2215
**Lemieux, Guy.** See SCHWARTZ, FALBRIARD and LEMIEUX 939
—. See SCHWARTZ, LEMIEUX and FALBRIARD *1042
—. See SCHWARTZ, LEMIEUX and FALBRIARD 2197

**Levin, Sam.** See VANAMEE, LAWRENCE, LEVIN, PETERSON and RANDALL *1051
**Levinsky, Norman G., Davidson, Douglas G.,** and **Berliner, Robert W.** Effects of reduced glomerular filtration on urine concentration in the presence of antidiuretic hormone 730
—, and **Berliner, Robert W.** The role of urea in the urine concentrating mechanism 741
**Levinson, Gilbert E.** See CARLETON, LEVINSON and ABELMANN *994
—. See FREINKEL, SANDERS, LEVINSON and ABELMANN *1005
**Levitin, Howard.** See EPSTEIN and LEVITIN *1001
—. See EPSTEIN, BECK, CARONE, LEVITIN and MANITIUS 1214
**Levitt, Marvin F., Levy, Marshall S.,** and **Polimeros, Demetra.** The effect of a fall in filtration rate on solute and water excretion in hydropenic man 463
**Levy, Marshall S.** See LEVITT, LEVY and POLIMEROS 463
**Lewallen, Charles G., Berman, Mones,** and **Rall, Joseph E.** Studies of iodoalbumin metabolism. I. A mathematical approach to the kinetics 66
—, **Rall, Joseph E.,** and **Berman, Mones.** Studies of iodoalbumin metabolism. II. The effects of thyroid hormone 88
**Lewis, Benjamin M., Lin, Tai-Hon, Noe, Frances E.,** and **Hayford-Welsing, Ernest J.** The measurement of pulmonary diffusing capacity for carbon monoxide by a rebreathing method 2073
**Lewis, Charles M.** See SLEISENGER, LAW, SMITH, PERT and LEWIS 2119
**Lewis, Jessica H.,** and **Merchant, William R.** Application of continuous flow electrophoresis to the study of the blood coagulation proteins. II. The hemophilias (A and B) 1924
**Liddle, Grant W.** See BLIZZARD, LIDDLE, MIGEON and WILKINS 1442
—. See COPPAGE, ISLAND, SMITH and LIDDLE 2101
**Lieber, Charles S.,** and **Lefèvre, André.** Ammonia as a source of gastric hypoacidity in patients with uremia 1271
**Lieberman, Seymour.** See JAILER, VANDE WIELE, CHRISTY and LIEBERMAN 357
**Lillington, Glen A., Fowler, Ward S., Miller, R. Drew,** and **Helmholz, H. Frederic, Jr.** Nitrogen clearance rates of right and left lungs in different positions 2026
**Lin, Tai-Hon.** See LEWIS, LIN, NOE and HAYFORD-WELSING 2073
**Lind, John.** See HUTCHINSON, GRAY, PLENTL, ALVAREZ, CALDEYRO-BARCIA, KAPLAN and LIND 971
**Lindemeyer, Robert I.** See SHERRY, LINDEMEYER, FLETCHER and ALKJAERSIG 810
**Linden, Ronald J., Mitchell, Jere,** and **Sarnoff, Stanley J.** The influence of sympathetic and vagal stimulation on the relationship between left ventricular end-diastolic pressure and fiber length *1020
**Lochte, Harry L., Jr.** See THOMAS, LOCHTE and SAHLER *1048
—. See THOMAS, LOCHTE, CANNON, SAHLER and FERREBEE 1709
**Loken, H. F.,** and **Gordan, G. S.** Renal mechanisms in the production of hypercalcemia in hyperparathyroidism and breast cancer *1021
**Lombardo, Carlos R.** See LONG and LOMBARDO *1021
**Long, Robert T. L.** See BRAUNWALD, LONG and MORROW *990
—, and **Lombardo, Carlos R.** Hemodynamic observations on the hepatic circulation: Modifications produced by portacaval shunting *1021
**Lospalluto, Joseph.** See ZIFF and LOSPALLUTO *1057
**Lotspeich, W. D.** See VISHWAKARMA and LOTSPEICH 414
**Louria, Donald B.** See BLUMENFELD, KILBOURNE, LOURIA and ROGERS 199
—, **Blumenfeld, Herbert L., Ellis, John T., Kilbourne, Edwin D.,** and **Rogers, David E.** Studies on influenza in the pandemic of 1957–1958. II. Pulmonary complications of influenza 213
**Lovejoy, Frank W., Jr.** See STANFIELD, PERKINS, CONSTANTINE, LURIA, FINLAYSON, LOVEJOY and YU *1045
**Lovice, Harris.** See CONNOR, CAREY, DAVIS and LOVICE *997
**Lowe, C. U., Sokal, J. E., Doray, B. H.,** and **Sarcione, E. J.** Biochemical studies and specific therapy in hepatic glycogen storage disease *1021
**Lowenstein, Louis, Cooper, Bernard A., Brunton, Lauder,** and **Gartha, Susan.** Antibodies in human and rabbit sera to hog intrinsic factor preparations *1022
**Lowry, Paul T.** See GILBERTSEN, LOWRY, HAWKINSON and WATSON 1166
**Lozano, Rodolfo.** See GIEBISCH and LOZANO 843
**Lubowitz, Herbert.** See BRICKER, DEWEY, LUBOWITZ, STOKES and KIRKENSGAARD 516
**Luria, Milton.** See STANFIELD, PERKINS, CONSTANTINE, LURIA, FINLAYSON, LOVEJOY and YU *1045
**Lynn, W. S., Jr.,** and **Brown, R. H.** The uptake of fatty acids by mitochondria and adipose tissue *1022

## Mc

**McCall, Mary Sue.** See UNGER, MADISON, MCCALL and LANZ *1050
**McCarthy, Elizabeth A.** See ISSELBACHER and MCCARTHY 645
**McCarty, W. Ross.** See JOHNSON and MCCARTY 1627
**McCollum, Robert W.,** and **Isacson, Peter.** The hemagglutination test in hepatic diseases *1022
**McGarry, Eleanor.** See FISHMAN, MCGARRY and BECK *1004
**McIntosh, Henry D., Gleason, William L., Miller, D. Edmond,** and **Bacos, James M.** Circulatory dynamics in polyostotic fibrous dysplasia (Albright's syndrome) *1023

## M

**Mackie, Joseph E.** See STORMONT and MACKIE *1047
**Madison, Leonard L., Combes, Burton, Strickland, William,** and **Adams, Reuben.** Effect of the slow infusion of glucagon-free insulin on the hepatic output of glucose in dogs with portacaval shunts *1023
—. See UNGER, MADISON, MCCALL and LANZ *1050
**Maffly, Roy H.** See LAMDIN, MAFFLY, HAYS and LEAF *1019
**Maher, John F.** See SCHREINER, MAHER and MARC-AURELE *1040
**Mahler, Robert.** See SCHMID and MAHLER *1040
—. See SCHMID and MAHLER 2044
**Mandel, William, Heaton, Angeline D., Russell, William F., Jr.,** and **Middlebrook, Gardner.** Combined

drug treatment of tuberculosis. II. Studies of antimicrobially-active isoniazid and streptomycin serum levels in adult tuberculous patients 1356
**Manfredi, F.** See MURDAUGH, SIEKER and MANFREDI 834
**Manitius, Andrezej.** See EPSTEIN, BECK, CARONE, LEVITIN and MANITIUS 1214
**Marc-Aurele, Julien.** See SCHREINER, MAHER and MARC-AURELE *1040
**Marden, Ethel.** See PIPBERGER, TABACK, MARDEN, MASON and FREIS *1031
**Marinetti, Guido.** See WATERHOUSE and MARINETTI *1053
**Marks, Paul A.** See BISHOP and MARKS 668
—, and **Gross, Ruth T.** Further characterization of the enzymatic defect in erythrocyte glucose-6-phosphate dehydrogenase deficiency: A genetically determined trait *1023
—, and **Gross, Ruth T.** Erythrocyte glucose-6-phosphate dehydrogenase deficiency: Evidence of differences between Negroes and Caucasians with respect to this genetically determined trait 2253
**Marshall, G. J.** See BIERMAN, KELLY, MARSHALL and BYRON *988
**Marshall, Hiram W.** See BROTMACHER, MARSHALL, CHEESMAN and DONALD *992
**Martin, Christopher M.,** and **Jandl, James H.** Inhibition of virus multiplication by transferrin *1024
**Martin, M. Mencer.** Combined anterior pituitary and neurohypophyseal insufficiency. Studies of body fluid spaces and renal function 882
**Martin, Margaret P.** See KNIGHT, HEMMERLY, MARTIN and WHITE *1018
**Mason, Henry L.** See PIPBERGER, TABACK, MARDEN, MASON and FRIES *1031
**Masouredis, S. P.** Reaction of I-131 trace-labeled human anti-$Rh_0$ (D) with red cells 279
—. The relationship between genotype and $Rh_0$ (D) antigen sites on the red blood cell *1024
**Mauer, Alvin M., Athens, John W., Ashenbrucker, Helen,** and **Cartwright, George E.** *In vitro* labeling of granulocytes with $DFP^{32}$ *1025
**Maxwell, George M.** See ROWE, MAXWELL, CASTILLO and CRUMPTON *1037
—. See ROWE, MAXWELL, CASTILLO, FREEMAN and CRUMPTON 2154
**Maxwell, Morton H.** See KLEEMAN, BERNSTEIN, DOWLING, KOPLOWITZ and MAXWELL *1018
**Meakin, J. William.** See NELSON and MEAKIN *1028
**Meilman, Edward.** See KURTZ, HOLTZMAN and MEILMAN 902
**Melby, James C.** Assessment of adrenocorticotropic activity with bacterial pyrogen in hypopituitary states *1025
**Mele, Rose H.** See STEFANINI, PIOMELLI and MELE *1045
**Mellinkoff, Sherman M.** See MENA, BENNETT and MELLINKOFF *1025
**Mena, Ismael, Bennett, Leslie R.,** and **Mellinkoff, Sherman M.** Hemodynamic patterns in portal cirrhosis determined by external scintillation detection *1025
**Merchant, William R.** See LEWIS and MERCHANT 1924
**Merlis, Jerome K.** See BORGES, MERLIS and BESSMAN 715
**Merrill, John P.** See FRANKLIN, NIALL and MERRILL *1005
—. See KUNIN, REES, MERRILL and FINLAND 1487
**Merritt, Francis L., Jr.** See BOGDONOFF, WEISSLER, MERRITT, HARLAN and ESTES *989
**Meschia, Giacomo.** See HELLEGERS, METCALFE, HUCKABEE, MESCHIA, PRYSTOWSKY and BARRON *1010
**Messer, Joseph V.** See GORLIN, BRACHFELD, TURNER and MESSER *1007
—. See GORLIN, BRACHFELD, TURNER, MESSER and SALAZAR 2144
**Metcalfe, James.** See HELLEGERS, METCALFE, HUCKABEE, MESCHIA, PRYSTOWSKY and BARRON *1010
**Metcoff, Jack, Frenk, Silvestre,** and **Antonowicz, Irena.** Relation of intracellular ions to certain carbohydrate metabolites and energy sequences in kwashiorkor *1025
**Middlebrook, Gardner.** See COHN, MIDDLEBROOK and RUSSELL 1349
—. See MANDEL, HEATON, RUSSELL and MIDDLEBROOK 1356
—. See RUSSELL, KASS, HEATON, DRESSLER and MIDDLEBROOK 1366
—. See HEATON, RUSSELL, DENST and MIDDLEBROOK 1376
**Migeon, Claude J.** See WALL and MIGEON 611
—, **Wall, Patricia E.,** and **Bertrand, Jean.** Some aspects of the metabolism of 16-$C^{14}$-estrone in normal individuals 619
—. See BLIZZARD, LIDDLE, MIGEON and WILKINS 1442
**Miller, Aaron,** and **Sullivan, John F.** Identification of the vitamin $B_{12}$ binding protein of normal and chronic myelogenous leukemia serum *1026
—, and **Sullivan, John F.** Electrophoretic studies of the vitamin $B_{12}$-binding protein of normal and chronic myelogenous leukemia serum 2135
**Miller, D. Edmond.** See MCINTOSH, GLEASON, MILLER and BACOS *1023
**Miller, R. Drew.** See LILLINGTON, FOWLER, MILLER and HELMHOLZ 2026
**Mills, Ivor H.** See BARTTER, MILLS and GANN *986
**Milnor, William R.** See JOSE and MILNOR 915
**Mirsky, I. Arthur, Perisutti, Gladys,** and **Davis, Neil C.** The destruction of glucagon, adrenocorticotropin and somatotropin by human blood plasma 14
**Mitchell, Jere.** See LINDEN, MITCHELL and SARNOFF *1020
—. See CHAPMAN, BAKER and MITCHELL 1202
**Mitchell, Marvin L.** See MOORE, MITCHELL and CHALMERS 1222
**Mitchell, Ross G.,** and **Cass, Rosemary.** Histamine and 5-hydroxytryptamine in the blood of infants and children 595
**Mogabgab, William J.** See JACKSON, DOWLING and MOGABGAB *1014
**Moloney, Peter J.** See EZRIN and MOLONEY *1002
**Money, William L.** See SONENBERG and MONEY *1044
**Moore, Edward.** See RALL, MOORE, TAYLOR and ZUBROD *1032
**Moore, Edward W., Mitchell, Marvin L.,** and **Chalmers, Thomas C.** Variability in absorption of insulin-$I^{131}$ in normal and diabetic subjects after subcutaneous and intramuscular injection 1222
**Moore, Francis D.** See GOLD, SMITH and MOORE 2238
**Morell, Anatol G.** See STERNLIEB, MORELL and SCHEINBERG *1046

**Morgan, Francis M.** See WATTEN, MORGAN, SONGKHLA, VANIKIATI and PHILLIPS 1879
**Morgan, H. E., Regen, D. M.,** and **Park, C. R.** Effect of insulin and anaerobiosis on the membrane transport and intracellular metabolism of glucose in diabetic muscle *1026
**Morgan, H. Gemmell.** See THOMAS, MORGAN, CONNOR, HADDOCK, BILLS and HOWARD 1078
**Morledge, John H.** See COBB, BRUCE and MORLEDGE *995
**Morrin, Peter A. F.** See BRICKER, MORRIN, KIME, SCHULTZE and KLEIN *990
**Morris, Charles E.** See UZMAN, BERING and MORRIS 1756
**Morrison, Ashton B.** The volume of distribution of lactose in the body fluids and the renal clearance of lactose *1027
—. The distribution of intravenously-injected inulin in the fluids of the nervous system of the dog and rat 1769
**Morrow, Andrew G.** See BRAUNWALD, LONG and MORROW *990
**Morse, Stephen I.** See COHN and MORSE *996
**Moss, William T.** See SWEANY, MOSS and HADDY 587
**Muehrcke, Robert C., Pollak, Victor E.,** and **Bonting, Sjoerd L.** Quantitative analyses of enzymes in glomeruli and renal tubular cells *1027
**Muenster, Joseph J.** See GRAETTINGER, MUENSTER, SELVERSTONE and CAMPBELL 1316
**Muirhead, E. E., Stirman, J. A.,** and **Jones, Frances.** Renal autoexplantation and a functional characterization of nonexcretory renal tissue *1027
**Muller-Eberhard, H. J.** See KUNKEL, FRANKLIN and MULLER-EBERHARD 424
**Mulrow, Patrick J.,** and **Cohn, George L.** Corticosteroid synthesis and release by human adrenal slices *1028
**Murdaugh, H. V., Jr., Sieker, H. O.,** and **Manfredi, F.** Effect of altered intrathoracic pressure on renal hemodynamics, electrolyte excretion and water clearance 834

N

**Nadas, Alexander S.** See HOFFMAN, RUDOLPH and NADAS *1012
**Necheles, Thomas,** and **Beutler, Ernest.** The effect of triiodothyronine on the oxidative metabolism of erythrocytes. I. Cellular studies 788
**Nelson, Don H.,** and **Meakin, J. William.** A new clinical entity in patients adrenalectomized for Cushing's syndrome *1028
—. See AUGUST and NELSON 1964
**Nemes, Marjorie M.** See TAMM and NEMES *1047
**Newton, Margaret.** See WOODS, WELT, HOLLANDER and NEWTON *1056
**Niall, John F.** See FRANKLIN, NIALL and MERRILL *1005
**Nims, Robert G.** See DALY, CALABRESI, NIMS and GRAY *998
**Noe, Frances E.** See LEWIS, LIN, NOE and HAYFORD-WELSING 2073
**Noyes, Ward D.** See GARBY and NOYES 1479
**Nugent, C. A.,** and **Tyler, F. H.** The renal excretion of uric acid in patients with gout and in nongouty subjects 1890

O

**Odell, Gerard B.** Studies in kernicterus. I. The protein binding of bilirubin 823
**Ohlson, Margaret A.** See HODGES, BEAN, OHLSON and BLEILER 1421
**Okada, Robert H.** See BRILLER and OKADA *990
**Oken, Donald E., Whittembury, Guillermo, Windhager, Erich E., Schatzmann, Hans J.,** and **Solomon, Arthur K.** Active sodium transport by the proximal tubule of necturus kidney *1029
**Olhagen, Börje.** See CARLSON and OLHAGEN 854
**Olson, Robert E.** See GURSEY, VESTER and OLSON *1008
**Oratz, M.** See ROTHSCHILD, DAVID, ORATZ and SCHREIBER 2224
**Orloff, Jack,** and **Davidson, Douglas G.** The mechanism of potassium excretion in the chicken 21
—. See RECTOR and ORLOFF 366
**Osborne, W.** See BALTCH, OSBORNE, BUNN, CANARILE and HASSIRDJIAN *985
**O'Shaughnessy, Patrick J.** See DEISS, O'SHAUGHNESSY and WYNN 334
**O'Toole, James J.** See PETERSON, O'TOOLE, KIRKENDALL and KEMPTHORNE 1644

P

**Pachuta, Bernice.** See KYLE, WERDEIN, CANARY and PACHUTA 1475
**Park, C. R.** See MORGAN, REGEN and PARK *1026
**Parsons, David W.** See HILLS, PARSONS, ROSENTHAL and KIEM *1011
**Pechet, Maurice M., Bowers, Blair,** and **Bartter, Frederic C.** Metabolic studies with a new series of 1,4-diene steroids. I. Effects in Addisonian subjects of prednisone, prednisolone, and the 1,2-dehydro analogues of corticosterone, desoxycorticosterone, 17-hydroxy-11-desoxycorticosterone, and 9α-fluorocortisol 681
—, **Bowers, Blair,** and **Bartter, Frederic C.** Metabolic studies with a new series of 1,4-diene steroids. II. Effects in normal subjects of prednisone, prednisolone, and 9α-fluoroprednisolone 691
—, and **Carroll, Evelyn L.** Studies of the influences of steroid hormones on the renal excretion of sodium *1029
**Perisutti, Gladys.** See MIRSKY, PERISUTTI and DAVIS 14
**Perkins, Peter.** See STANFIELD, PERKINS, CONSTANTINE, LURIA, FINLAYSON, LOVEJOY and YU *1045
**Perkoff, G. T., Schwartz, H. C., Hill, R. L.,** and **Tyler, F. H.** Studies of human myoglobin *1029
—, **Schwartz, Herbert C.,** and **Tyler, Frank H.** Incorporation of radioiron into myoglobin in an *in vitro* system 1599
**Perry, Elizabeth F.** See PERRY and PERRY 1452
**Perry, H. Mitchell, Jr.,** and **Perry, Elizabeth F.** Normal concentrations of some trace metals in human urine: Changes produced by ethylenediaminetetraacetate 1452
**Pert, James H., Davidson, Murray, Almy, Thomas P.,** and **Sleisenger, Marvin H.** Esophageal catheterization studies. I. The mechanism of swallowing in normal subjects with particular reference to the vestibule (esophago-gastric sphincter) 397

—. See SLEISENGER, LAW, SMITH, PERT and LEWIS 2119
**Pesch, LeRoy A., Segal, Stanton,** and **Topper, Yale J.** Steroid effects on galactose metabolism *1030
**Peterson, Ann S.** See VANAMEE, LAWRENCE, LEVIN, PETERSON and RANDALL *1051
**Peterson, Lysle H.,** and **Jensen, Roderick E.** The physical properties of arteries and their variation *in vivo* *1030
**Peterson, Malcolm L.** See HIRSCH, FARQUHAR, PETERSON and STOFFEL *1011
**Peterson, Ralph E.** See SLEISENGER, RICHARD, KOWLESSAR, CLARKSON, THOMPSON and PETERSON *1043
—. See YANKOPOULOS, DAVIS, KLIMAN and PETERSON 1278
**Peterson, Richard E., O'Toole, James J.,** and **Kirkendall, Walter M.** The variability of extracellular fluid space (sucrose) in man during a 24 hour period. With an appendix: An examination of a sequence of randomized errors by the Monte Carlo method, by **Oscar Kempthorne** 1644
**Phillips, Gerald B.** The phospholipid composition of human serum lipoprotein fractions separated by ultracentrifugation 489
**Phillips, Robert A.** See WATTEN, MORGAN, SONGKHLA, VANIKIATI and PHILLIPS 1879
**Pierce, John A.** See HEFLEY and PIERCE *1009
**Pierce, Lawrence E.** See WESTERMAN, PIERCE and JENSEN *1054
**Piomelli, Sergio,** and **Brooke, Marcus S.** Hematological studies of X-irradiated rabbits *1030
—. See STEFANINI, PIOMELLI and MELE *1045
**Pipberger, Hubert V., Taback, Leonard, Marden, Ethel, Mason, Henry L.,** and **Freis, Edward D.** Application of automatic processing techniques to medical data. I. The electrocardiogram *1031
**Pirofsky, Bernard.** The use of bromelin in the detection of erythrocyte antibodies *1031
**Plentl, Albert A.** See FRIEDMAN, GRAY, HUTCHINSON and PLENTL 961
—. See HUTCHINSON, GRAY, ALVAREZ, CALDEYRO-BARCIA, KAPLAN and LIND 971
**Polimeros, Demetra.** See LEVITT, LEVY and POLIMEROS 463
**Pollak, Victor E.** See MUEHRCKE, POLLAK and BONTING *1027
**Pollycove, Myron.** Bone marrow hemolysis in anemia. *1031
**Popenoe, Edwin A.** See SCHWARTZ, FONG, POPENOE, SILVER and SCHOESSLER *1041
**Popper, Hans.** See SCHAFFNER and POPPER *1039
**Portwood, Richard M., Seldin, Donald W., Rector, Floyd C., Jr.,** and **Cade, Robert.** The relation of urinary $CO_2$ tension to bicarbonate excretion 770
—. See SELDIN, PORTWOOD, RECTOR and CADE 1663
**Prystowsky, Harry.** See HELLEGERS, METCALFE, HUCKABEE, MESCHIA, PRYSTOWSKY and BARRON *1010
**Puletti, Ernesto J.** See TEXTER, LAZAR, PULETTI and VANTRAPPEN *1048

## R

**Raben, M. S.,** and **Hollenberg, C. H.** Effect of growth hormone on plasma fatty acids 484
—, and **Hollenberg, C. H.** Uptake and release of fatty acids by adipose tissue *1032
**Rabin, David D.** See ROSENMAN, BREALL, BYERS and RABIN 1434
**Rader, Bertha.** See SOBOL, KESSLER, RADER and EICHNA 557
**Raisz, Lawrence G.,** and **Scheer, Robert L.** Studies on the renal concentrating mechanism. II. Effect of small acute changes in solute excretion 1
—, **Au, William Y. W.,** and **Scheer, Robert L.** Studies on the renal concentrating mechanism. III. Effect of heavy exercise 8
—, **Au, William Y. W.,** and **Scheer, Robert L.** Studies on the renal concentrating mechanism. IV. Osmotic diuresis 1725
**Rall, David P.** See STABENAU, WARREN and RALL 373
—, **Moore, Edward, Taylor, Nathan,** and **Zubrod, Charles G.** Studies on the blood-cerebrospinal fluid barrier in man *1032
**Rall, Joseph E.** See LEWALLEN, BERMAN and RALL 66
—. See LEWALLEN, RALL and BERMAN 88
**Ramos, Oswaldo.** See JAVITT, WHEELER, BAKER and RAMOS *1015
—. See WHEELER and RAMOS *1055
**Ramot, Bracha, Szeinberg, Aryeh, Adam, Avinoam, Sheba, Chaim,** and **Gafni, Dora.** A study of subjects with erythrocyte glucose-6-phosphate dehydrogenase deficiency: Investigation of platelet enzymes 1659
—, **Fisher, Sharon, Szeinberg, Aryeh, Adam, Avinoam, Sheba, Chaim,** and **Gafni, Dora.** A study of subjects with erythrocyte glucose-6-phosphate dehydrogenase deficiency. II. Investigation of leukocyte enzymes 2234
**Randall, Henry T.** See VANAMEE, LAWRENCE, LEVIN, PETERSON and RANDALL *1051
**Ranney, Helen M.,** and **Kono, Paul.** Studies of the incoporation of $Fe^{59}$ into normal and abnormal hemoglobins 508
**Rattenborg, Christen.** See GERST, RATTENBORG and HOLADAY 524
**Rector, Floyd C., Jr.,** and **Orloff, Jack.** The effect of the administration of sodium bicarbonate and ammonium chloride on the excretion and production of ammonia. The absence of alterations in the activity of renal ammonia-producing enzymes in the dog 366
—. See PORTWOOD, SELDIN, RECTOR and CADE 770
—. See SELDIN, PORTWOOD, RECTOR and CADE 1663
**Reed, Claude F.** Studies of *in vivo* and *in vitro* exchange of erythrocyte and plasma phospholipids *1032
**Rees, Searle B.** See KUNIN, REES, MERRILL and FINLAND 1487
**Reeves, John T., Roberts, James E., Grover, Robert F., Filley, Giles F.,** and **Blount, S. Gilbert, Jr.** The cardiac output in normal resting man *1033
**Reeves, T. Joseph, Shourie, Leela, Hefner, Lloyd,** and **Taylor, S. H.** Hemodynamic relationships of the anacrotic slope of the central aortic pressure pulse in man at rest and during exercise *1033
**Regan, Timothy J., Christensen, Raymond C., Wada, Takashi, Talmers, Frederick N.,** and **Hellems, Harper K.** Myocardial response to acetyl strophanthidin in congestive heart failure: A study of electrolytes and carbohydrate substrates 306
—, **Binak, Kenan, Gordon, Seymour, DeFazio, Valentino,** and **Hellems, Harper K.** The modification of myocardial blood flow and oxygen consumption dur-

ing postprandial lipemia and heparin-induced lypolysis *1033
—, **DeFazio, Valentino, Binak, Kenan,** and **Hellems, Harper K.** Norepinephrine induced pulmonary congestion in patients with aortic valve regurgitation 1564
**Regen, D. M.** See MORGAN, REGEN and PARK *1026
**Reid, Maria B.** See RUDMAN, SEIDMAN and REID *1038
**Reiss, Eric.** See FIELD and REISS *1004
**Rejal, Habib.** See ABRAMSON, TUCK, BELL, BURNETT and REJAL 1126
**Relman, Arnold S.** See SCHWARTZ, HALL, HAYS and RELMAN 39
—, and **Lemann, Jacob, Jr.** Endogenous fixed acid production and its relation to renal acid excretion *1034
—. See LAMBIE, RELMAN and SCHWARTZ 1538
—. See LEMANN and RELMAN 2215
**Repplinger, Evalyn.** See STOLOFF, HAURANI and REPPLINGER *1046
**Reynolds, Edward S.,** and **Thiers, Ralph E.** Carbon tetrachloride poisoning, a mitochondrial lesion *1034
**Reynolds, Telfer B., Lanman, Hilda,** and **Tupikova, Natalia.** Tests of phosphate metabolism in hyperparathyroidism *1034
**Rich, Clayton, Bierman, Edwin L.,** and **Schwartz, Irving L.** Plasma nonesterified fatty acids in hyperthyroid states 275
**Richard, Jack.** See SLEISENGER, RICHARD, KOWLESSAR, CLARKSON, THOMPSON and PETERSON *1043
**Richards, John B., Dowling, J. Thomas,** and **Ingbar, Sidney H.** Alterations in the plasma transport of thyroxine in sick patients and their relation to the abnormality in Graves' disease *1035
**Richardson, David W.** See DOYLE, RICHARDSON and HARDIE *1000
**Rizack, M. A.** See DOLE, JAMES, WEBB, RIZACK and STURMAN 1544
**Robbins, J.** See BLUMBERG and ROBBINS *988
—. See BEIERWALTES and ROBBINS 1683
**Roberts, James E.** See REEVES, ROBERTS, GROVER, FILEY and BLOUNT *1033
**Roberts, Kathleen E.** See JOHNSON and ROBERTS *1015
**Robin, Eugene D., Bromberg, Philip A.,** and **Forkner, Claude E., Jr.** Diffusion characteristics of ammonia gas with special reference to intracellular acid-base relations *1035
—, **Travis, David M., Julian, Desmond G.,** and **Boshell, Buris R.** Physiologic sleep: I. Blood glucose regulation during sleep in normal and diabetic subjects 2229
**Rochester, Dudley.** See FRITTS, HARDEWIG, ROCHESTER and DURAND *1006
**Rogers, David E.** See BLUMENFELD, KILBOURNE, LOURIA and ROGERS 199
—. See LOURIA, BLUMENFELD, ELLIS, KILBOURNE and ROGERS 213
**Rogers, Richard.** See KINNEY, ZAREM and ROGERS *1017
**Rosen, Lawrence.** See GOODALL, KIRSHNER and ROSEN 707
**Rosenberg, I. N.** Zone electrophoretic studies of serum alkaline phosphatase 630
—, **Athans, J. C.,** and **Behar, A.** Effect of thyrotropin on inorganic iodine of the dog thyroid *1036
**Rosenfeld, R. S.,** and **Hellman, Leon.** The relation of plasma and biliary cholesterol to bile acid synthesis in man 1334
**Rosenman, Ray H.,** and **Byers, Sanford O.** Study of possible causal role of lipoprotein lipase deficiency in nephrotic hyperlipemia *1036
—, **Breall, William, Byers, Sanford O.,** and **Rabin, David D.** Hepatic metabolism of cholesterol in experimental nephrosis in rats 1434
**Rosenthal, Otto.** See HILLS, PARSONS, ROSENTHAL and KIEM *1011
**Ross, Joseph C., Frayser, Regina,** and **Hickam, John B.** A study of the mechanism by which exercise increases the pulmonary diffusing capacity for carbon monoxide 916
—, **Hickam, John B.,** and **Frayser, Regina.** The effect of changing cerebral blood flow on the response time of the respiratory center *1036
**Ross, Richard S.,** and **Hammond, John D. S.** The relationship between protein composition of serum and of edema fluid in heart failure *1037
**Ross, S. William,** and **Ebert, Richard V.** Microelectrophoresis of blood platelets and the effects of dextran 155
**Roston, Sidney,** and **Leight, Leonard.** A practical study of the air chamber model of the cardiovascular system 777
**Rothschild, M. A., Davis, A. L., Oratz, M.,** and **Schreiber, S. S.** Pulmonary transcapillary exchange of $Na^{24}$ and $P^{32}$-labeled phosphate in pulmonary emphysema 2224
**Rowe, George G.** See HOFFMAN and ROWE 138
—, **Maxwell, George M., Castillo, Cesar A.,** and **Crumpton, Charles W.** A study of cerebral hemodynamics and arteriovenous differences of glucose, lactate and pyruvate before and after eating *1037
—, **Maxwell, George M., Castillo, Cesar A., Freeman, D. J.,** and **Crumpton, Charles W.** A study in man of cerebral blood flow and cerebral glucose, lactate and pyruvate metabolism before and after eating 2154
**Rowe, Wallace P.** Quantitative studies of mouse polyoma (parotid tumor) virus infection *1037
**Rudman, Daniel, Seidman, Floyd,** and **Reid, Maria B.** Preparation of a lipemia-producing fraction from hog pituitary glands *1038
**Rudolph, Abraham M.** See HOFFMAN, RUDOLPH and NADAS *1012
**Russell, William F., Jr.** See COHN, MIDDLEBROOK and RUSSELL 1349
—. See MANDEL, HEATON, RUSSELL and MIDDLEBROOK 1356
—, **Kass, Irving, Heaton, Angeline D., Dressler, Sidney H.,** and **Middlebrook, Gardner.** Combined drug treatment of tuberculosis. III. Clinical application of the principles of appropriate and adequate chemotherapy to the treatment of pulmonary tuberculosis 1366
—. See HEATON, RUSSELL, DENST and MIDDLEBROOK 1376
**Ruszkowski, Marian, Baertl, Juan M.,** and **Gabuzda, George J.** Cysteinuria-like derangement of amino acid excretion in patients with hepatic cirrhosis given arginine intravenously *1038

S

**Saffran, Judith,** and **Kalant, Norman.** Mechanisms of hyperlipemia in experimental nephrosis 1717
**Sahler, Otto D.** See THOMAS, LOCHTE and SAHLER *1048
—. See THOMAS, LOCHTE, CANNON, SAHLER and FERREBEE 1709
**Salazar, Eduardo.** See GORLIN, BRACHFELD, TURNER, MESSER and SALAZAR 2144
**Salmon, William D., Jr.** Stimulation by growth hormone of sulfate uptake by cartilage of alloxan-diabetic, hypophysectomized rats *1038
**Sandberg, Avery A.** See SLAUNWHITE and SANDBERG 384
—, and **Slaunwhite, W. Roy, Jr.** Transcortin: A corticosteroid-binding protein of plasma. II. Levels in various conditions and the effects of estrogens 1290
**Sanders, Charles A.** See EARLEY and SANDERS 545
—. See FREINKEL, SANDERS, LEVINSON and ABELMANN *1005
**Sanford, Jay P., Barnett, Jack A.,** and **Gott, Cora.** The mechanism of the glycogenolytic action of bacterial endotoxin *1039
**Santos, Roberto F.** Sodium and water depletion and ammonia formation by the kidneys 193
**Sarcione, E. J.** See LOWE, SOKAL, DORAY and SARCIONE *1021
**Sarnoff, Stanley J.** See LINDEN, MITCHELL and SARNOFF *1020
**Sass-Kortsak, Andrew, Cherniak, Morris, Geiger, Douglas W.,** and **Slater, Robert J.** Observations on ceruloplasmin in Wilson's disease 1672
**Savitsky, J. Philip.** A change in the regulation of serum cholesterol induced by homologous and heterologous desoxyribonucleic acid *1039
**Schaffner, Fenton,** and **Popper, Hans.** Electron microscopy of drug-induced cholestatic jaundice *1039
**Scharff, Matthew.** See UHR and SCHARFF *1049
**Schatzmann, Hans J.** See OKEN, WHITTEMBURY, WINDHAGER, SCHATZMANN and SOLOMON *1029
**Scheer, Robert L.** See RAISZ and SCHEER 1
—. See RAISZ, AU and SCHEER 8
—. See RAISZ, AU and SCHEER 1725
**Scheinberg, I. Herbert.** See STERNLIEB, MORELL and SCHEINBERG *1046
**Schilling, Robert F.** See CALABRESI, EDWARDS and SCHILLING 2091
**Schmid, Karl.** See EARLE, HUTT, SCHMID and GITLIN 1412
**Schmid, Rudi,** and **Mahler, Robert.** Syndrome of muscular dystrophy with myoglobinuria: Demonstration of a glycogenolytic defect in muscle *1040
—, and **Mahler, Robert.** Chronic progressive myopathy with myoglobinuria: Demonstration of a glycogenolytic defect in the muscle 2044
**Schnabel, Truman G., Jr., Eliasch, Harald, Thomasson, Bengt,** and **Werkö, Lars.** The effect of experimentally induced hypervolemia on cardiac function in normal subjects and patients with mitral stenosis 117
**Schoessler, Mary Anne.** See SCHWARTZ, FONG, POPENOE, SILVER and SCHOESSLER *1041
**Schreiber, S. S.** See ROTHSCHILD, DAVIS and SCHREIBER 2224
**Schreiner, George E., Maher, John F.,** and **Marc-Aurele, Julien.** The dialysance of exogenous poisons and some common metabolites in the twin-coil artificial kidney *1040
**Schrier, Stanley L.** See KELLERMEYER, TARLOV, SCHRIER and CARSON *1016
**Schubart, Adalbert F.** The thermolabile inhibitor in the latex fixation test *1041
**Schultze, Raymond G.** See BRICKER, MORRIN, KIME, SCHULTZE and KLEIN *990
**Schwartz, Herbert C.** See PERKOFF, SCHWARTZ and TYLER 1599
**Schwartz, Irving L.** See RICH, BIERMAN and SCHWARTZ 275
—, **Fong, Conrad T. O., Popenoe, Edwin A., Silver, Lawrence,** and **Schoessler, Mary Anne.** Evidence for a covalent attachment of the antidiuretic hormone to its receptor site in the kidney *1041
**Schwartz, R. L.** See PERKOFF, SCHWARTZ, HILL and TYLER *1029
**Schwartz, Robert.** Drug induced immunological tolerance *1041
—, **Eisner, Anna,** and **Dameshek, William.** The effect of 6-mercaptopurine on primary and secondary immune responses 1394
**Schwartz, William B., Hall, Philip W., 3rd, Hays, Richard M.,** and **Relman, Arnold S.** On the mechanism of acidosis in chronic renal disease 39
—, **Bank, Norman,** and **Cutler, Robert W. P.** The influence of urinary ionic strength on phosphate $pK_2'$ and the determination of titratable acid 347
—, **Falbriard, Adrien,** and **Lemieux, Guy.** The kinetics of bicarbonate reabsorption during acute respiratory acidosis 939
—, **Lemieux, Guy,** and **Falbriard, Adrien.** The physiologic significance of renal bicarbonate reabsorption during acute respiratory alkalosis *1042
—. See LAMBIE, RELMAN and SCHWARTZ 1538
—, **Lemieux, Guy,** and **Falbriard, Adrien.** Renal reabsorption of bicarbonate during acute respiratory alkalosis 2197
**Schweinburg, F. B., Smiddy, F. G.,** and **Fine, J.** The granulocytopenic response in hemorrhagic shock 673
**Scott, K. G.** See WENNESLAND, BROWN, HOPPER, HODGES, GUTTENTAG, SCOTT, TUCKER and BRADLEY 1065
**Seegal, Beatrice C.** See KAYDEN, SEEGAL and HSU *1016
**Seegmiller, J. E.** See GRAYZEL and SEEGMILLER *1008
**Segal, Stanton,** and **Foley, Joseph B.** The metabolic fate of $C^{14}$ labeled pentoses in man 407
—. See PESCH, SEGAL and TOPPER *1030
**Seidman, Floyd.** See RUDMAN, SEIDMAN and REID *1038
**Seki, Masafumi, Field, Michael,** and **Chalmers, Thomas C.** Hormonal influence on iron absorption *1042
**Seldin, Donald W.** See PORTWOOD, SELDIN, RECTOR and CADE 770
—. See CARTER, SELDIN and TENG 949
—, **Portwood, Richard M., Rector, Floyd C., Jr.,** and **Cade, Robert.** Characteristics of renal bicarbonate reabsorption in man 1663
**Seligson, D., Bluemle, L. W., Jr., Webster, G. D., Jr., Senesky, D.** Organic acids in body fluids of the uremic patient *1042
**Selverstone, Louis A.** See GRAETTINGER, MUENSTER, SELVERSTONE and CAMPBELL 1316

**Senesky, D.** See SELIGSON, BLUEMLE, WEBSTER and SENESKY *1042
**Severseike, Odean.** See TOBIAN, CICH and SEVERSEIKE *1048
**Sha, Joanne.** See COHEN, HOLLAND, SHA and GOLDENBERG 1935
**Shafer, A. William,** and **Bartlett, Grant R.** Metabolic intermediates of the rabbit red blood cell during storage in acid-citrate-dextrose (ACD) and in ACD-inosine *1043
**Shafrir, Eleazar.** See BAXTER, GOODMAN and SHAFRIR *986
—. See VAUGHAN, STEINBERG and SHAFRIR *1051
**Shapiro, Alvin P., Braude, Abraham I.,** and **Siemienski, Jennie.** Hematogenous pyelonephritis in rats. IV. Relationship of bacterial species to the pathogenesis and sequelae of chronic pyelonephritis 1228
**Sharp, John Turner.** The effect of body position change on lung compliance in normal subjects and in patients with congestive heart failure 659
—. See CLEMENTS, SHARP, JOHNSON and ELAM 1262
**Sheba, Chaim.** See RAMOT, SZEINBERG, ADAM, SHEBA and GAFNI 1659
—. See RAMOT, FISHER, SZEINBERG, ADAM, SHEBA and GAFNI 2234
**Sherry, Sol, Lindemeyer, Robert I., Fletcher, Anthony P.,** and **Alkjaersig, Norma.** Studies on enhanced fibrinolytic activity in man 810
—. See FLETCHER, ALKJAERSIG and SHERRY *1005
—. See ALKJAERSIG, FLETCHER and SHERRY 1086
—. See FLETCHER, ALKJAERSIG and SHERRY 1096
—. See FLETCHER, SHERRY, ALKJAERSIG, SMYRNIOTIS and JICK 1111
**Shill, Otto S.** See BRAUER, SHILL and KREBS 2202
**Shourie, Leela.** See REEVES, SHOURIE, HEFNER and TAYLOR *1033
**Sieker, H. O.** See MURDAUGH, SIEKER and MANFREDI 834
**Siemienski, Jennie.** See SHAPIRO, BRAUDE and SIEMIENSKI 1228
**Silver, Lawrence.** See SCHWARTZ, FONG, POPENOE, SILVER and SCHOESSLER *1041
**Simmons, Richard L.** See JANDL, INMAN, SIMMONS and ALLEN 161
**Siperstein, Marvin D.** See WILSON and SIPERSTEIN 317
—, and **Guest, M. Joanne.** Studies on the homeostatic control of cholesterol synthesis *1043
**Sjoerdsma, Albert, Leeper, Lemuel C., Terry, Luther, L.,** and **Udenfriend, Sidney.** Studies on the biogenesis and metabolism of norepinephrine in patients with pheochromocytoma 31
**Slater, Robert J.** See SASS-KORTSAK, CHERNIAK, GEIGER and SLATER 1672
**Slaunwhite, W. Roy, Jr.,** and **Sandberg, Avery A.** Transcortin: A corticosteroid-binding protein of plasma 384
—. See SANDBERG and SLAUNWHITE 1290
**Sleisenger, Marvin H.** See PERT, DAVIDSON, ALMY and SLEISENGER 397
—, **Richard, Jack, Kowlessar, O. Dhodanand, Clarkson, Bayard, Thompson, David,** and **Peterson, Ralph E.** Effects of spirolactones on excretion of water and electrolytes, and on aldosterone metabolism in cirrhosis *1043
—, **Law, David H., Smith, Frederick W., Pert, James H.,** and **Lewis, Charles M.** Studies of colon contractility in dogs. I. Description of method and effect of parasympathomimetic agents and serotonin 2119
**Small, Walter.** See BALDINI, COSTEA and SMALL *985
**Smiddy, F. G.** See SCHWEINBURG, SMIDDY and FINE 673
**Smith, Frederick W.** See SLEISENGER, LAW, SMITH, PERT and LEWIS 2119
**Smith, Homer W.** See HULET and SMITH 1972
**Smith, Lloyd H., Jr.,** and **Baker, Faith A.** Pyrimidine metabolism in man. I. The biosynthesis of orotic acid 798
—, and **Baker, Faith.** Pyrimidine studies in pernicious anemia *1044
**Smith, Louis L.** See GOLD, SMITH and MOORE 2238
**Smith, Maureen.** See COPPAGE, ISLAND, SMITH and LIDDLE 2101
**Smyrniotis, Fotios E.** See FLETCHER, SHERRY, ALKJAERSIG, SMYRNIOTIS and JICK 1111
**Sobol, Bruce J., Kessler, Richard H., Rader, Bertha,** and **Eichna, Ludwig W.** Cardiac, hemodynamic and renal functions in congestive heart failure during induced peripheral vasodilatation; relationship to Starling's law of the heart in man 557
**Sokal, J. E.** See LOWE, SOKAL, DORAY and SARCIONE *1021
**Solomon, Arthur K.** See OKEN, WHITTEMBURY, WINDHAGER, SCHATZMANN and SOLOMON *1029
**Sonenberg, Martin,** and **Money, William L.** Inhibition of growth hormone activity with modified growth hormone preparations *1044
**Songkhla, Yachai Na.** See WATTEN, MORGAN, SONGKHLA, VANIKIATI and PHILLIPS 1879
**Sorensen, Dale K.** See JACKSON, SORENSEN, CRONKITE, BOND and FLIEDNER 1689
**Spaet, Theodore H.,** and **Cintron, Jose.** On the nature and properties of blood thromboplastin *1044
**Spoont, Stanley.** See FIELD, WEINBERG, JOHNSON and SPOONT *1003
**Squires, Russell D.,** and **Huth, Edward J.** Experimental potassium depletion in normal human subjects. I. Relation of ionic intakes to the renal conservation of potassium 1134
—. See HUTH, SQUIRES and ELKINTON 1149
**Stabenau, James R., Warren, Kenneth S.,** and **Rall, David P.** The role of pH gradient in the distribution of ammonia between blood and cerebrospinal fluid, brain and muscle 373
**Staib, Ingolf.** See EICH, STAIB and ENERSON 2035
**Stanbury, John B.** See LASSITER and STANBURY 784
**Stanfield, C. Alpheus, Perkins, Peter, Constantine, Herbert, Luria, Milton, Finlayson, James, Lovejoy, Frank W., Jr.,** and **Yu, Paul N.** The hemodynamic effects of methoxamine in mitral valve disease *1045
**Staub, Max C.** See DINGMAN, GAITAN and STAUB *999
**Stefanini, Mario.** See TURPINI and STEFANINI 53
—, **Piomelli, Sergio,** and **Mele, Rose H.** Antigenicity of human vascular endothelium and its relationship to the pathogenesis of vasculitis *1045
**Steinberg, Daniel.** See VAUGHAN, STEINBERG and SHAFRIR *1051
**Sterling, Kenneth.** $I^{131}$-albumin turnover studies in Cushing's syndrome *1045

**Sternlieb, Irmin, Morell, Anatol G.,** and **Scheinberg, I. Herbert.** Detection of the heterozygous carrier of the Wilson's disease gene *1046
**Stirman, J. A.** See MUIRHEAD, STIRMAN and JONES *1027
**Stoffel, Wilhelm.** See HIRSCH, FARQUHAR, PETERSON and STOFFEL *1011
**Stokes, James.** See BRICKER, DEWEY, LUBOWITZ, STOKES and KIRKENSGAARD 516
**Stollerman, Gene H.** See BERNHARD and STOLLERMAN 1942
**Stoloff, Irwin L., Haurani, Farid,** and **Repplinger, Evalyn.** The effects of total body irradiation on the production of antibody in man *1046
**Stormont, James M.,** and **Mackie, Joseph E.** An abnormality of nonesterified fatty acid metabolism in patients with cirrhosis *1047
**Strandjord, Paul E., Thomas, Kenneth E.,** and **White, Laurens P.** Studies on isocitric and lactic dehydrogenases in experimental myocardial infarction 2111
**Strickland, William.** See MADISON, COMBES, STRICKLAND and ADAMS *1023
**Sturman, M. F.** See DOLE, JAMES, WEBB, RIZACK and STURMAN 1544
**Sullivan, John F.** See MILLER and SULLIVAN *1026
—. See MILLER and SULLIVAN 2135
**Swan, H. J. C., Beck, Walter,** and **Burchell, Howard B.** Pulmonary vascular resistance following closure of the atrial septal defect in patients with severe pulmonary hypertension *1047
**Sweany, Stanford, K., Moss, William T.,** and **Haddy, Francis J.** The effects of chest irradiation on pulmonary function 587
**Szeinberg, Aryeh.** See RAMOT, SZEINBERG, ADAM, SHEBA and GAFNI 1659
—. See RAMOT, FISHER, SZEINBERG, ADAM, SHEBA and GAFNI 2234

## T

**Taback, Leonard.** See PIPBERGER, TABACK, MARDEN, MASON and FREIS *1031
**Talmers, Frederick N.** See REGAN, CHRISTENSEN, WADA, TALMERS and HELLEMS 306
**Tamm, Igor,** and **Nemes, Marjorie M.** Selective inhibition of poliovirus multiplication *1047
**Tarlov, Alvin R.** See KELLERMEYER, TARLOV, SCHRIER and CARSON *1016
**Taylor, Nathan.** See RALL, MOORE, TAYLOR and ZUBROD *1032
**Taylor, S. H.** See REEVES, SHOURIE, HEFNER and TAYLOR *1033
**Taylor, S. M.** See KERBY and TAYLOR 1059
**Teng, H. C.** See CARTER, SELDIN and TENG 949
**Tenney, S. M.** See VALTIN, WILSON and TENNEY *1050
**Terry, Luther L.** See SJOERDSMA, LEEPER, TERRY and UDENFRIEND 31
**Texter, E. Clinton, Jr., Lazar, Harold P., Puletti, Ernesto J.,** and **Vantrappen, Gaston.** The characteristic pattern of esophageal dysfunction due to hiatal hernia demonstrated by fluorocinematography and simultaneous pressure recording *1048
**Thiers, Ralph E.** See REYNOLDS and THIERS *1034
**Thomas, E. Donnall, Lochte, Harry L., Jr.,** and **Sahler, Otto D.** Treatment of acute leukemia by supra-lethal whole-body irradiation and isologous marrow transplantation *1048
—, **Lochte, Harry L., Jr., Cannon, Joe H., Sahler, Otto D.,** and **Ferrebee, Joseph W.** Supralethal whole body irradiation and isologous marrow transplantation in man 1709
**Thomas, Kenneth E.** See STRANDJORD, THOMAS and WHITE 2111
**Thomas, William C., Jr., Morgan, H. Gemmell, Connor, Thomas B., Haddock, Lillian, Bills, Charles E.,** and **Howard, John E.** Studies of antiricketic activity in sera from patients with disorders of calcium metabolism and preliminary observations on the mode of transport of vitamin D in human serum 1078
**Thomasson, Bengt.** See SCHNABEL, ELIASCH, THOMASSON and WERKÖ 117
**Thompson, David.** See SLEISENGER, RICHARD, KOWLESSAR, CLARKSON, THOMPSON and PETERSON *1043
**Tobian, Louis, Tomboulian, Alice,** and **Janecek, Jeannette.** The effect of high perfusion pressures on the granulation of juxtaglomerular cells in an isolated kidney 605
—, **Cich, John,** and **Svereseike, Odean.** Abnormal permeability of glomerular capillaries in hypertension and diabetes *1048
**Tomboulian, Alice.** See TOBIAN, TOMBOULIAN and JANECEK 605
**Tomita, Kenkichi.** See ALBRIGHT, TOMITA and LARSON *984
**Topper, Yale J.** See PESCH, SEGAL and TOPPER *1030
**Travis, David M.** See ROBIN, TRAVIS, JULIAN and BOSHELL 2229
**Troen, Philip.** Synthesis and metabolism of estrogens by perfused human placentas *1049
**Trout, D. L.** See ESTES, BOGDONOFF, FRIEDBERG, HARLAN and TROUT 2131
**Tschudy, Donald P., Bacchus, Habeeb, Weissman, Sherman, Watkin, Donald M., Eubanks, Marjoria,** and **White, Julius.** Studies of the effect of dietary protein and caloric levels on the kinetics of nitrogen metabolism using $N^{15}$ L-aspartic acid 892
**Tuck, Samuel, Jr.** See ABRAMSON, TUCK, BELL, BURNETT and REJAL 1126
**Tucker, I. N.** See WENNESLAND, BROWN, HOPPER, HODGES, GUTTENTAG, SCOTT, TUCKER and BRADLEY 1065
**Tupikova, Natalia.** See REYNOLDS, LANMAN and TUPIKOVA *1034
**Turino, Gerard M.** See GOLDRING, TURINO, COHEN, JAMESON and FISHMAN *1007
—, **Brandfonbrener, M.,** and **Fishman, A. P.** The effect of changes in ventilation and pulmonary blood flow on the diffusing capacity of the lung 1186
**Turner, John D.** See GORLIN, BRACHFELD, TURNER and MESSER *1007
—. See GORLIN, BRACHFELD, TURNER, MESSER and SALAZAR 2144
**Turpini, Rinaldo,** and **Stefanini, Mario.** The nature and mechanism of the hemostatic breakdown in the course of experimental hemorrhagic shock 53
**Tyler, F. H.** See PERKOFF, SCHWARTZ, HILL and TYLER *1029
—. See PERKOFF, SCHWARTZ and TYLER 1599
—. See NUGENT and TYLER 1890

U

**Udenfriend, Sidney.** See SJOERDSMA, LEEPER, TERRY and UDENFRIEND 31

**Uhr, Jonathan W.,** and **Scharff, Matthew.** The effect of X-radiation upon delayed hypersensitivity and antibody formation in guinea pigs *1049

**Ulmer, David D., Wacker, Warren E. C.,** and **Vallee, Bert L.** Magnesium deficiency tetany in man *1049

**Ulstrom, Robert A.,** and **Colle, E.** Adrenal cortical function in the newborn period *1050

**Unger, Roger H., Madison, Leonard L., McCall, Mary Sue,** and **Lanz, Henry.** Demonstration of a relationship between insulin binding and insulin action in the peripheral tissues of normal man *1050

**Uzman, L. Lahut, Bering, Edgar A., Jr.,** and **Morris, Charles E.** The neuraminic acid content of cerebrospinal fluid as affected by neurological diseases 1756

V

**Vallee, Bert L.** See ULMER, WACKER and VALLEE *1049

**Valtin, H., Wilson, I. D.,** and **Tenney, S. M.** The role of the left atrial stretch receptor mechanism in carbon dioxide diuresis *1050

**Vanamee, Parker, Lawrence, Walter, Jr., Levin, Sam, Peterson, Ann S.,** and **Randall, Henry T.** The effect of high carbohydrate intake and of hydrochloric acid administration on fat absorption in gastrectomized patients *1051

**VanderLaan, W. P.,** and **Cassidy, Carl.** The thyroid suppression test in the prognosis of hyperthyroidism treated with antithyroid drugs *1051

**Vande Wiele, Raymond.** See JAILER, VANDE WIELE, CHRISTY and LIEBERMAN 357

**Vanikiati, Bunam.** See WATTEN, MORGAN, SONGKHLA, VANIKIATI and PHILLIPS 1879

**Vantrappen, Gaston.** See TEXTER, LAZAR, PULETTI and VANTRAPPEN *1048

**Vaughan, Martha, Steinberg, Daniel,** and **Shafrir, Eleazar.** The effect of epinephrine, glucagon and adrenocorticotropic hormone (ACTH) on phosphorylase activity in adipose tissue *1051

**Vester, John W.** See GURSEY, VESTER and OLSON *1008

**Vignos, Paul J., Jr.,** and **Lefkowitz, M.** A biochemical study of certain skeletal muscle constituents in human progressive muscular dystrophy 873

**Vishwakarma, P.,** and **Lotspeich, W. D.** The excretion of L-malic acid in relation to the tricarboxylic acid cycle in the kidney 414

W

**Wacker, Warren E. C.** See ULMER, WACKER and VALLEE *1049

**Wada, Takashi.** See REGAN, CHRISTENSEN, WADA, TALMERS and HELLEMS 306

**Waddell, William J.,** and **Butler, Thomas C.** Calculation of intracellular pH from the distribution of 5,5-dimethyl-2,4-oxazolidinedione (DMO). Application to skeletal muscle of the dog 720

**Walker, James E. C.** See WELLS, WALKER and HICKLER *1053

**Wall, Patricia E.,** and **Migeon, Claude J.** *In vitro* studies with 16-$C^{14}$-estrone: Distribution between plasma and red blood cells of man 611

—. See MIGEON, WALL and BERTRAND 619

**Wallace, Eleanor Z.** See CHRISTY, WALLACE, GORDON and JAILER 299

**Wallach, Stanley,** and **Carter, Anne C.** Effects of acute hypercalcemia in dogs *1052

**Walser, Mackenzie.** The ionic composition of uremic plasma *1052

—, and **Browder, Ann A.** Ion association. III. The effect of sulfate infusion on calcium excretion 1404

—, and **Bodenlos, Leonard J.** Urea metabolism in man 1617

**Warren, Kenneth S.** See STABENAU, WARREN and RALL 373

**Warren, Leonard.** Sialic acid in human semen and in the male genital tract 755

**Waterhouse, Christine,** and **Marinetti, Guido.** Tracer studies of plasma lipids in human subjects *1053

**Watkin, Donald M.** See TSCHUDY, BACCHUS, WEISSMAN, WATKIN, EUBANKS and WHITE 892

—. See WEINSTEIN, WEISSMAN and WATKIN 1904

**Watson, C. J.** See GILBERTSEN, LOWRY, HAWKINSON and WATSON 1166

—. See GILBERTSEN, HAWKINSON and WATSON 1175

**Watten, Raymond H., Morgan, Francis M., Songkhla, Yachai Na, Vanikiati, Bunam,** and **Phillips, Robert A.** Water and electrolyte studies in cholera 1879

**Wayne, Leo.** See GLUECK, GOLDSMITH, WAYNE and BERRY *1006

**Webb, J. P. W.** See DOLE, JAMES, WEBB, RIZACK and STURMAN 1544

**Webster, G. D., Jr.** See SELIGSON, BLUEMLE, WEBSTER and SENESKY *1042

—, and **Huth, E. J.** Carbonic anhydrase inhibition in renal tubular acidosis *1053

**Weil, Max H.** See WYMAN, WEIL and BLANKENHORN *1056

**Weinberg, Arnold.** See FIELD, WEINBERG, JOHNSON and SPOONT *1003

**Weinstein, I. Bernard, Weissman, Sherman M.,** and **Watkin, Donald M.** The plasma vitamin $B_{12}$ binding substance: I. Its detection in the seromucoid fraction of plasma from normal subjects and patients with chronic myelocytic leukemia 1904

**Weissler, A. M.** See BOGDONOFF, WEISSLER, MERRITT, HARLAN and ESTES *989

—. See KARP, WEISSLER and HEYMAN *1016

**Weissman, Sherman.** See TSCHUDY, BACCHUS, WEISSMAN, WATKIN, EUBANKS and WHITE 892

—. See WEINSTEIN, WEISSMAN and WATKIN 1904

**Weller, John M.** Changes in acid-base balance and plasma electrolytes after administration of sodium cycle resin *1053

**Wells, Roe E., Jr., Walker, James E. C.,** and **Hickler, Roger B.** Effects of cold air upon the normal and abnormal respiratory tract *1053

**Welt, Louis G.** See WOODS, WELT, HOLLANDER and NEWTON *1056

—. See WILLIAMS, FORDHAM, HOLLANDER and WELT 1587

**Wennesland, R., Brown, Ellen, Hopper, J., Jr., Hodges, J. L., Jr., Guttentag, O. E., Scott, K. G., Tucker, I. N.,** and **Bradley, B.** Red cell, plasma and blood volume in healthy men measured by radiochromium ($Cr^{51}$) cell tagging and hematocrit: Influence of age, somatotype and habits of physical activity on the variance after regression of volumes to height and weight combined 1065

**Werdein, Edward J.** See KYLE, WERDEIN, CANARY and PACHUTA 1475
**Werkö, Lars.** See SCHNABEL, ELIASCH, THOMASSON and WERKÖ 117
**West, Ann F.** See COLE, HENDERSON and WEST *996
**Westerman, Maxwell P., Pierce, Lawrence E., and Jensen, Wallace N.** Lipid quantification in normal young and normal aged circulating erythrocytes *1054
**Weston, Raymond E.** The effects of 3:5:3′ triiodothyropropionic acid on serum lipids of hypercholesterolemic euthyroid and hypothyroid subjects *1054
**Wheeler, Henry O.** See JAVITT, WHEELER, BAKER and RAMOS *1015
—, and **Ramos, Oswaldo.** Determinants of bile secretion in the dog *1055
**White, Arthur.** See KNIGHT, HEMMERLY, MARTIN and WHITE *1018
**White, Julius.** See TSCHUDY, BACCHUS, WEISSMAN, WATKIN, EUBANKS and WHITE 892
**White, Laurens P.** On the mechanism of toxicity of nitrogen mustard *1055
—. See STRANDJORD, THOMAS and WHITE 2111
**Whittembury, Guillermo.** See OKEN, WHITTEMBURY, WINDHAGER, SCHATZMANN and SOLOMON *1029
**Wilkins, Lawson.** See BLIZZARD, LIDDLE, MIGEON and WILKINS 1442
**Williams, T. Franklin, Fordham, Christopher C., III, Hollander, Walter, Jr., and Welt, Louis G.** A study of the osmotic behavior of the human erythrocyte 1587
**Wilson, I. D.** See VALTIN, WILSON and TENNEY *1050
**Wilson, Jean D., and Siperstein, Marvin D.** Studies on the relationship between glucose oxidation and intermediary metabolism. III. The influence of pyridine nucleotides on protein synthesis 317
**Wilson, S. G. F.** See HEYMANN and WILSON 186
**Windhager, Erich E.** See OKEN, WHITTEMBURY, WINDHAGER, SCHATZMANN and SOLOMON *1029
**Wood, J. Edwin.** The mechanism of venous pressure elevation with exercise in human congestive heart failure *1055
**Woods, James W., Welt, Louis G., Hollander, Walter, Jr., and Newton, Margaret.** Susceptibility to experimental pyelonephritis during and after potassium depletion *1056
**Worley, William E.** See LATHEM and WORLEY 474
**Wright, Verna, and Johns, Richard J.** The quantitative measurement of joint stiffness *1056
**Wyman, Milford G., Weil, Max H., and Blankenhorn, David H.** Partial cardiopulmonary by-pass utilizing selective veno-arterial perfusion *1056
**Wyngaarden, James B.** See ELDER and WYNGAARDEN *1001
**Wynn, James O.** See DEISS, O'SHAUGHNESSY and WYNN 334
—. Characterization of the serum $I^{197}$ iodoaminoacids *1057

## Y

**Yakulis, Vincent.** See HELLER, YAKULIS and ZIMMERMAN *1010
**Yalow, Rosalyn S.** See BERSON and YALOW 1996
—. See BERSON and YALOW 2017
**Yankopoulos, Nicholas A., Davis, James O., Kliman, Bernard, and Peterson, Ralph E.** Evidence that a humoral agent stimulates the adrenal cortex to secrete aldosterone in experimental secondary hyperaldosteronism 1278
**Yu, Paul N.** See STANFIELD, PERKINS, CONSTANTINE, LURIA, FINLAYSON, LOVEJOY and YU *1045
**Yü, T'sai Fan, and Gutman, Alexander B.** Study of the parodoxical effects of salicylate in low, intermediate and high dosage on the renal mechanisms for excretion of urate in man 1298
—. See GURMAN, YÜ and BERGER 1789

## Z

**Zak, Solomon J., and Good, Robert A.** Immunochemical studies of human serum gamma globulins 579
**Zarem, Harvey.** See KINNEY, ZAREM and ROGERS *1017
**Zierler, Kenneth L.** Hyperpolarization of muscle induced by insulin in the absence of glucose *1057
**Ziff, Morris, and Lospalluto, Joseph.** Unusual chromatographic behavior of serum macroglobulins *1057
**Zimmerman, Hyman J.** See HELLER, YAKULIS and ZIMMERMAN *1010
**Zubrod, Charles G.** See RALI, MOORE, TAYLOR and ZUBROD *1032
**Zucker, Marjorie B., and Borrelli, Jennie.** Platelets as a source of serum acid nitrophenylphosphatase 148
**Zumoff, Barnett.** See HELLMAN, BRADLOW, ZUMOFF, FUKUSHIMA and GALLAGHER *1010

# SUBJECT INDEX

*(Page numbers marked with an asterisk refer to abstracts)*


**A**

**Acetate,** radiolabeled
and bile synthesis, 1334–1338
in cholesterol synthesis, 1043*, 1334–1338
lipid synthesis from, 1718–1723
in protein synthesis, 317–324
**Acetazolamide**
in acidosis
metabolic, 1664–1670
renal tubular, 1053*
respiratory, 236, 771–776, 943, 1664–1670
and alkalosis, 774, 777, 1053*, 1307–1308, 1311–1314
and bicarbonate, excretion, 770–776
and reabsorption, 943, 1663–1670
and carbon dioxide tension, 236, 770–776, 1664–1666
and carbonic anhydrase, 943, 1053*, 1063–1670
cerebrospinal fluid-plasma sodium exchange, 1700, 1701, 1704
and electrolyte excretion, 1736–1744
in chicken, 24
in influenza hypercapnia, 229–230, 236, 247
and magnesium excretion, 986*, 1736–1744
and reticulocyte iron uptake, 172
and salicylate excretion, 1307–1308, 1312–1314
site of action, 775, 776
structural formula, 907, 914
and uric acid synthesis, 1019*
and water diuresis, 771–776
**2-Acetylamino-1,3,4-thiadiazole,** 907
**Acetylcholine**
colonic responses, 2119–2130
and di-isopropylfluorophosphate, 2120, 2121
and methacholine, 2119, 2121
and serotonin, 2120–2130
and fibrinolytic activity, 817–821
in paroxysmal nocturnal hemoglobinuria, 703, 1009*
**Acetyl-CoA,** in tricarboxylic acid cycle, 414
**N-Acetylneuramic acid,** and sialic assay, 755–760
**Acetylphenylhydrazine,** and glutathione, 1660
**Acidity, titratable of urine**
after ammonium chloride, 194–198
and blood pH, 354
and chloramphenicol, 1273, 1275
and desoxycorticosterone, 1156, 1160–1167
and dietary anion-cation balance, 1034*, 1156
and erythromycin, 1274, 1275
in hypercalcemia, 1052*
after methionine, 2215–2223
and oxytetracycline, 1272–1273
and phosphate dissociation constant, 347–356
in potassium depletion, 1137–1143, 1147, 1153, 1156
in renal disease, 40–42, 49, 51
in respiratory acidosis, 953
**Acidosis**
and acetazolamide, 236, 771–776, 943, 1053*, 1664–1670
and ammonia distribution, 373–382
and carbon dioxide tension, 378, 771–776
in cholera, 1883, 1887–1889
diabetic, and insulin, 556, 1004*
and muscle pH, 728
and plasma potassium concentration, 2176–2188
in renal disease, 39–51
renal tubular, 51
and alkali therapy, 1053*
respiratory, 234, 939–944, 2176–2188
and blood pH, 378, 380, 949–959
and carbonic anhydrase, 944, 955–958
electrolyte exchanges in, 949–959
and glutaminase enzyme system, 944, 955–957
in influenza complications, 230, 234
and potassium excretion, 25–26
after sodium chloride, 955
after rubidium, 1538–1542
and urine bicarbonate, 771–776, 939–944, 951, 959, 1042*, 1664
uremic, 42, 45–46, 50–51
**Aconitase,** and citrate metabolism, 1605–1616
**ACTH.** *See* Adrenocorticotropic hormone
**Addison's disease.** *See* Adrenal gland, insufficiency
**Adenosine**
diphosphate, 452, 1574, 1575
and inosine, 1043*
of erythrocytes, 1557–1562, 1577–1579, 1584
after storage, 1043*
in glucose degradation to lactate, 1574, 1575
and methemoglobin reduction to hemoglobin, 1557–1562
monophosphate, 1012*, 1052*
inhibition of mammary system, 1012*
triphosphate, 452, 876, 1043*, 1574–1579, 1584
and carbon tetrachloride, 1034*
and protein synthesis, 319–324
requirement of glycolysis, 1583
and salicylate, 1002*, 1003*
**Adrenalectomy**
and adrenocorticotropic tumor, 1028*, 1029*
and albumin turnover rate, 1046*
in breast cancer, 1012*
and hypocalcemia, 1018*
and muscle glucose uptake, 1017*
**Adrenal gland**
cortex, 1120–1125
and adrenocorticotropic hormone, 292–293, 357, 699
in aldosterone secretion, 1028*, 1278–1289, 1442–1450, 1964–1970
and calcium mobilizing mechanism, 1018*
corticosteroid synthesis, 1028*
and electrolyte metabolism, 1966
hyperplasia, 357–364, 1028*, 1450
in newborn, 1050*
and spinal cord transection, 1122–1125
SU-4885 and steroidogenesis, 2101–2110
triolein uptake, 540, 543
fetal, tritium uptake, 975–976
hyperfunction, 357–364
albumin turnover, 1045*
insufficiency, 357, 1964–1970
$\Delta^1$-corticosterone effects, 681, 688
cortisol effects, 681–697
cortisone effects, 681–700
and desoxycorticosterone effects, 681, 683, 686
and $\Delta'$-desoxycorticosterone effects, 681, 683, 686, 687
and electrolyte metabolism, 681–700, 1966
and eosinophiles, 681, 684, 700
and fluorocortisol effects, 681, 682, 684, 687, 699
and fluorohydrocortisone effects, 682, 1966
and fluoroprednisolone effects, 681–684, 687, 695, 696, 699
and glomerular filtration rate, 688, 690, 1011*
and prednisolone, 681–685, 689, 691–697
and prednisone, 681–689, 693, 694, 698
and renal function, 681–700, 1011*
and serum constituents, 682–687, 692, 696–699
and vasopressin, 1969–1970
medulla
and endotoxin, 1120–1125, 1039*
and epinephrine production, 1121
and norepinephrine production, 1121
tumor catechol amine production, 36–37
and urea reabsorption, 1011*
and urinary 17-ketosteroids, 357–364, 697, 699, 700
weight, 295–296
**Adrenocorticotropic hormone**
and adrenal gland, 292–293, 357, 699
and aldosterone secretion, 1288
after vasopressin, 999*
in cirrhosis, 302–304
and cortisol metabolites, 2246–2251
depletion after cortisone, 291–297

after endotoxin, 1122
eosinopenic response and pantothenic acid, 1423–1424
and fatty acids, 486, 1022*
growth hormone and antiserum, 1004*
in hypopituitarism, assay, 1025*
and insulin resistance, 553–556
and iron absorption after hypophysectomy, 1042*
pituitary secretion, 291–297
in plasma, 14–20, 302–304
in pregnancy, 302–304
and SU-4885, 2101–2110
tumor, after adrenalectomy, 1028*
and stress, 297
in newborn, 1050*
and subcutaneous fat, 1032*
and urinary 17-ketosteroids, 359–364

**Agammaglobulinemia**
immunochemical studies, 581–585
and serum gamma globulins, 582, 585, 1058*

**Age**
aldosterone excretion
and sodium deprivation, 1442–1450
alkaline phosphatase concentration in dysplasia, 1023*
and aortic elasticity, 778–783
and atherosclerosis, 1016*
and blood histamine concentration, 595–603
and blood 5-hydroxytryptamine concentration, 600, 602–603
and copper concentration, 1675
in dystrophy, and muscle constituents, 875–880
of erythrocytes. *See* Erythrocytes, age effects
and fatty acid uptake, 1022*
of gestation and amniotic fluid-fetus-mother water exchange, 977–980
and joint stiffness, 1056*
and liver phenylalanine hydroxylation, 2189–2196
of newborn, and lung weight, 2169, 2170
and renal L-diiodotyrosine clearance, 785–786
and serum Candida reacting antibody, 992*
and tissue antigenicity, 1010*

**Agglutination**
of erythrocytes, 1022*
in ascites tumor, 997*
and bromelin, 1031*
after hog intrinsic factor, 1022*
and isoantibodies, 279
sheep cell, rheumatoid factor, 427–433

**Alanine,** and phenylpyruvate transaminases, 2192

**Albumin**
bilirubin protein-binding, 826–831
and cardiac function, 131
corticosteroid binding, 384–391
double, genetic anomaly, 1412–1419
in edema fluid, 1037*
and estrogen, binding and transport, 390
and fatty acid uptake, 1022*
and glomerular nephritis, 988*
protein-lipid ratios, 186–191
immune reactions, 864
and insulin, 987*, 1225–1227
and liver function, 1992
metabolism, 863–871
kinetic analysis, 66–100
in myxedema, 91–100
and thyroid hormone, 88–100
and nitrogen mustard toxicity, 1055*
palmitic acid binding capacity, 1721
pH, and methemalbumin migration, 475, 476
in plasma. *See* Plasma, albumin
pulmonary vascular engorgement after infusion, 922, 923–924
and reticulocyte iron uptake, 164
in serum. *See* Serum, albumin
during streptokinase therapy, 1101
and thyroxine, 88–100, 1683–1687
turnover, and adrenal function, 1045*, 1046*

**Alcohol**
and antidiuretic hormone release, 1001*
brain stem norepinephrine, and serotonin concentration, 1008*
and intrathoracic pressure, 837
and kidney diluting capacity, 519

**Aldolase**
in erythrocyte fraction, 1579
and aging, 1584
in glucose degradation to lactate, 1574, 1575

**Aldosterone**
and electrolyte metabolism, 1966
secretion, 1278–1289
and adrenal cortex, 1028*, 1442–1450, 1964–1970
and hypertension, 985*
inhibition by SU-4885, 2101–2110
and thyroid-carotid arterial junction denervation, 986*
and vasopressin, 999*
and sodium retention, 1278–1289, 1964–1970
urinary excretion, 2102–2110
and sodium intake, 1442–1450
and spirolactone therapy, 1044*

**Alakaline phosphatase.** *See* Phosphatase, alkaline

**Alkalosis**
and acetazolamide, 771–776, 1664
and ammonia distribution, 373–382
and bicarbonate, 28–29, 1053*
excretion, 771–776
reabsorption, 1042*, 1664, 2197–2201
and bile azopigments, 648
and carbon dioxide tension, 378, 771–776
and citrate excretion, 421
and pH gradients, 378, 379, 381, 728
in potassium depletion, 1147
extracellular, 1149–1164
respiratory, 771–776, 1053*, 2176–2188, 2197–2201
and spinal fluid glutamine concentration ratios, 379
after sodium cycle resin, 1053*

**Alveolus**
carbon dioxide, and oxygen tension, 1010*
carbon monoxide tension, 1187–1200
dead space, and hemorrhage, 525–536
diffusing capacity, 1198–1199
in pregnancy, at high altitude, 1010*

**American Society for Clinical Investigation**
constitution, 1838–1839
history, 1784–1819, 1865–1877
Officers, 1840
proceedings of fifty-first annual meeting, 981–982
papers presented, 983*–1058*
roster of members, 1841–1864
active, 1841–1849
deceased, 1864
emeritus, 1850–1863

**Amino acids**
*See also* under specific names
and fibrinolytic activity, 819–820
iodinated, in serum, 1057*
and liver, 1038*
phenylpyruvate transaminases, 2192–2195
and methemoglobin reduction to hemoglobin, 1557–1562
and myoglobin iron uptake, 1603, 1604
and norepinephrine metabolism, 35
oxidative pathway and sulfur metabolism, 2222
protein uptake and salicylates, 1003*
sulfobromophthalein complexes, 1985–1987

**o-Aminophenol,** glucosiduronate formation, 454

**2-Amino-1,3,4 thiadiazole**
structural formula, 907
and uric acid production, 909–910

**Ammonium**
and bicarbonate, 42–45, 1139
in blood. *See* Blood, ammonia
chloride, 42–45, 1034*
and electrolyte metabolism, 194–198
and metal excretion, 1458–1459
renal enzyme adaptation, 366–371, 957
urate excretion after salicylate, 1312
and weight loss, 195–198
distribution ratios in acidosis and alkalosis, 373–382
excretion, 366–371, 1034
and desoxycorticosterone, 1156
and potassium depletion, 1139–1140, 1147, 1153, 1156
in renal disease, 40–42, 45, 50–51
in respiratory acidosis, 952–953
after rubidium, 1540
and sodium chloride, 956–957
after sulfate, 1034*, 2215–2223
and titratable acidity, 45, 50–51, 194–198, 1139
gastric secretion, 1271–1275
and chloramphenicol, 1273, 1275
and erythromycin, 1274, 1275
and oxytetracycline, 1272–1273
metabolism, 1035*
in hypercalcemia, 1052*
after nephrectomy, 378–379
production, in dog, 366–371

**Ammonium** (*cont'd*)
and in rat, 370–371
and sodium and water depletion, 197
toxicity in hepatic coma, 381
uric acid synthesis from, 912
thiadiazole effect, 912
urinary concentration, 1139, 1540
and $pK_3'$ phosphate, 351–356
**Amobarbital,** and isoniazid, 1357
**Amyloidosis,** serum protein changes, 993*
**Analbuminemia,** 863–871
**Androgen**
peripheral metabolism, 1010*–1011*
protein binding, 385, 391
**Androsterone**
excretion in adrenal hyperplasia, 358
after adrenocorticotropin, 359–364
hypocholesteremic effect, 1010*
in myxedema, 1010*–1011*
**Anemia**
and aconitase activity, 1610–1612
bone marrow hemolysis, 1031*
cobalt uptake, 178
fecal urobilinogen-mesobilifuscin ratios, 1175–1185
hemolytic, 178, 1176–1179, 1183–1184
in hemoglobinuria, 1009*
primaquine-sensitive, 1016*
of infection, 1019*
and iron-poor diet, 1610–1612
megaloblastic, 1184
*See also* Anemia, pernicious
pernicious, 178, 1183
blood cells, enzyme pattern, 1044*
hog intrinsic factor, and vitamin $B_{12}$ absorption, 1022*
pyrimidine metabolism, 1044*
"sideroachrestic," 998*
**Antibiotics**
*See also* specific antibiotics
blood clearance in renal diseases, 1487–1518
and gastric ammonia concentration in uremia, 1274–1275
and hemorrhagic shock, 678
granulocytopenic response, 677
in influenza complications, 223, 226, 243, 247–253
sensitivity of specific, 233
and staphylococcal resistance, 1018*
for urinary infections, 990*
**Antibody**
and antigens, 279, 1003*, 1010*
Candida reactions, 992*
diphosphopyridine nucleotidase, 1943–1948
to Ehrlich ascites tumor, 996*
erythrocyte, Bromelin test, 1031*
formation, 1022*
after bone marrow transplantation, 1046*
after irradiation, 1046*, 1049*
and 6-mercaptopurine, 1394–1402
hemaglutinating, to growth hormone, 1004*
and hog intrinsic factor, 1022*
in influenza, 206–209, 211, 219–220, 231
and insulin, 1002*
macroglobulin, 431
nephrotoxic, 1718
in rheumatic fever, 1944, 1946–1948
and rheumatoid factor precipitin curves, 430–431
serum. *See* Serum antibodies
in streptococcal disease, 1943–1948
synthesis, 1003*
in newborn, 583
and thrombolysis, 1627–1641
**Antigen**
anterior pituitary hormones as, 1004*
and antibody, 279, 992*, 1003*
in connective tissue, 1010*
erythrocyte, 279
sites, 289, 1024*
and 6-mercaptopurine, 1041*, 1396, 1400–1402
and vasculitis, 1045*
viral, in influenza, 211
**Antihemophilic factor,** in hemophilia, 1924–1926
**Aorta**
atherosclerotic, 1016*
triolein uptake in, 340–343, 539–543
cholesterol concentration and nicotinic acid, 1331
insufficiency of, 778–781
and influenza complications, 217, 224
lipoproteins, 1016*
pressure-flow relationships, 778–781
stenosis, 217, 224
**Aortic valve**
regurgitation, 992*
and norepinephrine, 1564–1570
**Apoferritin,** and aconitase, 1613
**Arabinose**
structural formulas, 407
urinary excretion, 408, 410–412
**Arfonad®**
in congestive heart failure, 557–578
and digitalis, 574–578
**Arginine**
in serum albumin, and pH, 1419
urinary excretion in hepatic cirrhosis, 1038*
**Arsenate,** and reticulocyte iron uptake, 172
**Arterenol.** *See* Norepinephrine
**Ascites**
cardioportal circulation times, 1025*
after hypertonic saline injection, 1015*
tumor, and circulating antibody, 996*
**Ascorbic acid**
and aconitase reactivation, 1607, 1609
and methemoglobin reduction, 1557–1562
**Asian influenza,** 199–273
*See also* Influenza
**Aspartate**
carbamyltransferase in pyrimidine synthesis, 1044*
in orotic acid formation, 800–808
pH, 802–803
and serum albumin concentration, 1419
and phenylpyruvate transaminases, 2192
**Asthma,** respiratory airflow resistance in, 1054*
**Atelectasis**
focal, and chest irradiation, 591
and hyaline membranes, 2169
**Atherosclerosis**
lipoproteins in serum and aortic wall, 1016*
and triolein entry to plaques, 539–540
**Atrium**
pressure, 1047*
and carbon dioxide diuresis, 1050*
after epinephrine, 1000*
in gas-free excised lung, 458
and hypovolemia, 120, 131
and isoproterenol, 344
septal defect closure, 1047*
**Atropine**
and colonic responses to acetylcholine, serotonin, and diisopropylfluorophosphate, 2124, 2128
and monamine oxidase inhibitor, 2124
and fibrinolytic activity, 815
and pulmonary diffusing capacity, 922–924
**Autotransplantation.** *See* Transplant
**Azide,** and reticulocyte iron uptake, 172
**Azotemia,** and zoxazolamine, 997*

## B

**Barbituric acid,** and isoniazid, 1357
**Bicarbonate**
and acetazolamide, 770–776, 943, 1664–1670
and ammonium, 42–45
excretion, 1139
carbon dioxide tension, 770–776, 939, 1042*, 1664
and carbonic anhydrase, 2201
in renal disease, 1053*
colon secretion, 437–441
and electrolyte excretion, 1736–1744
rates and test procedures, 1736
excretion, 771–776, 1139, 1153, 1178
in renal disease, 40–42, 44, 50–51
and hydrogen, 1159–1160
intake and nitrogen excretion, 1156
and kaluresis, 28–29
loss, in feces and urine, 1885
plasma concentration, 771–776, 2197–2201
and blood and cerebrospinal fluid pH, 381
and ionic movements, 437
and iron uptake, 167, 172
and magnesium excretion, 1736–1744
in potassium depletion, 1162–1163
in pulmonary complications of influenza, 230
and urinary phosphate concentration, 773

renal reabsorption, 1042*
in respiratory acidosis, 939–944, 959, 1663–1670
in respiratory alkalosis, 1042*, 1664, 2197–2201
and sodium-hydrogen exchange, 50
of serum. *See* Serum bicarbonate
and sodium chloride, 956–957
transfer, 1159–1160
across colon, 435–441
urine concentration, 771–776
**Bile**
bilirubin liberation, 650
cholate concentration, 1040*
in nephrosis, 1438–1440
cholesterol concentration, 1334–1338
excretion, 1055*
and nicotinic acid, 1329, 1333
after vanadium, 1253–1255
obstruction, 1990
and fecal urobilinogen-mesobilifuscin ratios, 1181–1183
intrahepatic, 1040*
5-hydroxyindole metabolism, 934–937
pH, 1011*, 1055*
pigments, 648–651
in dyserythropoiesis, 1014*
after glucuronidase, 647–650
after sulfate, 646
and serum phosphatase, 632–633, 638–642
after sodium taurocholate, 1055*
sulfobromophthalein, 997*
conjugates, 1426–1432, 1981–1988
retention, 1990
secretion after hepatic and portal vein injections, 2202–2214
and triiodothyronine, 1011*–1012*
**Bilirubin**
in carbon tetrachloride poisoning, 1513
conjugates, 645–651
conversion to dipyrrylmethene, 1173–1174
in erythroblastosis, 825–826
excretion, 1168–1174
in congenital hemolytic anemia, 1168, 1173–1174
nitrogen incorporation, 1171, 1173
in parenchymal liver disease, 1183, 1184
and liver function, 1992
pigments, 651
and diazomethane, 648, 650
and hydroxyamine, 648, 650
protein binding, 823–832
serum. *See* Serum, bilirubin
van den Bergh reaction, 649, 826
**Bisdiazobenzidine,** hog intrinsic factor binding, 1022*
**Bishydroxycoumarin**
in hemorrhagic diathesis, 1105
in myocardial infarction, 1112, 1114
**Blood**
ammonia concentration, 716
after nephrectomy, 378–379
arabinose disappearance, 408–412
arterial
krypton clearance, 990*
arteriovenous, cerebral carbohydrate concentration, 2155–2157
carbon dioxide tension, 381, 1157, 1342
cardioportal shunt and circulation time, 1025*
chromium concentration after irradiation, 1030*
coagulation, 230–231
after electroshock, 814
after epinephrine, 816–817, 821
after exercise, 816–817, 821
fibrinolytic system, 810–821, 1086–1118, 1628
in hemophilia, 1924–1926
in hemorrhagic shock, 53–65
in hyperglobulinemia, 1006*
after ischemia, 816–817, 821
and phosphatide, 1044*
and plasmin, 1086–1094, 1099
after pyrogens, 816–817, 821
after splenectomy, 63
and streptokinase, 1100–1102, 1627–1641
cord
cortisol binding, 1291
and water transfer, 972–980
cross-circulation into adrenals, 1286
and aldosterone secretion, 1279–1282
and arterial pressure, 1279–1282
and corticosterone secretion, 1279–1282, 1284
and venous pressure, 1279–1282
electrolytes, 949–959
in cholera, 1880–1881
and desoxycorticosterone, 1157
and urea, 752
fatty acids transfer, and breast milk, 449–450
freezing point depression, 1588–1593, 1597
gas, 229–230, 502–507
glucose, 856, 857, 1037*
in diabetes and sleep, 2229–2233
after glucagon injection, 1022*
and insulin response, 671–672, 2133
after meal ingestion, 1037*, 2155–2156
in neoplastic disease, 668–672
and salicylates, 1003*
after strophanthidin, 310, 315
and tolbutamide, 902–905
glutamine concentration, 379
goitrin recovery, after progoitrin, 1468–1470
hematocrit and estrone disappearance, 612
histamine concentration, 595–603
and cortisone, 599
hormone destruction, 14–20
5-hydroxytryptophan concentration, 716–719
iodine disappearance, 1012*
ketone bodies, 230
lactate in hemorrhage, 530, 533
lipids concentration, 856–861
in viral hepatitis, 858, 861
lipoprotein lipase, hepatic removal of, 1746–1754
loss, 528–533
and blood pressures, 526
lyxose clearance, 408–412
mucoid concentrations and ulcer susceptibility, 1002*
mustard treated homogenates, 1055*
oxygen. *See* Oxygen
palmitic acid clearance, 1720, 1723
pH, 230, 236, 951, 957
and acid-base disturbances, 2177, 2178
and ammonia distribution ratios, 230, 236, 373–382
and breath holding technique, 926, 927
and carbon dioxide, 725, 1036*
after hemorrhage, 530, 533
in hyperhemorrhea, 1007*
and iron uptake, 171
and methionine, 2215–2223
after partial cardiopulmonary bypass, 1057*
in potassium depletion, 1144, 1150, 1157
and pulmonary diffusing capacity, 921–923, 926, 927
in respiratory acidosis, 378, 380, 949–959
in respiratory alkalosis, 380
and respiratory center response time, 1036*
and urine titratable acid, 353, 354
platelet, and dextran, 155–159
after transfusion, fresh and lyophilyzed, 1690–1696
portal
isocitric and lactic dehydrogenase, 2115
proteins, 1064
in hemophilia, 1924–1926
in pulmonary complications of influenza, 229–231, 235, 236
D-ribose disappearance, 408–412
serotonin concentration, 595–603, 716–719, 1063
transfusions and hemoglobin iron uptake, 513
triolein concentration in malabsorption syndrome, 1014*
urea nitrogen, 1492, 1517
and chloramphenicol, 1273, 1275
and erythromycin, 1274, 1275
and *Escherichia coli*, 1228–1239
after nephrectomy, 379
and oxytetracycline, 1272–1273
in pulmonary complications of influenza, 230
in pyelonephritis, 1230–1232, 1235
venous
catechol amines, after endotoxin, 1120–1125
electrical potential versus colon lumen, 436
volume, 502, 526–532, 777
and aldosterone secretion, 986*
in aortic incompetence, 145
after blood donation, 1073
and body composition, 1065
and cardiac function, 117–136, 560
after epinephrine, 1000*, 1001*
and estrone distribution, 612
in fetulas, 1324
hea[illegible] and weight relation, 1069–107[illegible], 1075–1076
after hexamethonium, 1001*
in hypoxia, 1007*

**Blood** (*cont'd*)
in idiopathic high cardiac output state, 2146
and iron exchange in man, 393
and isoproterenol, 995*
after norepinephrine, 1566, 1569–1570
in pneumonia, 227–228
and positive pressure breathing, 840
seasonal fluctuations, 1072–1073
xylose, disappearance, 408–412
**Blood-brain barrier,** 1032*
for ammonia, 373–382
for inulin, 1776
and sodium exchange, 1703, 1705–1706
**Blood flow**
adrenal, and cross-circulation of blood, 1279–1282
cardioportal circulation time, 1025*
cardiovascular changes and Starling's law, 575–576
cerebral and carbohydrate uptake, 2154–2157
cerebral and eating, 1037*, 2155
and respiratory center response time, 1036*
in vasodepressor syncope, 1016*
coronary, 1034*
and heparin, 1034*
and veno-arterial perfusion, 984*–985*
forearm, and anaerobic exercise, 1126–1133
and bath temperature, 1128
and muscle temperature, 1133
and head injury, 1000*
hepatic, 1021*, 2202–2214
and insulin, 1023*
iron turnover, 392–395
and methoxamine in mitral valve disease, 1045*
myocardial, 1324–1325
in postprandial lipemia, 1033*
peripheral, 557–576
effective rate, 777
in polyostotic fibrous dysplasia, 1023*
pulmonary, 1915–1922
and alveolar-gas exchange, 1199
and atrial septal defect closure, 1047*
carbon monoxide measurement, 1186, 1199
and hemorrhage, 525–536
in hyperpnea, voluntary, 1188–1193
in hypoxia, 1007*
and lung expansion at birth, 456–462
in mitral stenosis, 1191, 1193–1195, 1200
and pulmonary artery occlusion, 1190, 1195–1197
in Valsalva maneuver, 1916–1921
renal, 571–573
and perfusion pressures, 609
and ureteral clamping, 991*
and urine solute concentration, 470
and water reabsorption, 12
shunts, 1915–1922
intracardiac, 1917–1921
portacaval, 1021*
in thyrotoxicosis, 1324–1325
**Blood pressure.** *See* Pressure, blood
**Body**
composition
and acid-base disturbance, 2179
in anterior and neurohypophyseal insufficiency, 884
and potassium, exchangeable, 2179
size
and electrocardiographic image torso, 991*–992*
erythrocyte and plasma volume, 1074–1076
and pulmonary diffusing capacity, 920–930, 1187
and ventilatory function, 501
somatotypes, 1066–1068
water. *See* Water, body
**Bone**
calcium
and parathyroid, 999*
in respiratory acidosis, 955, 958–959
electrolytes, 954
marrow
in anemia, 1031*–1032*, 1176–1184
and antineoplastic agents, 988*
and hemoglobin synthesis, 1002*
iron, after citrate loading, 1614–1615
megaloblastic arrest, 1183
and mesobilifuscin excretion, 1172–1173, 1182, 1183
myeloid-erythroid ratio, 1032*
normoblasts, 1176–1179, 1183, 1184
in rheumatoid disease, 1184
in shock, species difference, 679
transplantation, 1046*, 1048*, 1709–1716
viable fetal liver cells after infusion, 1014*
**Brain**
aconitase and iron-deficiency, 1608
ammonia concentration, 373–382
blood flow, 1037*
and respiratory response, 1036*
in vasodepressor syncope, 1016*
carbohydrate uptake, 1037*, 2154–2158
copper concentration and age, 1675
electrolyte concentration, 752
glucose uptake, 1037*, 2154–2158
glutamine concentration, 379
inulin space, 1776
lactate concentration, 1037*
metabolism postprandial, 1037*, 2154–2158
pyruvate concentration, 1037*
serotonin after ethanol, 1008*
sodium exchange, 1703, 1705–1706
water concentration of nephrectomized dogs, 752
**Breast**
cancer, 1021*
pyridine nucleotide, 1012*
milk fatty acids and dietary intake, 443–450
**Bromsulphalein.** *See* Sulfobromophthalein
**Bronchiolitis,** and influenza, 217, 237
**Bronchitis**
and influenza, 237
respiratory air flow resistance, 1054*
**Buffer**
anion in respiratory acidosis, 952
capacity of extracellular fluid, 2181
pH, 1532
and bilirubin concentration, 826
and double albumin, 1417–1419
and erythrocyte binding, 285–287, 289
after hemorrhage, 530
and phosphatase activity, 639
and reticulocyte iron uptake, 166, 174
and transcortin binding, 388
and urine titratable acid, 353–357

C

**Cadmium,** urine concentration, 1452–1462
**Calcification**
of basement membranes, 1215–1220
and calcium oxalate, 1001*
**Calcium**
bone concentration, 999*
in respiratory acidosis, 955, 958–959
chloride, 1407
and electrolyte excretion, 1736–1744
excretion
after acetazolamide, 986*
after lactate, 1735
after sulfate infusion, 1404–1410
in uremic syndrome, 1052*
and hog intrinsic factor in small intestine, 103–108
in hypercalcuria, 1021*
and hyperglobulinemia, 1006*
in hypocalcemia, 1018*
and magnesium excretion, 986*, 1736–1744
metabolism
in adrenal cortical insufficiency after steroids, 682–687, 691, 693, 695
and dietary intake, 894–895
and vitamin D, 1078–1083
mitochondrial, in carbon tetrachloride poisoning, 1034*
myocardial, and strophanthidin, 312, 314
phosphate, 1004*, 1052*
plasma. *See* Plasma, calcium
protein binding, 1021*
renal reabsorption, 994*, 1004*, 1021*
serum. *See* Serum, calcium
and thrombin time in hyperglobulinemia, 1006*
transport in erythrocytes, 1579–1580
and refrigeration time, 1580–1581
urinary concentration, 986*
and $pK_2'$ phosphate, 351–356
in subfractions, 1932–1933
and vitamin $B_{12}$ binding, 108
**Calorie**
balance and carbohydrate oxidation, 1017*
dietary intake, 444–450
and breast milk composition, 448, 450

and metabolic pool turnover, 899–901
percentage of corn oil, and fatty acids, 448

**Cancer**
*See also* specific site
insulin response in, 670–672
and renal calcium reabsorption, 1021*
and serum phosphatase, 632–633, 635–636, 640–643

**Capillary**
blood flow, 1198–1200
and strophanthidin, 307–308
and supine position, 1199
carbon dioxide tension, 930
dilatation, and chest irradiation, 591
fragility, and streptokinase, 1101, 1103
membrane, and protein composition, 1037*
permeability, in diabetic hypertension, 1048*
vascular bed, 1199–1200
and fibrinolytic activity, 821

**Caproic acid,** and plasma streptokinase, 1091–1092

**Carbamylaspartate,** synthesis, 800–804

**Carbamylphosphate,** synthesis, 800, 801, 806

**Carbamyltransferase,** 802–803, 806

**Carbohydrate**
cerebral uptake and blood flow, 2154–2158
concentration in rheumatoid factor, 429–430, 433
intake, and fat absorption in gastrectomized patients, 1051*
metabolism, 795–796
and cortisone, 993*
myocardial extraction, 310
oxidation, 1017*
tricarboxylic acid cycle, 414

**Carbon dioxide**
alveolar, in pregnancy at high altitude, 1010*
and bicarbonate excretion, 770–776
5,5-dimethyl-2,4-oxazolidinedione, 728
and potassium depletion, 1139–1141, 1144, 1150
retention, in pulmonary complications of influenza, 230, 236
and strophanthidin, 310
tension, 381
after acetazolamide, 236, 770–776, 1664–1666
and acid-base balance, 2177, 2178
and bicarbonate, 770–776, 939, 1042*, 1664, 2197–2201
and epinephrine, 1001*
and exercise, 1196
after head injury, 1000*
and hemorrhage, 525–536
after hexamethonium, 1001*
and hydrogen ion secretion, 944
in hyperhemorrhea, 1007*
and isoproterenol, 343–345
and muscle pH, 724–728
in obesity, 502–506
in pulmonary complications of influenza, 230
and pulmonary diffusing capacity, 921–923, 1187, 1196, 1342
in respiratory acidosis, 949–959
in respiratory alkalosis, 1042*
after sodium cycle resin, 1053*

**Carbonic acid**
in respiratory acidosis, 944, 955–956
and urinary carbon dioxide tension, 776

**Carbon monoxide**
and pulmonary diffusing capacity, 920–921, 1186–1200
and exercise, 916, 1188–1193, 1200

**Carbon tetrachloride,** poisoning, 1034*

**5-Carboxymethylhydantoin,** 801
in orotic acid biosynthesis pathway, 800

**Carcinoma.** *See* Cancer

**Cardiac output**
and alkaline phosphatase, 1023*
after Arfonad®, 557–578
and digitalis, 574–575, 577–578
and arterial oxygen saturation, 574
in arteriovenous fistula, 1325
and chest irradiation, 587–592
after dextran, 133–136
after epinephrine, 922–924, 1000*, 1001*
and exercise, 922–930, 1318–1325
after head injury, 1000*
and hemorrhage, 532
after hexamethonium, 1001*
in hyperhemorrhea, 1007*
in hypovolemia, 134
and hypoxia, 574
idiopathic high, 2144–2153
and isoproterenol, 995*
and methoxamine, 1045*
after norepinephrine, 922–924, 1566, 1569–1570
and oxygen uptake, 1033*
in polyostotic fibrous dysplasia, 1023*
and positive pressure breathing, 840
and pulmonary diffusing capacity, 922–930
after atropine, 922–924
carbon monoxide, 920–930
and renal hemodynamics, 571–573
and resistance, 590
and strophanthidin, 307–308
in thryrotoxicosis, 1318–1325
in valvular incompetence, 140–146
and vasodilatation, 565, 570
and veno-arterial perfusion, 984*–985*

**Cardiovascular system**
air chamber model, 777–783
and alkaline phosphatase, 1023*
and arterial wall motion, 1030*
hypertensive, 220, 308
and strophanthidin, 308
and hypovolemia, 136
and influenza virus pneumonia, 220, 260–264

**Carotid artery**
constriction and aldosterone excretion, 986*
pressure after epinephrine, 1000*

**Casein**
and acid-base balance after rubidium, 1538–1542
and plasmin, 984*

**Catechol amines**
adrenal venous, after endotoxin, 1120–1125
in hyperhemorrhea, 1007*
plasma concentration, in idiopathic high cardiac output state, 2146
and pressor response to acute hypoxia, 1007*

**Catheterization**
artifact in hepatic and portal flow sampling, 2211, 2212
cardiac, 778–781, 1033*
in high cardiac output, 2144–2153
in hyperhemorrhea, 1007*
in hypoxia, 1007*
in polyostotic fibrous dysplasia, 1023*
femoral artery, in partial cardiopulmonary by-pass, 1057*

**Cations**
*See also* specific cations
depletion
after acidifying salts, 194, 198
after sodium taurocholate, 1055*
heteroionic exchange and transfer in hypercalcemia, 1052*
transport systems and erythrocyte aging, 1572, 1584

**Cells**
*See also* Erythrocytes; Leukocytes
ammonium diffusion, 1035*
basophils, and histamine in children, 597–599, 601–603
electrolyte exchanges in acidosis, 949–959
endothelial proliferation, after irradiation, 591
eosinophils, 597–599, 601–603
and 1,4-diene steroids, 681, 684–685, 688–690
epithelial, hydropic swelling, 1215–1220
Kupffer, in hypercholesteremia, 1440
juxtaglomerular, and perfusion pressure, 605–610
osmotic fragility of aging, 990*
reticuloendothelial, hemoglobin degradation, 1485–1486
sheep, rheumatoid factor, 433
stem, maturation, 1001*
streptomycin-susceptible bacterial growth, 1355
tubule, 370, 1215–1220
virus susceptibility and transferrin, 1024*

**Cephalin,** serum concentration, 490–493, 1006*

**Ceruloplasmin,** in Wilson's disease, 1672–1681

**Chenodeoxycholic** acid, and triiodothyronine, 1012*

**Chloramphenicol**
and gastric secretion in uremia, 1273, 1275
persistence in serum, 1498–1507
structural formula, 1499

**Chloride**
and acetazolamide, 986*
and aldosterone, 1965–1967

**Chloride** (*cont'd*)
and ammonium excretion, 1139
dialysance, in artificial kidney, 1040*
gastric secretion, 1149
and chloramphenicol, 1273, 1275
and erythromycin, 1274, 1275
and oxytetracycline, 1272–1273
intake, 46, 381
and metabolism, 894–895
and nitrogen excretion, 1156
and rubidium, 1538–1542
plasma. *See* Plasma, chloride
serum. *See* Serum, chloride
transfer across colon, 435–441
urinary excretion of, 46, 1153, 1965–1967
after ammonium chloride, 194–198
after lactate, 1735
and $pK_3'$ phosphate, 351–356
and potassium depletion, 1137–1143, 1147, 1150
in renal disease, 42–46
in respiratory acidosis, 952–954
after SU-4885, 2103, 2104
**Chlorosulfonic acid,** and bilirubin, 650
**Chlorpromazine,** and isoniazid concentration, 1357
**Chlortetracycline**
persistence in blood, 1487–1495
plasma protein binding, 1956–1958, 1961
structural formula, 1951
and urea synthesis, 1621, 1623
urinary excretion, 1954–1956, 1961
**Cholera,** water and electrolyte studies in, 1879–1889
**Cholesterol**
and androsterone, 1010*
and basal metabolic rate, 1055*
biliary excretion, 1334–1338
after nicotinic acid, 1329–1330, 1333
after L-triiodothyronine, 1012*
body-intestine interchange, 1252
and diet, 448
digitonin precipitable Liebermann-Burchard reaction, 1253, 1255
erythrocyte, 1054*
esters, 1336–1338, 1546, 1721
and corn oil ingestion, 1549, 1550
lipid fractions, isolation, 1053*
and ethanolamine, 1013*
extraction from urinary RS-1 solids, 1522
fecal excretion, 1255–1260, 1337–1338
in glomerular nephritis, 186–191
and glucose, 986*
intestinal absorption, 1329
of lipoproteins, 493, 1016*
mitochondrial uptake, 1022*
in nephrosis, 1434–1440, 1718–1723
and nicotinic acid, 1330, 1332
plasma. *See* Plasma, cholesterol
serum. *See* Serum, cholesterol
and starvation, 856
synthesis, 1434–1440
homeostatic control, 1043*
and vanadium, 1251–1260
and thyroxine-binding, 1684
and L-triiodothyronine, 277
**Cholic acid**
biliary excretion, and nicotinic acid, 1329–1330
and cholesterol, 1438
esters, 1336–1338
and L-triiodothyronine, 1011*–1012*
**Cholinesterase**
colon, inhibition, 2121–2123
and acetylcholine, methacholine and serotonin, 2121–2122
and atropine, 2124, 2125
and di-isopropylfluorophosphate, 2120–2128
**Chondroitin sulfates,** acid mucopolysaccharides, 1061–1063
**Christmas factor,** 1924–1926
**Chromium,** radiolabeled
and platelet storage, 985*
for red cell, plasma and blood volume, 1065–1067
**Chylomicron,** and fatty acids
and coconut oil ingestion, 1550, 1551
and corn oil ingestion, 1549, 1551
in nephrotic hyperlipemia, 1720–1723
plasma concentration, 1546
and postheparin clearing, 857, 859
**Circulation.** *See* Blood flow
**Cirrhosis**
amino acid excretion after arginine, 1038*
and antidiuretic hormone secretion, 545
cardioportal circulation time, 1025*
and chloramphenicol metabolism, 1505
and cortisol metabolism, 299, 302–304
hemagglutination test, 1023*
5-hydroxyindole metabolism, 933–937
lipoprotein lipase, after heparin, 1751–1754
and mesobilifuscin-urobilinogen ratios, 1180, 1182, 1183
nonesterified fatty acids, and insulin, 1047*
plasma 17-OH-corticosteroid and adrenocorticotropic hormone, 302–304
and plasma cortisol binding, 1293
and serum ceruloplasmin, 1673–1675
and serum lysolecithin, 1006*
and sulfobromophthalein retention, 994*, 1990
**Citrate**
and acid nitrophenylphosphatase activity, 151–152
and erythrocyte glucose and oxygen consumption, 792–796
excretion, and acid-base balance, 420–421
and malate excretion, 416, 419
and mitochondria, exposure to carbon tetrachloride, 1034*
of muscle in kwashiorkor, 1026*
plasma concentration
in iron-deficiency, 1613–1615
in uremic syndrome, 1052*
and reticulocyte iron uptake, 172
in tricarboxylic acid cycle, 414
tubular synthesis and secretion, 420–421
urinary excretion, 1018*, 1613–1615
**Coagulation** of blood. *See* Blood, coagulation
**Cobalt,** radiolabeled
in iron transfer study, 161–183
and vitamin $B_{12}$-binding, 102–108
in leukemic serum, 2135–2143
**Colchicine,** and erythrocyte iron uptake, 1002*
**Collagen,** in dystrophy and neurogenic atrophy, 875–880
**Coma**
and blood gas, in influenza, 229–230
hepatic, and ammonia toxicity, 381
**Common cold,** specific immunity, 762–768
**Compound F.** *See* Cortisol
**Connective tissue**
adenosine metabolism, 452
antigenicity, 1010*
mucopolysaccharides, metabolism, 451–455
muscle replacement in muscular dystrophy, 875, 876
**Copper,** in Wilson's disease, 1046*, 1672–1681
**Coronary artery**
disease, 260–261
and hypercholesterolemia, 1055*
and influenza, 217, 260–261
insufficiency, 1112, 1054*
and streptokinase therapy, 1118
**Coronary sinus,** isocitric and lactic dehydrogenase in myocardial infarction, 2111–2118
**Corticosteroid**
adrenal synthesis and release, 1028*
and endotoxin, 1121–1125
globulin, binding, 998*, 999*
and transcortin, 386–387
**Corticosterone**
cortisol competition for transcortin, 386
1,2-dehydro analogues in adrenal cortical insufficiency, 681–690
globulin affinity for, 998*
secretion, and cross-circulation of blood, 1279–1282, 1285
transcortin binding, types of sites for, 389–390
and water diuresis, 688–690
**Cortisol**
and adrenal cortex
hyperfunction, 1028*
insufficiency, 681–697
binding, 998*
transcortin, 384–391, 1290, 1293
in cirrhosis, 299, 302–304
and endotoxin, after adrenalectomy, 1039*
glucuronide metabolism, 995*
in influenza, and pulmonary complications, 223, 226, 248, 253
and kidney function, 843–852, 884–890
in lymphocytic neoplasms, 993*
metabolism, kinetic analysis, 2238–2251
in pituitary insufficiency, 884–890, 1025*
plasma. *See* Plasma, cortisol
in pregnancy, 299–304, 386–388, 391

after streptokinase, 1100
and fibrinogen, 1103–1104
SU-4885 inhibition, 2101–2109
urinary concentration, in hydropenia, 843–852
**Cortisone**
in adrenal insufficiency, 681–690, 1011*
and electrolyte metabolism, 1965–1967
and adrenocorticotropic hormone concentration, 292–293
and aldosterone, 1965–1967
in virilizing adrenal hyperplasia, 1446
and calcium metabolism, 682–683, 686, 693, 695, 1080
and carbohydrate metabolism, 993*
and cerebrospinal fluid sodium exchange, 1700–1706
in diabetes insipidus, 890
and eosinophils, 599, 600, 681, 684
and fatty acid, 487
mitochondrial uptake, 1022*
and glomerular filtration rate, 884, 889–890
in hemolytic anemia, 1182
and inulin clearance, 688, 689
and iron absorption after hypophysectomy, 1042*
in lymphocytic neoplasm, 993*
in malabsorption syndrome, 1014*
and nitrogen metabolism, 682–687, 693, 694
in nontropical sprue, 1080
and phosphorus metabolism, 682–683, 693
in pituitary insufficiency, 884–890
and plasma carotene concentration, 1014*
and potassium metabolism, 685–687, 689, 695
protein binding, 385
and renal hemodynamics, 885–890
and sodium retention, 696
in tuberculosis, 1369
and virus isolation, 267–268
and water clearance, 886–890
**Cortolone,** and cortisol metabolism pathway, 2238–2252
**Coxsackie B. virus,** and transferrin, 1024*
phosphate, and protein synthesis, 319–324
**Creatine**
kinase, in dystrophy, 876, 878
and neurogenic atrophy, 880
and magnesium excretion, 1028*
and malic acid excretion, 415–418
and mannitol diuresis, 844
and nitrogen excretion, 1624
**Creatinine**
clearance
in adrenal cortical insufficiency, 684–686, 1011*
and artificial kidney, 1040*, 1492–1495, 1503–1507
and bicarbonate clearance, 1303
and chloramphenicol excretion, 1500
after chloride infusion, 548
and chlortetracycline excretion, 1490
and desoxycorticosterone, 845
after exercise, 2–6, 8–12
in hydropenia, 2–6
and osmostic diuresis, 847
and phosphate excretion, 1034*
and renal function, 44, 1517
and salicylate, 1302
in uremia, 1488–1489
and vasopressin, 846–847, 999*
excretion
in potassium depletion, 1137–1143, 1147
after SU-4885, 2102–2105
**Cushing's syndrome.** *See* Adrenal gland, hyperfunction
**Cysteic acid,** and sulfur metabolism, 2222
**Cysteine**
in albumin B, 1419
and fatty acids, 1032*
and iron uptake, 1602, 1604
and transfer, 171
sulfinate, oxidation, 2221, 2222
and sulfobromophthalein metabolites, 1015*, 1984–1987
**Cystine,** in hepatic cirrhosis, 1038*
**Cytidine,** and muscle hyperpolarization, 1057*

D

**DCA.** *See* Desoxycorticosterone
**1-Dehydrocorticosterone**
in adrenal cortical insufficiency, 681, 684–690
and eosinophils, 681, 684–685
and water excretion, 688
**1-Dehydrodesoxycorticosterone**
in adrenal cortical insufficiency, 683, 686, 689
and sodium retention, 1029*
**Dehydroisoandrosterone,** in adrenal hyperfunction, 358–364
**Demethylchlortetracycline,** blood clearance, 1951, 1954–1959, 1961, 1966
**Deoxyadenosine,** and methemoglobin in erythrocytes, 1557–1562
**Deoxycholic acid,** and triiodothyronine, 1011*–1012*
**Deoxyguanosine,** and methemoglobin in erythrocytes, 1557–1562
**Deoxyhexose,** in urine subfractions, 1931–1933
**Deoxyribonucleic acid**
and lupus erythematosus cells, 326–332, 1031*
and methemoglobin reduction, in erythrocytes, 1557–1562
and serum cholesterol concentration, 1039*
and uric acid excretion, 1891
**Desoxycorticosterone**
in adrenal cortical insufficiency, 681–690, 1029*, 1966–1970
and aldosterone, SU-4885 inhibition, 2101–2110
and antidiuretic hormone release, 1001*
and bicarbonate concentration, 1164
and cortisone withdrawal, 1966–1970
and endotoxin after adrenalectomy, 1039*
in hydropenia, 843–852
in lymphocytic neoplasms, 993*
and metabolic alkalosis, 1163
in panhypopituitarism, 1029*
and potassium, 987*
depletion, 1149–1164
protein-binding, 385
and sodium, 1163
exchange, plasma-cerebrospinal fluid, 1700–1706
retention, 1029*, 1964–1970
transfer, in intestine, 987*
**Desoxycortisol,** and aldosterone, SU-4885 inhibition, 2101–2110
**Deuterium oxide,** and water transfer, 976–980
**Dextran**
and blood platelets, 155–159
and cardiac function, 122–125, 131
and hemoglobin, 122–125, 157, 159, 1611
**Diabetes, alloxan**
and cellular permeability, 1049*
of glucose, 1017*
growth hormone, 1038*
and fatty acids, 485
and protein synthesis, 319
**Diabetes insipidus,** 882–890
and cortisone, 888–890
**Diabetes mellitus**
*See also* Diabetes, alloxan
albumin absorption, 1225–1227
blood glucose during sleep, 2229–2233
and influenza, 217
and insulin, 1018*
absorption rates, variability, 1222–1223
in acidosis, 556, 1003*–1004*
pancreatic increased production, 1003*–1004*
resistance, 551–556
and muscle glucose uptake, 1018*, 1027*
permeability of glomerular capillaries, 1048*
and salicylates, 1003*
**N,O-Diacetylneuramic acid,** 760
**2,6-Diaminopurine ribose,** and methemoglobin, in erythrocytes, 1557–1562
**2,5 Diamino-1,3,4 thiadiazole,** 907
**Diamox®.** *See* Acetazolamide
**o-Diazo-acetyl-L-serine,** and uric acid synthesis, 911, 1019*
**Diazomethane,** and bile pigments, 648, 650
**6-Diazo-5-oxo-L-norleucine,** and uric acid synthesis, 911, 1008*, 1019*
**Dibenamine,** in hemorrhagic shock, 678–680
**Dicumarol®.** *See* Bishydroxycoumarin
**Diet**
and acid-base balance after methionine, 2215–2223
adaptive response, 449, 1390
and aldosterone excretion, 1442–1450
and basal metabolic rate, 895
butter, and plasma lipids, 1548–1553
caloric intake. *See* Calories
and cholesterol. *See* Cholesterol
coconut oil, and plasma lipids, 1548–1553

**Diet** (*cont'd*)
corn oil, and plasma lipids, 1019*, 1389–1391, 1548–1553
and electrolyte excretion, 954
and endotoxin response, 1039*
and fatty acids. *See* Fatty acids
and galactose cataract development, after progesterone, 1030*
and glomerular filtration rate, 464–472, 735, 748
gluten intake, 1014*
in hyperlipemia, 1019*, 1544–1553
essential, 854
iron absorption from, 394
and aconitase activity, 1610–1612
and liver glycogen concentration, 1039*
mother's, and milk fatty acids, 445–447
in nephrosis, 1436
and nitrogen metabolism, 892–901
and pantothenic acid deficiency, 1425
potassium depletion, 1056*
and renal conservation, 1134–1147
protein
kidney responses, 736
plasma lipids, 1389–1391
and protein synthesis, 1241–1250
and urine concentrating ability, 741–748
in pyelonephritis, 1056*
rice, 1019*, 1389–1391
and serum phospholipid concentrations, 1389–1391
sodium, 1134–1147, 1442–1450
restriction, 464–472
transport into medullary fluid, 748
and triglycerides, diurnal variations, 1019*, 1392
and uric acid, 748, 1891
**1-[*p*-(β-diethylaminoethoxy)-phenyl]-1-(*p*-tolyl)-2-(*p*-chlorophenyl),** ethanol and hypotensive therapy, 1013*
**Digitalis**
in congestive heart failure, 574–578
and mitochondrial fatty acid uptake, 1022*
**Dihydroorotate,** synthesis, 802–808, 1044*
**Dihydrothymine,** and dihydroorotase synthesis, 806–807
**Dihydrouracil,** and dihydroorotase synthesis, 806–807
**3,4-Dihydroxymandelic acid**
identification, 709–710
and norepinephrine metabolism, 33, 35, 37
**Dihydroxyphenylethylamine,** 33, 37
**Diiodotyrosine**
and erythrocyte metabolism, 784–786, 792–796
excretion rate constant, 71
**Di-isopropylfuorophosphate**
and bowel cholinesterase, 2120–2123, 2125, 2127–2129
and atropine, 2125
granulocyte labeling, *in vitro*, 1025*
**Dimercaprol**
antiviral activity, 1024*
and copper excretion, 1673
and electrolyte excretion, 26–27
**Dimethylbenzimidazole,** and hog intrinsic factor, 103–108
**5,5-Dimethyl-2,4-oxazolidinedione,** and intracellular pH, 720–728
**Dinitrophenol**
and phosphorus-adenosine triphosphate exchange, 1003*
and reticulocyte iron uptake, 173
**Dinitrotyrosine,** and erythrocyte metabolism, 792–796
**Diphenylhydantoin,** and sodium exchange, 1700, 1703, 1705, 1706
**Diphosphoglycerate,** in glucose degradation, 1574, 1575
**Diphosphopyridine nucleotide**
in breast cancer, 1012*
in glucose degradation to lactate, 1574, 1575
in leukocyte sonicate, 802
metabolism, 1558
in connective tissue, 452
in pharyngitis, 1944–1946, 1948
and protein synthesis, 319–324
in rheumatic fever, 1944, 1946–1948
specific antibody properties, 1943
in streptococcal disease, 1943–1948
and thiadiazoles, 914
**Dipyrrylmethene,** and fecal, and hemoglobin metabolism, 1172–1173
**Diuresis**
and antidiuretic hormone, 5, 545–549, 730, 1001*, 1041*
and desoxycorticosterone, 850
in hyponatremia, 1001*
and left atrial stretch receptor, 1050*
in pituitary insufficiency, 882–890
and pressure breathing changes, 841
in congestive heart failure, 557–578
and creatinine clearance, 548
and exercise, 10–11
and glomerular filtration rate, 730, 738, 742, 889
in hydropenia, 10–12, 843, 847, 850, 1000*, 1028*
in influenza complications, 229–230, 236
and low protein diet, 743
and magnesium excretion, 986*, 1028*
mannitol, 736, 837–841, 1216, 1220
mercaptomerin and 5-hydroxytryptophan, 716, 717
mercurial, 986*
and sodium excretion by diseased kidneys, 991*
after parathyroid extract, 1216
and renal concentrating capacity, 5, 517, 736, 843, 1215–1220, 1725–1731
hemodynamics and intrathoracic pressure, 836–841
and spirolactone therapy, 1044*
sulfate, 1410
and calcium clearance, 1408
and electrolyte excretion, 2215–2223
urea, 736
and urine osmolality, 890
after vasopressin, 847
and sodium retention, 1969
water, 882–890, 1001*
after Arfonad®, 557–578
and bicarbonate excretion, 771–776
and cortisone, 888–890
after digitalis, 574–575, 577–578
after sodium chloride infusion, 548–549
after sugar infusion, 548
after urea, 1000*
**DNA.** *See* Deoxyribonucleic acid
**Dyspnea**
and body position, 665–666
in congestive failure, 560
on exercise, and ventilation, 1347
in influenza complications, 217, 220, 227
**Dystrophy,** muscular
and muscle constituents, 873–880
with myoglobinuria syndrome, 1040*

**E**

**Edema**
cerebral, and ventricle fluid, 1763, 1767
in heart failure, 560
protein composition, 1037*
and hypertonic saline, intravenous, 1015*
peripheral, 1015*
in influenza complications, 227, 237
**EDTA.** *See* Ethylenediaminetetraacetic acid
**Electrolyte**
*See also* specific electrolyte
and ammonium chloride, 194–198
balance
and aldosterone synthesis, 1000*, 1450
and blood urea concentration, 750–751
in kwashiorkor, 1026*
in renal disease, 42–51
after rubidium chloride, 1538–1542
bile acid secretion, 1055*
bone composition, 955
in carbon tetrachloride poisoning, 1034*
excretion
and acid-base balance, 27
after Arfonad®, 557–577
in congestive heart failure, 557–577
after digitalis, 574–577
and intake, 1137–1143, 1147
and intrathoracic pressure, 836–841
after lactate, 1735–1737
after mersalyl, 26
after methionine, 2215–2223
in pituitary insufficiency, 884
after spirolactones, 1043*
after strophanthidin, 309
in influenza complications, 230
metabolism and SU-4885, 2101–2110
and mitochondria function, 1034*
plasma. *See* Plasma
in potassium depletion, 1141
renal transport and ion-pair formation, 1410

in respiratory acidosis, 949–959
after sodium cycle resin, 1053*
serum. *See* Serum
and water studies, in cholera, 1879–1889
**Electron microscopy,** in cholestatic jaundice, 1039*
**Emotion**
and fibrinolytic activity, 817
and nonesterified fatty acid concentration, 989*
**Emphysema**
respiratory airflow resistance, 1054*
sodium and phosphate transfer, 2224–2228
and ventilation efficiency, 494–498, 1341, 1347
**Endocarditis,** and staphylococcal disease, 986*
**Endothelium**
antigenicity, and vasculitis, 1045*
capillary permeability in diabetes, 1048*
**Endotoxin**
and adrenal glands, 1025*
cortical and medullary differences, 1120–1125
and dibenamine, 679, 680
and dietary regimens, 1039*
enterococcus, and kidney obstruction, 1009*
and epinephrine release, 1039*
*Escherichia coli,* 1120–1125, 1228–1239
leukopenic response, 675
glycogenolytic action, 1039*
granulocytopenic response, 673–680
and tolerance development, 679–680
and hemorrhagic shock, 679
and 17-hydroxycorticosteroid secretion, 1121–1125
and kidney function, 1228–1239
*Proteus morganii,* 1228–1239
in pyelonephritis, 1229
*Streptococcus zymogenes,* 1231–1239
**Enzymes**
carbonic anhydrase in respiratory acidosis, 944
connective tissue and mucopolysaccharide metabolism, 455
erythrocyte, 1574
assay, in fractions, 1579
genetic deficiency, 1024*, 1659–1661, 2234–2237, 2253–2262
in glomeruli and renal tubular cells, 1027*
in glucose degradation, 455
to lactate, 1574, 1575
glutaminase system, in acidosis, 957
myocardial assays after infarction, 2115, 2116
thyroxine-deiodinating, in extrathyroidal tissues, 1902
**Eosinopenia,** and pantothenic acid, 1423–1424
**16-Epiestriol**
and chorionic gonadotropin, 1049*
fractionation, 620–628
**Epinephrine**
and adipose tissue, 1022*
phosphorylase, 1051*
adrenal secretion, 1124
after endotoxin, 1121
and arterial system, 1030*
biosynthesis, 33
and cardiac output, 1001*
and cellular permeability of glucose, 1017*
and central nervous system, 1124
and dopamine, 34
and fatty acids, 1022*
and growth hormone, 485
nonesterified, 989*, 1007*
and fibrinolytic activity, 817–821
and ganglionic blockade, 1000*
and granulocytopenia, 678
and hypertension in hypoxia, 1007*
leukopenic response, 677
and liver glycogen, 1039*
plasma concentrations, 817–821
fluorometric determination, 1935–1940
half-life, 1937, 1940
and pulmonary diffusing capacity, 922–924
secretion after pancreatectomy, 904
and subcutaneous fat, 1032*
**Erythrocyte**
acetylcholinesterase in hemoglobinuria, 702–706, 1009*
age effects, 162–168, 178–183, 989*–990*, 1002*, 1024*, 1584, 1660
and adenosine triphosphate, 1584
chromium, radiolabeled, 989*–990*
and hemoglobin iron uptake, 514
lipid, and surface area, 1054*
metabolic and cation changes, 1572–1585
plasma volumes, 1071, 1075–1076
and primaquine sensitivity, 1017*
agglutination
and bromelin, 1031*
in Ehrlich ascites tumor, 996*
and hog intrinsic factor, 1022*
and isoantibodies, 279
antigen sites, 1024*
and anti-$Rh_0$ (D) radioiodine labeled, 279–289
cation transport and temperature, 1580
cobalt, uptake, 178, 182
congenital methemoglobinemia, 1560
and methylene blue, 1561
2:3 diphosphoglycerate, 1577–1579
electron transfer system, 795, 796
estrone adsorption, 611–622
and glucose, 789–796
degradation to lactate, 1574, 1577, 1582
after storage in acid-citrate-dextrose, 1043*
and glucose-6-phosphate
dehydrogenase deficiency, 1023*, 1024*, 1659–1661, 2234–2237, 2253–2262
in hemoglobinuria, 1009*
glutathione sensitivity, 1660
of hereditary spherocytosis, 1033*
in hypercalcemia, 1052*
iron, 162–168, 176, 178–183, 393–394
in anemia, radiolabeled, 1018*–1019*
and hemoglobin synthesis, 1002*
after hypophysectomy, 1042*
in sickle cell trait, 513
life span, 1171, 1174, 1177
after irradiation, 1030*
in parenchymal liver disease, 1180, 1182
after renal ablation, 1028*
lipid loss, 1054*
mass, 284
in obesity, 502, 503, 505
and mesobilifuscin in feces, 1171–1174, 1177
methemoglobin reduction by purine nucleosides, 1555–1562
mitosis and colchicine, 1002*
nitrogen concentration, 1170
orotic acid synthesis, 798–802
osmotic behavior, 1587–1597
oxidative metabolism, 788–796
and methylene blue, 795, 796
oxygen consumption, 789–794
permeability, to ribose, 1559
phosphoglucomutase, 1009*
phospholipids, 1033*
lecithin and sphingomyelin exchange, 1032*
orthophosphate, radiolabeled uptake *in vivo,* 1032*
after platelet transfusion, fresh and lyophilized, 1690–1696
in respiratory acidosis, 958
sedimentation rates in influenza, 205, 216, 221–222, 257
and triiodothyronine, 788–796, 1684, 1687
volume, 1073
and body composition, 1065
height and weight relation, 1069–1071, 1075–1076
and race, 1066–1068
seasonal fluctuations, 1072–1073
**Erythromycin**
blood clearance in renal disease, 1509–1518
and gastric secretion in uremia, 1274, 1275
**Erythropoiesis**
cobalt stimulation, 179, 182
and erythron destruction in marrow, 1032*
and fecal urobilinogen-mesobilfuscin ratios, 1176–1179, 1183–1184
in parenchymal liver disease, 1180, 1182
in renal insufficiency, 1019*
and siderocyte iron recycling, 998*
**Esophagus**
catheterization studies, 397–405
dysfunction and hiatal hernia, 1048*
peristalsis, 401
primary and secondary, 110–116
pressure, 666
interruption of flow, 1263–1270
in pneumothorax, 1346
and work performed on lungs, 1345–1347
sphincteric action, 405
independence of diaphragm, 404
**Estradiol**
in breast cancer, 1012*
and chorionic gonadotropin, human, 1049*

**Estradiol** (*cont'd*)
citrate excretion, 422
corticosteroid-binding competition in plasma, 385
formation, from estrone, 617
fractionation, 620–628
and transcortin, cortisol binding, 1292
**Estriol**
and chorionic gonadotropin, human, 1049*
fractionation, 620–628
transcortin binding competition, 386
**Estrogens**
albumin-binding, 390
in breast cancer, 1013*
metabolism, 619–628
by perfused human placentas, 1049*
and plasma corticosteroid binding globulin, 999*
and thyroxine, 1683–1687
and transcortin, 385, 391, 1292
**Estrone**
corticosteroid-binding competition by, 385
and transcortin, 386
and gonadotropin, 1049*
metabolism, 619–628
plasma and erythrocyte distribution, 611–617
**Ethanolamine**
and cholesterol, in hypertension, 1013*
and fatty acids, 1032*
**2-Ethylamino-,1,3,4 thiadiazole**, uricogenic effect, 907–914, 1019*
**Ethylenediamine**, in anemia differentiation, 1018*
**Ethylenediaminetetraacetate**
and acid nitrophenylphosphatase activity, 151–152
and carbon tetrachloride, 1034*
and erythrocyte glucose and oxygen consumption, 792–796
and hog intrinsic factor, in intestine, 103–108
and leukocyte dihydroorotase synthesis, 802
and urine metal excretion, 1459–1462, 1673
and platelets, 985*
and reticulocyte iron uptake, 165–167, 169, 174, 180
**Etiocholanolone**
and adrenocorticotropin, 359–364
and androsterone ratio in adrenal hyperfunction, 363
in myxedema, 1010*–1011*
urinary excretion, 358–359
**Exercise**
anaerobic and forearm oxygen uptake, 1126–1133
aortic pressure pulse, 1033*
and cardiodynamics in idiopathic high output state, 2147
and erythrocyte and plasma volume, 1072, 1075–1076
and fibrinolytic activity, 817–821
and glucose uptake, 1005*
of diabetic muscle, 1027*
in heart disease, 1191–1193, 1318–1325
and insulin metabolism, 1005*
in muscular dystrophy with myoglobinuria syndrome, 1040*
and pulmonary diffusing capacity, 916, 922–930, 1186, 1200
and renal concentrating ability, 2–12
in thyrotoxicosis, 1318–1325
ventilation efficiency, 1341, 1347
and ventricular pressure, 1202–1212
warming-up effects, 1133
**Exophthalmos**, and mucopolysaccharides of skin, 946–947
**Extremity**
*See also* Forearm
arteriovenous nonesterified fatty acid, 2131–2134
and insulin, 1005*, 2131–2134
in muscular dystrophy with myoglobinuria syndrome, 1040*
glucose utilization, 1005*
venous pressure in heart failure, 1056*
**Eye**
exudate, and streptokinase, 1118
and thyroid-stimulating hormone, 989*

F

**Fatty acids**
aortic uptake, 543
and carbohydrate intake, 1051*
in chylomicron, 1551
clearance after injection, 1720–1721
in cystic fibrosis and pancreatic extract, 1019*
and energy expenditure, 1017*
extraction from urinary RS-1 solids, 1522
fecal excretion, in malabsorption syndrome, 1014*
after gastrectomy, 1051*
and growth hormone, 487, 993*
in hyperlipemia, 855, 1019*, 1036*, 1719
measurement, 1475–1478
mobilization, glucose inhibition, 993*
muscle, in muscular dystrophy, 875, 876
in nephrotic syndrome, 1719–1723
nonesterified, 855
adipose tissue, 1011*, 1032*, 1720
arteriovenous differences in limb, after insulin, 2131–2134
in breast milk and fat-free diet, 446, 449
and coconut oil ingestion, 1550–1551
and corn oil ingestion, 1549, 1551
and dietary fat, 1548–1553
and emotional arousal, 989*
and epinephrine, 989*, 1007*
and glucose, 987*
and heparin, 1036*
in hyperthyroidism, 275–277
metabolism, 999*, 1047*
plasma concentration, 275–277, 1053, 1546
in starvation period, 856, 859, 861
serum concentration, 855, 1391, 1718–1723
**Feces**
anemias and pigment excretion, 1175–1185
bicarbonate, 1883, 1885, 1886
bilirubin, 1168, 1173–1174
chloride, 2216
cholera, 1880–1881
cholesterol, 1337–1338
and serum lipids after vanadium, 1253–1255
chromium after irradiation, 1031*
copper, in Wilson's disease, 1678
coprostanol, 1337–1338
diarrhea, 1881–1886
electrolytes, 1880
in acidosis, 43–44, 47
after methionine, 2216
malabsorption syndrome, 1014*
mesobilifuscin
dipyrrylmethene pigments, 1166–1174, 1184
and urobilinogen ratios, 1175–1185
nitrogen, 1153, 1167–1174, 2216
in parenchymal liver disease, 1180, 1182
phosphorus, 2216
potassium loss, 1142, 1153, 2216
sodium, 1153, 2216
after sodium infusion, 1883–1885
after water, 1885
solids, 1153
after steroids, in adrenal insufficiency, 682–685, 692–700
and streptokinase, 1103
triolein, 1014*
**Fetus**
hematopoietic tissue transplantation, after irradiation, 1013*
maternal-amniotic fluid exchange, of water, 971–980
and sodium, 961–970
plasma, corticosteroid binding, 998*
**Fever**
after endotoxin and adrenal venous catechol amines, 1121–1125
influenza, 202–203, 220
in pulmonary complications, 227, 230, 234
**Fibrinogen**
conversion to fibrin in hyperglobulinemia, 1006*
after electroshock, 814–815
fibrinolytic activity, 810–821
in hemophilia, 1924–1926
in hemorrhagic shock, 58, 62, 64–65
nomenclature, 1094, 1097, 1109
and streptokinase therapy, 1090–1091, 1635
time factor after infusion, 1100
**Fibrosis**
interstitial and chest irradiation, 591
in muscular dystrophy, 875, 876
**Fistula**
arteriovenous, in thyrotoxicosis, 1324–1325
biliary, 1012*
and bile acid synthesis, 1338
**Fluid**
amniotic
and cortisol binding, 998*

fetal-maternal exchange, 963–964, 972–974
kinetic model, 965
and maternal serum, sodium and water exchange, 972–974
cerebrospinal
amonia concentration, role of pH gradient, 373–382
inulin concentration, 1769–1776
neuraminic acid concentration, 1756–1767
and plasma sodium exchange, 1698–1706
protein concentration, 1767
edema, in heart failure, 1037*
electrolyte
and ionic movements, 437
replacement in cholera, 1885
extracellular, 959
ammonium concentrations, 1035*
and body weight, 884
after desoxycorticosterone, 1158–1159
and erythrocyte osmotic activity, 1588–1597
after hypertonic saline injection, 1015*
and kidney diluting capacity, 520
and plasma potassium concentration, 2179–2186
space variability, 1644–1657
sucrose infusion technique, 1644–1657
intracellular, 959, 1035*
pH calculation, 720–728
intravenous therapy in cholera, 1883–1885
medullary interstitial hypertonic, 738, 740, 1219
permeability to carbon dioxide, 1035*
potassium shift from extracellular into cellular, 1053*
retention in cirrhosis, and spirolactones, 1043*
tubular, ionic strength from glomerulus to urine, 1410
ventricle, in cerebral edema, 1767
volume in lungs and vascular congestion effects, 462

**Fluorocinematography,** in esophageal dysfunction, 1048*

**9α-Fluorocortisol**
in adrenal insufficiency, 682–690, 1966
and calcium metabolism, 682, 695
and nitrogen metabolism, 682, 684, 687–690, 695–696, 699

**9α-Fluoroprednisolone**
in adrenal insufficiency, 681–682, 684, 687, 688
and calcium metabolism, 682, 695
and nitrogen metabolism, 684, 687, 695
and phosphorus metabolism, 682, 685–686, 695
and sodium retention, 684, 687, 688, 696, 699, 1029*

**Forearm**
blood flow, and anaerobic exercise, 1126–1133
venous pressure, and isoproterenol, 344

**Formaldehyde,** acid nitrophenylphosphatase inhibition, 152

**Fructosediphosphate,** of erythrocytes after storage, 1043*

**Fructose-6-phosphate**
in erythrocyte metabolism, 795, 796
in glucose degradation to lactate, 1574, 1575

**Fumarate**
and malate reabsorption, 418–419, 422
and methemoglobin reduction, 1557–1562
in tricarboxylic acid cycle, kidney, 414

G

**Galactosamine,** of acid mucopolysaccharides, 1061–1063

**Galactose,** and progesterone, 1030*

**Gallamine triethiodide,** 1000*–1001*

**Gas**
alveolar-capillary exchange, 1198
arterial blood, in influenza, 229–230
concentration of expired, and krypton, 990*
pulmonary inertance and resistance, 1268

**Gastrointestinal tract**
and acetylcholine, 2119–2129
cholinesterase inhibition, 2120–2123
endotoxin absorption in hemorrhagic shock, 1008*
fat absorption, 1051*
intrinsic factor action in everted sacs, 102–108
ionic and water transfer across, 435–441
irritation of para-aminosalicylic acid, 1371
and lipid transport and synthesis, 999*
and methacholine, 2119–2130
sodium and potassium transfer, and desoxycorticosterone, 987*
symptoms and influenza, 203–204
L-valine transport, 999*
vanadium absorption and serum free cholesterol, 1255–1256

**Glass factor,** in hemophilia, 1924–1926

**Globulin**
alpha
antiricketic effect in, 1081–1083
familial increase in thyroxine-binding sites, 1683–1687
and transcortin, 384–391
alpha$_2$, 987*
alkaline phosphatase activity site, 631
after glomerulonephritis, 988*
in nephrosis, 993*
antigen bound, 1396, 1400–1402
beta, 388, 987*
beta$_2$, in amyloidosis, 993*
corticosteroid binding, 998*
*See also* Transcortin
gamma, 388, 1057*
in agammaglobulinemina, 582, 1058*
anti-human absorption-precipitin study, 581, 583
antistreptolysin O serum concentration, 988*
calcium binding in hyperglobulinemia, 1006*
half-life, 582, 585
after hog intrinsic factor, 1022*
immunochemical studies, 579–585
insulin-like activity, 987*
isoelectric points of platelets after dextran, 157, 159
of lupus, 326–332
molecular weights, 1057*
in neonatal period, 583–585
in poststreptococcal glomerulonephritis, 988*
rheumatoid factor isolation from, 425, 428
sedimentation characteristics, 2159–2167
and streptokinase therapy, 1101–1102
glycoprotein components and protein-bound sodium ratios, 1767
and rheumatoid factor, 430–433

**Glomerular filtration rate,** 575, 991*
after acetazolamide and magnesium excretion, 1741–1744
in adrenal insufficiency, 1011*
and alcohol, 519, 837, 840–841
in alloxan diabetes, 1049*
in aminonucleoside-induced disease, 518–519
and antidiuresis of positive pressure breathing, 840
bicarbonate reabsorption and plasma concentration, 2197–2201
and calcium excretion, 1052*
after sulfate, 1407–1410
after citrate, 420, 422
and cortisol, 884
and cortisone, 884, 885, 889–890
in diabetes insipidus, 890
hemodynamics, 885–890
hemoglobin excretion and reabsorption, 655–658
in hypercalcemia, 1052*
in hypertension, 985*
and intrathoracic pressure, 836–841
α-ketoglutarate infusion, 420, 422
after lactate, 1735
and low protein diet, 742
and low salt diet, 464–472
and malic acid excretion, 415–418
and mannitol diuresis, 742, 747, 844
after parathyroid extract, 1215–1220
and phosphate excretion, 1035*
in pituitary insufficiency, 884–890
reduction in hydropenia, 463–472
in respiratory acidosis, 939–944
and sodium excretion, 470, 688, 690, 991*
and solute diuresis, 743
after succinate, 422
and thyroid, 884
and urea, 468, 747, 1782
urine concentration, 468
and antidiuretic hormone, 730–740
after thyroid, 885, 889
and vasodilatation in congestive failure, 571–573
and water excretion, 518

**Glomerulonephritis**
and albuminemia, 191, 998*
poststreptococcal serum protein patterns, 987*
and sodium excretion, 990*–991*
**Glossitis,** after thiadiazoles, 908, 911
and nicotinamide, 1019*
**Glucagon**
and adipose tissue phosphorylase, 1051*
and glycogen breakdown, 1022*
hydrolysis by plasma, 14–20
therapy, glycogen storage disease, 1021*
**Glucosamine**
and serum isoniazid concentration, 1357
of thrombocyte acid mucopolysaccharides, 1062
**Glucose**
blood. *See* Blood, glucose
cerebral, after meal ingestion, 1037*, 2155–2157
and corticotropin-induced fatty acid release, 1032*
degradation to lactate, 1574, 1577, 1582
dietary intake and rubidium, 1538–1542
and erythrocytes, 789–796
storage in acid-citrate-dextrose, 1043*
and esterification in adipose tissue, 1032*
and fat metabolism after growth hormone, 485, 993*
and heart, 1026*, 1027*
stroke index, 120–121
hepatic output and portacaval shunts, 1023*
and hyperlactacidemia, 1022*
induced hypervolemia, 117–136
and insulin, 671–672, 1018*, 1023*, 1026*
hepatic output in portacaval shunts, 1023*
membrane transport, 1026*
and plasma fatty acids, 485–487, 2132–2133
uptake in anaerobic conditions, 1027*
metabolism in neoplastic disease, 668–672
and methemoglobin reduction, 1559–1560
mucopolysaccharide metabolism, synovial tissue, 455
and muscle, 1026*, 1040*
hyperpolarization, 1057*
myocardial extraction, 310
and nonesterified fatty acids after starvation, 856–857
plasma, 277, 485
protein-sparing effect, 323–324
and reticulocyte iron uptake, 172
and serum lipids and lipoproteins in nephrosis, 986*
and sodium excretion by diseased kidneys, 991*
after strophanthidin, 310, 315
tolerance, 668
viral hepatitis, 857
after triiodothyronine, 2, 77, 789–796
tubular reabsorption, 1027*
uptake, 1040*, 1057*
and salicylates, 1003*
uridine diphosphoglucose synthesis from, 451–455
urinary concentration and $pK_a'$ phosphate, 351–356
utilization, 1017*, 1057*
in exercised extremity, 1005*
**Glucose-1-phosphate,** and lactate formation, 1040*
**Glucose-6-phosphate**
in glucose degradation to lactate, 1574, 1575
hexokinase inhibition, 1017*
in methemoglobin reduction, 1559
and protein synthesis, 319–324
**Glucose-6-phosphate dehydrogenase**
deficiency, 1023*, 1024*, 1659–1661, 2234–2237, 2253–2262
in hemoglobinuria, 1009*
in leukocytes, 1024*, 2234–2237, 2253–2262
in platelets, 2235
and primaquine, 1017*
and erythrocytes, 792–796, 1024*, 1559, 1574–1575, 2253–2262
**Glucuronic acid**
metabolism in connective tissue, 452
sulfobromophthalein conjugate, 1430
**Glucuronides**
and bile azopigments, 647–651
enzymatic hydrolysis of steroid, in canine and human plasma, 995*
17-hydroxycorticosteroid in pregnancy, 301
metabolism in connective tissue, 451–455
synthesis, in liver disease, 1505
urinary metabolites after estrone, 623
**Glutamic acid**
and ammonium chloride, 360–370
biliary excretion, 997*, 1426
in orotic acid biosynthesis pathway, 800
oxidation in carbon tetrachloride poisoning, 1034*
and phenylpyruvate transaminases, 2192–2195
in respiratory acidosis, 379, 944, 955–957
and sulfobromophthalein metabolites, 997*, 1015*, 1984–1987
transaminase, 1513
in kidneys, 369–371
in myocardial infarction, 2111, 2117
**Glutamine**
and ammonia infusion, 369, 379
and phenylpyruvate transaminases, 2192–2195
and sodium bicarbonate, 369
synthetase in kidney cortex, 369
**Glutathione**
erythrocyte sensitivity and acetylphenylhydrazine, 1660
and fatty acids, uptake by adipose tissue, 1022*
and intrahepatic bromsulphalein conjugation, 1015*
and iron uptake, 171
myoglobin, 1602
**Glyceraldehyde-3-phosphate**
in erythrocyte metabolism, 795, 796
in glucose degradation to lactate, 1574, 1575
**Glycerol**
and lipoproteins, 1016*, 1748–1754
platelets, protection in freezing, 996*
**Glycine**
biliary excretion, 1426, 1984–1987
in hyperoxaluria, 1001*
and myoglobin iron uptake, 1603, 1604
nitrogen-labeled fecal mesobilifuscin precursor, 1173
and reticulocyte iron uptake, 172
and sulfobromophthalein metabolites, 997*, 1015*, 1984–1987
**N-Glycolylneuraminic acid,** 755
isolation, 760
**Goitrin**
and basal metabolic rate, 1470
progoitrin conversion to, without myrosin, 1465
**Gonadotropin**
chorionic and placental estrogen metabolites, 1049*
pituitary, and antiserum, 1004*
**Gout**
and 6-diazo-5-oxo-L-norleucine, 1008*
dietary intake, 1891
renal urate excretion, 1781, 1891–1897
and salicylate, 1298–1314
and zoxazolamine, 997*
**Granulocytes**
di-isopropyl fluorophosphate labeling *in vitro*, 1025*
endotoxin responses, 673–680
in hemorrhagic shock, 673–680
and epinephrine, 680
iron concentration and turnover, 997*, 1025*
**Graves' disease.** *See* Hyperthyroidism
**Growth hormone.** *See* Pituitary growth hormone
**G suit,** inflation, and pulmonary vascular engorgement, 922, 923–924
**Guanine** structural formulas, 1401
**Guanosine,** and methemoglobin reduction, 1557–1562
triphosphate and protein synthesis, 319–324

## H

**Hageman factor,** in hemophilia, 1924–1926
**Head injury,** and circulation, 1000*
**Heart**
aconitase in iron deficiency, 1608
and arterial oxygen saturation, 1917–1921
calcium ion transfer, 312, 314
catheterization, 777–781
for cardiac output, 1033*
cycle duration, 777–781
decompensation and neuroeffector system, 1056*
and electrocardiographic torso image, 991*–992*

filling pressures, 129–131, 134
glucose uptake, 120–121, 1026*, 1027*
hemodynamics, 138–146
and vasodilatation, 562–570
in hyperhemorrhea, 1007*
and hypervolemia, 117–136
murmurs, 1007*, 2145–2152
potassium transfer from, 313
premature beats, 310
and strophanthidin, 312
rate, 308–309, 561–570, 2146–2152
and aortic pressure pulse, 1033*
and dextran, 122–125
and epinephrine, 1001*
and head injury, 1000*
after hexamethonium, 1001*
shunts, krypton in detection and localization, 990*
size
and bacterial species in pyelonephritis, 1230–1239
in idiopathic high cardiac output state, 2145
and thrombolytic therapy, 1116
stroke index, 120–121, 130–132, 307–308
isoproterenol, 995*
and strophanthidin, 308–309, 312, 314
sympathetic-vagal nerve, ventricular relationship, 1021*
thyroxine, deiodination to triiodothyronine, 1902
valvular incompetence, 138–146
water and electrolyte content of, 752
work, 570, 574–575
and Arfonad® and digitalis, 574, 577–578
and partial cardiopulmonary bypass, 1056*
and Starling's law, 574–576

**Heart disease**
and influenza, 224
antecedent, 217, 227–228, 237, 262
arteriosclerotic, 217, 220, 224, 260–261
hypertensive, 217, 248
rheumatic, 202, 203, 210, 217, 220, 224, 241–245, 260–264
pulmonary diffusing capacity, 1193
and strophanthidin, 308
and thyrotoxicosis, 1318, 1320–1325

**Heart failure,** congestive
and arteriovenous oxygen differences, 559
and blood volume, 560
and body position, 659–667
edema fluid, and protein composition of serum, 1037*
and hemodynamics, 562–570, 1318, 1321–1325
hypertensive, 564, 566–568, 570
and hyperthyroidism, 1316–1325
and influenza complications, 227, 258
lung compliance, 659–667
peripheral vasodilatation, 557–576
and strophanthidin, 308–310
and veno-arterial perfusion, 984*–985*
and venous pressure, 1055*

**Hematinic acid,** after mesobilifuscin, 1171–1172

**Hematocrit**
and anti-neoplastic chemotherapy, 988*
and estrone adsorption, 612, 616
and glucuronoside fraction from erythrocytes, 622
in healthy men, 1066–1068
in heart failure, 560
and strophanthidin, 308–309
and hemorrhage, 528, 533
in idiopathic high cardiac output state, 2146
and iron, 393
after irradiation and platelet transfusion, 1690
and nitrogen mustard, 988*
in obesity, 502
in potassium depletion, 1150
and pulmonary function, 228, 1342
after streptokinase, 1103
in myocardial infarction, 1105

**Hemodynamics**
and blood redistribution, 1001*
cerebral
arteriovenous glucose, lactate and pyruvate, 1037*
and eating, 2155
in congestive failure, 571–575, 1316
in high cardiac output, 2146–2152
and hypertension, 564
in hyperthyroidism, 1316
and isoproterenol, 995*
in mitral valve disease and methoxamine, 1045*
myocardial, after strophanthidin, 306–315
after norepinephrine, in aortic insufficiency, 1566–1570
after portacaval shunt, 1021*
renal, 570–573
and intrathoracic pressure, 834–841
in portal cirrhosis, 1025*
in thyrotoxicosis, 1324
after vasodilatation, 557, 562–570
and venous tone, 1001*

**Hemoglobin**
alkali-resistant, 508–514
in anemia, 508–514, 1032*, 1167–1168, 1173–1174
after bleeding, 1611
after citrate loading, 1614–1615
C trait, 508–514
and dextran, 122–125, 157, 159, 1611
electrophoretic mobility, 1029*
and erythropoiesis, 1002*
fetal, in multiple myeloma, 511
fractions, 478
glomerular clearance, 655–658
and glucose, 120–121
and hypervolemia, 120–125
in hypovolemia, and pulmonary arterial pressure, 129
iron, 508–514, 997*, 998*, 1610–1611
metabolism pathways, 1484–1486
uptake from iron-binding protein, 169–170
isoelectric points of platelets, 157, 159
and kidney aconitase activity, 1610
metabolism, 1032*
and fecal dipyrrylmethene compounds, 1166–1174
and methemalbumin, 475–477, 480
and myoglobin, 1600
binding sites, 1020*
nitrogen incorporation into, 1167, 1170
after phenylhydrazine, 1611
plasma, 474–483, 653–658
pool kinetics, 1479–1482
in potassium depletion, 1150
protein-bound, 478
in extravascular sites, 483
protoporphyrin, 1167–1168, 1173–1174
renal transport, 655–658
sedimentation rate, 1030*
sickle cell, 508–514
in sideroachrestic anemia, 998*
synthesis, and mesobilifuscin formation, 1183–1184
and stroke index, 132–134
in thyrotoxicosis and exercise, 1318–1325
transport, free and protein-bound, 483
urinary excretion, 483
and reabsorption, 653–658

**Hemoglobinuria**
paroxysmal nocturnal, 702–706, 1009*

**Hemophilia,** 1924–1926

**Hemorrhage**
carbon dioxide tension difference in, 528–530
and chest irradiations, 591
diathesis and fibrin polymerization, 1005*
in influenza, 237
intra-alveolar, 237
platelets, transfusions in thrombocytopenia, 1689–1696
and pulmonary circulation, 524–536
and respiratory gas exchange, 524–536
and shock, 53–65
and endotoxin defenses, 1008*
and streptokinase, 1104, 1105, 1109, 1114

**Heparin**
and chylomicrons, *in vitro* clearing, 857
in essential hyperlipemia, 856–857, 859, 861
cofactor, in hemophilia, 1924–1926
and fatty acid uptake, 1022*
and glycerol production, 1748–1754
and lipemia clearance, 1034*
and lipoprotein lipase, 1748–1754

**Hepatitis**
cholangiolitic, 634
mesobilifuscin-urobilinogen ratio
fecal, 1180, 1182
urine, 1183
viral, 1022*
and blood lipid concentration, 858
and sulfobromophthalein retention, 994*, 1990

**Heredity**
double albumin, 1412–1419
erythrocyte glucose-6-phosphate dehydrogenase, 1659–1661, 2234–2237
racial factor, 2253–2262

**Hernia,** hiatal
fluorocinematography, 1048*
sphincteric action, 404
**Hexamethonium**
and colonic response to acetylcholine and serotonin, 2124, 2125, 2128
and epinephrine, 1000*, 1001*
and plasma nonesterified fatty acids, 1007*
and stroke volume, 1000*–1001*
**Hexosamine**
in acid mucopolysaccharides, 1060, 1062
in amyloidosis, 993*
of isolated rheumatoid factor, 429–430, 433
in urine subfractions, 1931–1933
RS-1 solids, 1522
**Hexose**
concentration, of rheumatoid factor, 429–430, 433
in glucose degradation to lactate, 1574, 1575
and glucose-6-phosphate, 1017*
after hypophysectomy, 1018*
metabolism in connective tissue, 452
and methemoglobin reduction, 1557–1562
and muscle glucose utilization, 1018*
of urine subfractions, 1930–1933
RS-1 solids, 1522
**Hexuronic acid**
in acid mucopolysaccharides, 1060
in urine subfractionations, 1931–1933
RS-1 solids, 1522
**Histamine,** in blood
*See* Blood, histamine concentration
**Histidine,** in serum albumin and pH, 1419
**Histone,** and lupus erythematosus cell factor, 1013*
**Hog intrinsic factor**
and antibody formation, 1022*
**Hormones**
*See also* specific glands; specific hormones
antidiuretic, 5, 883–890, 1050*
and anterior pituitary insufficiency, 882–890
and desoxycorticosterone, 850
excretion and serum osmolality, 545–549
in hyponatremia, 1001*
and membrane, 1019*–1020*
and renal hemodynamics, 838
plasma degradation, 14–20
thyroid-stimulating, 334
**Hyaline membrane,** in influenza complications, 237
disease, lung static volume-pressure relations, 2168–2174
**Hyaluronidase**
serum antibody titers, 1943
after glomerulonephritis, 987*–988*
in rheumatic fever, 1944, 1946–1948
in streptococcal disease, 1944–1948
testicular, thrombocyte fraction hydrolysis, 1063
**Hydrocephalus,** ventricular fluid sodium, 1762, 1766–1767
**Hydrochloric acid**
and ammonia distribution, 373–382
and fat absorption in gastrectomized patients, 1051*
and pH, blood and cerebrospinal fluid, 381
and renal bicarbonate reabsorption, 1668
**Hydrocortisone.** *See* Cortisol
**Hydrogen ion**
and anion intake, 1156
and bicarbonate, 1667
internal transfers, 1159–1160
reabsorption, 2197–2201
and cation, 1156
-carrier complex, 29
gastrointestinal secretions, 1053*
and hydroxyl ion exchange, 943–944
and intracellular anion exchange, 958
and myoglobin iron uptake, 1601
and potassium, 27–29
depletion, 1159–1160, 1164
distribution, 2176–2188
in renal disease, 39, 48–50
in respiratory acidosis, 957
shift from extracellular fluid, 1149
and sodium exchange, 27–29
after acetazolamide, 771–776
urine excretion, 1147, 1153
**Hydropenia**
and desoxycorticosterone, 845, 850
and glomerular filtration rate, 463–472
and negative pressure breathing, 1974–1979
renal concentrating mechanism, 468–469
and exercise, 2–12
after urea, 1000*
and vasopressin, 846, 999*, 1000*
**Hydropyrimidine hydrase,** 806–807
**3α-Hydroxyandrostane-17-one.** *See* Androsterone
**11β-Hydroxyandrostenedione,** transcortin binding, 385, 389
**β-Hydroxybutyrate,** in carbon tetrachloride poisoning, 1034*
**17-Hydroxycorticosteroids**
adrenal output after endotoxin, 1121–1125
plasma concentration, and cortisol, 995*, 1292–1296
urinary excretion after SU-4885, 2102–2110
**6-β-Hydroxycortisol,** in newborn period, 1050*
**16α-Hydroxy-11-desoxycorticosterone,** and sodium retention, 1029*
**17-Hydroxy-11-desoxycorticosterone**
1,2-dehydro analogues in adrenal cortical insufficiency, 681–690
**16α-Hydroxyestrone,** urinary glucuronoside fraction, 623–628
**3α-Hydroxyetiocholane-17-one.** *See* Etiocholanolone
**5-Hydroxyindole,** in hepatic cirrhosis, 934–937
**5-Hydroxyindoleacetic acid,** 1043*
urinary excretion, 716, 717–719, 934–937
**Hydroxylamine,** and bile pigments, 648, 650
**5-Hydroxytryptamine.** *See* Serotonin
**5-Hydroxytryptophan,** in liver disease, 715–716, 719
**Hypercalcemia**
and adrenal steroids, 1018*
and antiricketic activity of sera, 1080
in breast cancer, 1021*
and cortisone, 1080
in hyperparathyroidism, 1021*
metabolic effects, 1052*
and renal concentrating ability, 1214, 1220
**Hypercalciuria**
of hyperparathyroidism, 994*
and renal concentrating ability, 1120
and sulfate infusion, 1410
**Hypercapnea**
influenza virus pneumonia, 236
in obesity, 502, 505, 506
ventilation efficiency, 1341
**Hypercholesterolemia**
and dietary intake, 1386–1387, 1392
fatty acid composition, 1011*
and hepatic cholesterol metabolism, 1434–1440
and serum lipids, 1054*
diurnal patterns, 1386–1387
and glucose, 986*
and triiodothyropropionic acid, 1054*
**Hyperemia**
alveolar, in influenza, 237
interstitial areas and chest irradiation, 591
submucosal, 237
**Hyperglobulinemia**
and osteoporosis, 1006*
serum fractionation, 1058*
**Hyperhemorrhea**
of unknown cause, 1007*
**Hyperkalemia,** and sulfate, calciuretic action, 1407–1408
**Hyperlipemia**
and dietary intake, 1386–1387
essential, 854
and starvation, 856–861
in glomerular nephritis, 186–191
nephrotic, 1717–1723
and lipoprotein lipase deficiency, 1036*
serum lipid patterns, 1386–1387
**Hypernatremia,** and water intake, 952
**Hyperoxaluria,** 1001*
**Hyperparathyroidism**
and antiricketic activity of sera, 1080
and calcium metabolism, 994*, 1021*, 1220
and phosphate, 1034*
tubular reabsorption, 1004*
renal phenomena in breast cancer, 1021*
and vitamin D-resistant rickets, 1004*
**Hyperphosphatasemia,** plasma electrophoretic pattern, 632–635
**Hyperphosphatemia** after hypercalcemia, 1052*

**Hyperplasia**
adrenal cortical, 1028*
aldosterone excretion in virilizing, 1450
and urinary 17-ketosteroids, 357–364
bone marrow in normoblastic anemia, 1183
**Hyperplasminemia,** 1005*
**Hyperpnea**
and lung diffusing capacity, 1188–1189, 1192, 1194–1196, 1200
in mitral stenosis, 1191, 1193–1195
in rheumatic heart disease, 1191–1193
**Hyperpotassemia.** *See* Hyperkalemia
**Hypertension**
and cardiac output in hyperhemorrhea, 1007*
and carotid sinus denervation, 986*
and congestive heart failure, 559, 564
and diabetes, 1048*
essential, 985*
hepatic sinusoidal, and choice of operation, 1021*
hydropenic, 1974
and hyperaldosteronism, 985*
in idiopathic high cardiac output state, 2145
in influenza complications, 237, 258
natriuresis, spontaneous, 1978
and negative pressure breathing, 1978
pulmonary, 1199
in hypoxia, 1007*
and isoproterenol, 995*
and resistance, 1047*
secondary to mitral valvular lesions, 258
in pyelonephritis, and bacterial types, 1230–1239
after renal autoexplantation, 1028*
and vasodilatation in congestive heart failure, 571–573
**Hyperthyroidism**
albumin metabolism, 94
androsterone production, 1010*–1011*
and congestive heart failure, 1316–1325
and nonesterified fatty acids, 275–277
progoitrin therapy, 1470
thyroid suppression test, 1051*
and thyrotropin, 336–340
and thyroxine, plasma transport, 1035*
and triiodothyronine, 277
**Hyperventilation**
and isoproterenol, 343–345
and plasma-urine carbon dioxide tension, 773
and pregnancy at high altitude, 1010*
and pulmonary diffusing capacity
in steady state, 921–923
in supine position, 921–923
and respiratory alkalosis, 771–776
**Hypoalbuminemia,** of acute glomerular nephritis, 190
**Hypocalcemia**
of hypoparathyroidism, 1018*
and serum vitamin D concentration, 1080–1081
and sulfate infusion, 1410
**Hypochloremia,** in respiratory acidosis, 952
and carbon dioxide, 958
**Hypoglycemia**
nocturnal variation, 2230–2232
postprandial, after glucagon injection, 1022*
tolbutamide, after pancreatectomy, 902–905
**Hypokalemia**
after 9α-fluorocortisol and 9α-fluoroprednisolone, 696, 699
in papilla, and lactic dehydrogenase, 1027*
**Hyponatremia**
and antidiuretic hormone release, 1001*
and hypertonic saline, 1015*
serum and urinary sodium excretion, 1001*
**Hypoparathyroidism**
vitamin $D_3$ and antiricketic activity of serum, 1079
**Hypopituitarism**
adrenocorticotropic assay in diagnosis, 1025*
anterior, 882–890
and cortisol, 1025*
plasma fatty acids and growth hormone, 486
posterior, 882–890
**Hypoproteinemia,** in glomerular nephritis, 190–191
**Hypotension**
after endotoxin, 1122
and glomerular filtration rate, 465–469, 471
pulmonary circulation, 531
and ventilation, 535
and renal insufficiency, 467–469, 1005*
**Hypothyroidism.** *See* Myxedema
**Hypoventilation,** in obesity, 500–506
**Hypovolemia,** and cardiac function, 117–136
**Hypoxanthine,** structural formulas, 1401
**Hypoxia,** 235
and cardiac function with digitalis, 574, 577–578
in influenza virus pneumonia, 234, 235
in obesity, 502, 505
pressor, effects, 1007*
ventilation efficiency, 1341
**Hysteresis,** and volume-pressure curves, 663, 665

I

**Ilium,** arteriovenous oxygen differences, 1023*
**Immune reaction**
in analbuminemia, 870–971
delayed hypersensitivity after irradiation, 1049*
gamma globulin fractions in serum and urine, 2159–2167
and mercaptopurine, 1041*, 1394–1402
specific to common cold, 762–768
streptokinase, 1106, 1101
to viruses, 1014*
**Infants**
aldosterone excretion, 1442–1450
bilirubin concentration, 826
and binding, 831
blood, histamine and serotinin concentration, 595–603
and Candida reacting antibody, 992*
hypogammaglobulinemia, 584–585
idiopathic hypercalcemia and vitamin D intoxication, 1080
newborn
gamma-reactive globulin, 583–584
hyaline membrane disease, 2168–2175
stillborn, lung in asphyxia, 2169
transcortin cortisol binding, 1291
**Influenza,** 199–273
*See also* Pneumonia
and acetazolamide, 223, 226, 229–230, 236, 247
antibiotic sensitivities, 233
bacteriologic studies, 218–219, 221, 223, 226
case reports, 238–256
categorization of syndromes, 216
concomitant virus and bacterial infection, 214, 224–227, 235–238, 256
coronary artery occlusion, 217
and cortisol, 248, 253
epidemiology
intrahospital, 199–211, 234–235, 258–264
pandemic, 213, 262–264
fatality, and underlying disease, 258, 260–264
postmortem findings, 236–238
and pregnancy, 216, 217, 224, 251, 260, 264
pulmonary syndrome, 213–264
differentiation studies, 256–258
respiratory tract involvement, 210, 213–214, 216–217, 234, 256
roentgenography, 218, 221, 225, 238–246, 248, 252, 255–257
serologic methods, 206–209, 211, 219–220
therapy, 223, 226, 234, 251, 253
virologic data studies, 219, 222, 223, 226, 269
comparison in syndromes, 232–234, 256–258
influenza A virus isolation, 266–273
serum cold agglutinins, 231
**Inosine**
erythrocyte preservation, 1043*
methemoglobin reduction, 1557–1562
and methylene blue, 1560
and reticulocyte iron uptake, 172
**Insulin**
and anaerobic glucose transport, 1027*
antagonist and adrenocorticotropic hormone, 553–556
antigenicity, 1002*
binding, and action correlation, 1050*
in diabetes, 1026*, 1222

**Insulin** (*cont'd*)
absorption variability, and injection site, 1222–1227
acidosis, 556, 1003*–1004*
effects in extremity, 1005*
arteriovenous difference, 2131–2134
and glucose. *See* Glucose
and growth hormone, 485–487, 1038*
and hyperlactacidemia, 1022*
and muscle, 1026*
hyperpolarization, 1057*
in neoplastic disease, 671–672
and nonesterified fatty acids, 485–487, 1022*, 1032*, 1047*, 2131–2134
and portacaval shunt, 1023*
resistance, 551
and adrenocorticotropic hormone, 553–555
and plasmin, 14–20
sensitivity, and pantothenic acid, 1424
and sodium exchange, 1700–1706
and tolbutamide activity after pancreatectomy, 905
**Intestine.** *See* Gastrointestinal tract
**Inulin, clearance**
and bicarbonate reabsorption after acetazolamide, 1664
and glomerular filtration rate, 465, 733
and mannitol diuresis, 735
in pituitary insufficiency, 885–890
in pulmonary complication of influenza, 230
after purines in gout, 1893–1895
and renal hemoglobin excretion, 655
and salicylate, 1305–1306
after steroids, in adrenal insufficiency, 688, 689
and uric acid excretion, 1302, 1892–1896
and urine osmolality, 733
**Inulin distribution**
and blood-brain barrier, 1776
and central nervous system, 1769–1776
in dogs, 1772
in rat, 1773–1774
cerebrospinal-extracellular fluid ratios, 1772
**Iron**
absorption, 1042*
aconitase activity and citrate metabolism, 1605–1616
and cysteine, 171, 1602, 1604
erythrocyte uptake, 162–164, 1485–1486
from conalbumin, 168–169
exchange, 392–395
and menstruation, 395
hemoglobin uptake of radiolabeled, 508–514
myoglobin uptake of radiolabeled, 1599–1604
plasma reappearance, after hemoglobin injection, 1484–1486
protein binding, 161–183
and transferrin, 1485–1486
reticulocyte uptake, 161–183, 393, 1002*
siderocyte recycling, 997*
stores in anemia, radioiron chelate determination, 1019*
turnover, 392
of total miscible body iron, 395
**Irradiation**
and antibody production, 1046*, 1049*
delayed hypersensitivity, 1049*
chest
and cardiac output, 590
and pulmonary function, 587–592
in leukemia, 1014*
liver and spleen cell infusions after, 1013*–1014*
of ovaries, after radioiodine, 1012*
and red blood cell mass, 1030*, 1031*
thrombocytopenia, and platelet transfusions, 1689–1696
transplant after, 1013*
bone marrow, 1709–1716
**Isocitric acid**
dehydrogenase, serum concentration in myocardial infarction, 2111–2118
in tricarboxylic acid cycle, 414
**Isoniazid**
and panmyelophthisis, 1182
in tuberculosis therapy, 1349–1374
and para-aminobenzoic acid, 1364, 1369–1370, 1372–1373
and para-aminosalicylic acid, 1361, 1364, 1369–1370
and streptomycin in combination, 1349–1355, 1370–1374
**Isoproterenol**
and atrial pressure and venous tone, 342–345
in pulmonary hypertension, 995*

J

**Jaundice,** intrahepatic cholestasis, 1039*
**Jejunum,** sodium absorption, and mercaptomerin, 1003*
**Joint,** stiffness measurement, 1056*

K

**Kaluresis,** after bicarbonate, 28–29
**Kanamycin,** in renal disease, and blood clearance, 1509–1518
**16-Ketoestradiol,** fractionation, 621–628
**16-Ketoestrone,** fractionation, 621, 625–628
**11-Ketoetiocholanolone,** urinary excretion, and adrenocorticotropin, 359–364
**α-Ketoglutarate**
excretion, and acid-base balance, 420
in kwashiorkor, 1026*
and malate excretion, 416, 419
in tricarboxylic acid cycle, 414
tubular synthesis and transport, 420, 421
**Ketone bodies,** in influenza complications, 230
**17-Ketosteroids**
in adrenal cortical hyperplasia, 357–364
and adrenocorticotropic hormone, 357
and 1,4-diene steroids, 699–700
and SU-4885, 2102–2109
and thyroxine-binding, 1683–1687
after vanadium, 1256
**Kidney**
aconitase in iron deficiency, 1608–1610
and ammonia formation
adaptation of enzymes, 193–198, 366–371
and ammonium ion excretion, 1139–1140, 1147
artificial, 1040*, 1492–1495, 1503–1507
autoexplantation, 1027*
bicarbonate reabsorption, 1663–1670
clearance, 1040*
of diiodotyrosine and iodine, 784–786
fetal, 975–976
hydrogen isotope concentrations, 975
and thorax volume receptor areas, 841
thyroxine, 1900–1902
and triolein, 540–543
tritium, 975–976
water, 841, 1005*
compression of, intra-pelvic and urinary pH, 991*
concentrating ability
in aminonucleoside-induced disease, 516–522
collecting ducts, 1219
and desoxycorticosterone acetate, 1160–1167
Henle's loop, 1219
medullary, 737, 1005
and osmotic diuresis, 1725–1731
and parathyroid extract, 1214–1220
and persisting nephrons, 517–522
and solute excretion, 1–12
copper concentration, and age, 1675
disease, 1053*
and acidosis, 39–51
and antibiotic clearance from blood, 1487–1518
and chloramphenicol, 1498–1507
and chlortetracycline, 1487–1495
and erythromycin, 1512–1518
isosthenuria, 522, 1005*
and kanamycin, 1512–1518
and penicillin, 1510–1518
and streptomycin, 1510–1518
and tetracycline, 1487–1495
excretion
and electrolytes, in chicken, 21–29
sodium, 990*
and extracellular acidosis after rubidium, 1542
function
and acetazolamide, 1053*
and endotoxins, 1009*, 1228–1239
and glomerular filtration rate, 467, 472, 731
in gout, 1892
and hypertension, 985*
and intrathoracic pressure, 836–841
in pituitary lesions, 882

and vasodilatation in congestive heart failure, 570–573
and vitamin D, 1220
glutaminase, 366–371
in respiratory acidosis, 955–956
hemoglobin reabsorption, 655–658
intravascular fibrin deposition, 59–61, 65
juxtaglomerular cell granulation, 605–610
and low protein diet, 744–745
in malic acid synthesis, 419–422
and plasma lipid concentration, 1718–1720
in potassium depletion, 1056*, 1160–1167
in pyelonephritis, grading lesions, 1229, 1232–1239
and serum isocitric and lactic dehydrogenase concentration, 2116
toxicity, of mustard treated homogenates, 1055*
tricarboxylic acid cycle members, 422
triiodothyronine, 984*, 1900–1902
tubules, 422, 1219, 1782
and magnesium excretion, 1742, 1744
and sodium transport, 1029*
**Krypton,** in shunt detection, 990*, 1006*
**Kwashiorkor**
carbohydrate metabolites, 1025*–1026*
plasma protein concentration, 1243

L

**Lactate**
in erythrocyte metabolism, 795, 796
and aging, 1584
glucose conversion to, 1557, 1561, 1574, 1575
glycogen breakdown, after glucagon, 1022*
and magnesium excretion, 1734–1738
and pyruvate ratio in kwashiorkor, 1026*
in uremia, body fluids, 1043*
**Lactose,** distribution, 1027*
**Latex fixation test,** 1041*
**Lauric acids**
in breast milk, 448–450
and epididymal fat uptake, 1032*
**Lead**
and heme synthesis, 173
and reticulocyte iron uptake, 172, 173
urine concentration, 1452–1462
after ethylenediaminetetraacetate, 1462
**Lecithin**
erythrocyte and plasma exchange, 1032*
lipid fractions, 1053*
serum concentration, 490–493
in hepatic and pancreatic diseases, 1006*
**Leucine,** and phenylpyruvate transaminases, 2192, 2193
**Leukemia**
hemorrhagic complications, and defective fibrin polymerization, 1005*
irradiation in, 1048*, 1709–1716
and marrow restoration, 1709–1716
isologous transplantation, 1048*
mycotic infections, 992*
vitamin $B_{12}$ binding, 1026*, 2135–2143
**Leukocytes**
aconitase activity, in iron deficiency, 1611
and antineoplastic agents, 988*
aspartate carbamyltransferase, 801–802, 805–806
species difference, 807
carbamylaspartate, 802–808
and connective tissue antibodies, 1010*
dihydroorotic dehydrogenase, 802–806
in endotoxemia, 675, 679
enzyme patterns, in pyrimidine synthesis, 1044*
and erythrocyte volume in healthy men, 1074
glucose-6-phosphate dehydrogenase deficiency, 1024*, 2234–2237
racial factor, 2253–2262
in hemorrhagic shock, 678–679
in influenza complications, 204–205, 216, 218, 221, 225, 227, 257
neutrophilic, 236, 237
after irradiation
in leukemia, 1048*
and platelet transfusion, 1690
labeling *in vitro,* 1025*
orotic acid synthesis, 802–808
polymorphonuclear, and staphylococci, 996*
**Leukopenia**
and endotoxemia, 675, 678
in hemorrhagic shock, 679
in influenza, 205, 211
**Levarterenol.** *See* Norepinephrine
**Linoleic acids,** in breast milk, 449
**Lipid**
*See also* Cholesterol; Fatty acids
acetate incorporation in, 1718
in atheromatous plaque, 543
breast milk fatty acid patterns, 448
cholesterol-esters, 1546, 1549, 1550
and coronary blood flow, 1033*
and erythrocyte integrity, 1054*
extraction from urinary RS-1 solids, 1522
fecal excretion, after vanadium, 1253–1255
fractions, 1053*
and heparin, 856–861, 1034*
after hog pituitary extracts, 1038*
in hypercholesterolemia, 1386–1387
in hyperlipemia, 854–855, 1386–1391, 1718
intestinal absorption, 1329
metabolism, 860–861, 999*, 1392, 1716–1723
and autonomic nervous system, 989*
in nephritis, 186–191
in nephrosis, 986*–987*
and nicotinic acid, 1329
and oxygen diffusion, 1033*
serum, lysolecithin isolation, 1006*
and triiodothyropropionic acid, 1054*
**Lipoprotein,** 1016*
in essential hyperlipemia, 860–861
and glucose, 986*–987*
lipase system, 1036*, 1746–1754
in nephrosis, 986*–987*, 1036*
phospholipid composition, 489–493
synthesis, and liver damage, 860
**Liver**
aconitase, in iron deficiency, 1608
blood flow, 1021*
cells, 1055*
drug-induced cholestatic jaundice, 1039*
glycolysis and protein synthesis, 324
cholesterol
and bile acid synthesis, 1334–1338
in nephrotic hypercholesteremia, 1434–1440
and rabbit antirat kidney serum, 1434–1440
cirrhosis. *See* Cirrhosis
in congestive heart failure, and vasodilation, 560
copper concentration and age, 1675
disease, 1006*, 1013*, 1058*
and blood 5-hydroxtryptophan concentration, 715–716, 719
hemagglutination test, 1022*
5-hydroxyindole metabolism, 933–937
mesobilifuscin-urobilinogen ratio, 1183
and serum phosphatase, 632
fatty, in kwashiorkor, 1026*
fatty acids, 1719
fetal, 1013*
hydrogen isotope exchange, 975–976
function, 1990
and chloramphenicol, 1504, 1505
and lipoprotein lipase removal, 1746–1754
in pulmonary complications of influenza, 230
glucose output and insulin, 1023*
glucose-6-phosphate dehydrogenase deficiency, 1024*
glycogen, 1022*
after endotoxin, 1039*
storage disease, 1021*
hemodynamics, 1021*
in hemorrhagic shock, 679, 680
intravascular fibrin deposition, 59–61, 65
in iron-deficiency, aconitase, 1608
isocitric and lactic dehydrogenase concentration, 2115
lipoprotein lipase, from blood, 1746–1754
phenolphthalein release, 454
and phenylalanine metabolism, 2189–2196
and phenylpyruvate metabolism, 2192, 2193
protein synthesis, 322, 1992
in alloxan diabetes, 319
and sulfobromophthalein retention, 994*, 1990
uptake after hepatic and portal vein injections, 2202–2214
triiodothyronine metabolism, 984*, 1902
toxicity of mustard treated homogenates, 1055*

**Liver** (*cont'd*)
and triolein, iodinated, 540, 543
tyrosine formation, from phenylalanine and age of liver, 2189–2196
vitamin $B_{12}$, intrinsic factor action, 105
water and electrolyte concentration after nephrectomy, 752
**Lungs**
blood flow, 1006*
arteriovenous shunt, 1916–1921
breath sounds, 221
and chest irradiation, 587–592
chronic disease and cold air exposure, 1054*
compliance, 587–592, 1009*, 1268
and body position, 659–667
and hemorrhage, 526
in hyaline membrane disease, 2173–2174
in obesity, 504, 505
and pulmonary disease, 1054*
congestion, 460, 665
copper concentration, and age, 1675
diffusing capacity, 589–590
breath holding technique, 925–930
carbon monoxide, 916–930, 1186–1200
in mitral stenosis, 1191, 1193–1195
in rheumatic heart disease, and exercise, 1191–1193
and voluntary hyperpnea, 1188–1189, 1192, 1194–1196
distention, and airway pressure, 460–461
elastic properties, 460
after elastin removal, 1009*
fetal, hydrogen isotope distribution, 975–976
gas volume, 229–230
and alveolar-capillary gas exchange, 1198
and heart failure, 227
in hemorrhagic shock, 679, 680
in hypotension, 531
hysteresis, volume-pressure curve, 663
inflation at birth, and pulmonary vascular distention, 456–462
in influenza. *See* Influenza
intravascular fibrin deposition, 59–61, 65
mechanical work, in emphysema, 1343
and oxygen uptake, and arterial saturation, 1917–1921
resistance, 661, 663, 1262–1270
in asthma, 1266
and chest irradiation, 590
in congestive heart failure, 562–570
and esophageal pressure, 1266
in hyperthyroidism, 1319
and vasodilatation, 562–570
in stillborn infants, intrauterine asphyxia, 2168–2175
transcapillary sodium and phosphate exchange, 2224–2228
in tuberculosis. *See* Tuberculosis
vital capacity, 510, 1342
volume, 930
and body position change, 661–662
after irradiation, 587–592
in pneumothorax, 1346
and pressure, in hyaline membrane disease, 2168–2175
weight, in newborn and stillborn infants, 2169, 2170
**Lupus erythematosus phenomenon,** 325–332
antibodies to cell constituents, 1013*
**Lymph**
cholesterol and lipid concentration, and nicotinic acid, 1329
dilation and chest irradiation, 591
erythrocyte output, after platelet transfusion, 1690–1696
flow rate, 1689–1696
**Lymphocytopenia,** in influenza, 205, 211
**Lymphoma,** mycotic infections, 992*
**Lysine**
anomalous, albumin B, 1419
urinary excretion, in hepatic cirrhosis, 1038*
**Lysolecithin**
lipid fractions, 1053*
serum concentration, 490–493
in hepatic and pancreatic diseases, 1006*
**D-lyxose,** urinary excretion, 408, 410–412

**M**

**Macroglobulinemia**
fecal urobilinogen and mesobilifuscin ratio, 1184
isolated rheumatoid factor, 430–431
serum fractionation, 1058*
**Magnesium**
bone concentration, in respiratory acidosis, 955, 958–959
and calcium excretion, 1407, 1052*
after sulfate, 1407–1410
chelate complexes, 1742–1743
excretion, 986*, 1028*
after acetazolamide, 1736, 1738, 1740
and calcium infusion, 1736, 1740, 1744
and electrolytes, 1736–1744
in kwashiorkor, 1026*
after lactate, 1735, 1737–1744
and magnesium intake, 1736, 1740, 1744
after mercurial diuretics, 1736, 1740, 1744
and para-aminohippuric acid saturation, 1736–1744
and probenecid, 1736–1744
in uremic syndrome, 1052*
and urinary phosphate, 351–356
urine-plasma ratio, 1028*
mitochondrial concentration, in carbon tetrachloride poisoning, 1034*
phosphate, 1052*
sulfate, 1736–1744
tetany syndrome in man, 1049*–1050*
and thrombin time, in hyperglobulinemia, 1006*
transport in erythrocytes, and aging, 1579–1580
tubular reabsorption, 1742
**Malabsorption syndrome,** 1014*
**Malic acid,** excretion, and tricarboxylic acid cycle, 414–423
**Manganese,** urine concentration, 1452–1462
**Mannitol diuresis,** 837–841
and glomerular filtration rate, 517–518, 735, 740
in kidney disease, 517–518, 991*
and plasma bicarbonate concentration, 940
and urine, 740, 844, 1220, 1726–1731
and urea, 743
and water reabsorption, 747, 852
**Menstruation**
iron turnover during 393–395
and organic acid excretion, 422
**Meralluride,** and sodium exchange, 1700, 1703, 1705, 1706
**Mercaptide,** in sulfobromophthalein metabolites, 1985, 1987
**Mercaptoethanol**
and fatty acids, 1032*
rheumatoid factor, dissociation with, 430, 432
**β-Mercaptoethylamine,** and subcutaneous fat, 1032*
**Mercaptomerin**
and 5-hydroxytryptophan excretion, 716, 717
and intestinal absorption of sodium, 1003*
**6-Mercaptopurine,** and immune responses, 1394–1402
tolerance induction, 1041*
**Mersalyl,** and electrolyte excretion, 26
**Mesobilifuscin**
dipyrrylmethene pigments, 1166–1174
fecal excretion, in anemias, 1175–1185
urinary excretion, in parenchymal liver disease, 1183, 1184
**Metacortandracin.** *See* Prednisone
**Metacortandralone.** *See* Prednisolone
**Methacholine**
colonic responses, 2119–2129
**Methemalbumin,** 475–476, 480–483, 653, 657–658
**Methemoglobin,** reduction, 1555–1562
**Methionine**
metabolism pathways, 2222
and plasma protein synthesis, 1243–1250
recoverable as net acid, 1034*
and sulfur metabolism, 2215–2223
and urine sulfur excretion, 1244, 1247
**Methotrexate,** 1032*
**Methoxamine,** in mitral valve disease, 1045*
**2-Methoxyestrone**
and chorionic gonadotropin, human, 1049*
polarity, 628
**3-Methoxy-4-hydroxymandelic acid**
in pheochromocytoma, 35–37
urinary excretion, 708–710
**2-Methyl-1,2-bis-(3-pyridyl)-1-propanone (SU-4885)**

structural formula, 2101
and urinary electrolytes and steroid excretion, 2101–2110
**16α-Methyl-17α-hydroxy-11-desoxycorticosterone,** and sodium retention, 1029*
**Mitochondria**
in carbon tetrachloride poisoning, 1034*
and serum fatty acid exchange, 1022*
swelling after thyroxine, 793–794
triiodothyronine metabolism, 984*
**Mitral valve**
insufficiency, 145
and influenza complications, 217, 220, 224, 260–261
regurgitant flow, 994*–995*, 1045*
stenosis, 217, 260–261, 995*, 1200
and high cardiac output, 2149
and hypertension, 1199
and hypervolemia, 117–136
and pulmonary diffusing capacity, 1191, 1193, 1195
and right ventricular stroke work, 132
**Molybdenum,** urine concentration, 1452–1462
**Monamine,** oxidase inhibitor and colonic response to acetylcholine and serotonin, 2124, 2126
**Mucopolysaccharides**
metabolism, in connective tissue, 451–455
of skin, in pretibial myxedema, 945–947
thrombocytes of rheumatoid arthritis, 1059–1064
and thyroid stimulating hormone, 989*
**Mucoproteins,** and vitamin $B_{12}$ binding, 1026*
**Muscle**
in alkalosis, 378–381, 724–728
ammonia concentration, 373–382
dystrophic, 873–880
and adenosine triphosphatase, 876, 877
fibrous tissue content, 875, 876, 879–880
juvenile, and neurogenic atrophy, 873–880
myoglobins, 1029*–1030*, 1040*, 1600–1604
electrical potential across membrane, 1057*
electrolyte concentration, 752
in respiratory acidosis, 954–955, 958
extraocular, and thyroid stimulating hormone, 989*
glucose uptake
and cellular permeability, 1017*, 1027*
in exercise, 1005*–1006*
and hexokinase, 1017*
glutamine concentration, 379
and insulin, 1004*, 1057*
intracellular pH, 720–728
mass, and erythrocyte volume, 1076
pharyngeal, in swallowing, 401
radioactivity, after radioiodine, 1012*
respiratory, in emphysema, 494–498
temperature and oxygen uptake after anaerobic work, 1130–1133
thyroxine, deiodination to triiodothyronine, 1902
toxicity of mustard treated homogenates, 1055*
skeletal, 752, 873–880
water content, 752, 875–880
**Myeloma**
and influenza complications, 224, 261
serum fractionation, 1058*
and transcortin cortisol binding, 1293
**Myocardium**
failure, and veno-arterial shunt, 985*
infarction
isocitric and lactic dehydrogenases, 2111–2118
and one stage prothrombin time, 1105
and streptokinase therapy, 1112, 1118
transaminase concentration, 1113, 114
urokinase excretion, 1114
and influenza, fatal, 260–261
left ventricular pressure, and fiber length, 1021
oxygen consumption, 1033*
and strophanthidin, 306–315
vectorcardiography, 991*
**Myoglobin,** 1020*
in muscular dystrophies, 1029*, 1030*, 1040*, 1600–1604
**Myosin,** of dystrophic muscle, 877–880
**Myristic acids,** in breast milk, 448–450
**Myrosin,** and goitrin formation, 1465–1474
**Myxedema**
iodoalbumin metabolism, 88–100
and thyroid hormone, 91–100
pretibial, mucopolysaccharide measurement, 945–947
serum lipid concentrations, 1054*
and testosterone conversion to androsterone, 1010*–1011*

**N**

**Neomycin**
and malabsorption induction, 1014*
and urea synthesis, 1617, 1623–1625
**Neoplasm.** *See* Cancer
**Neostigmine,** and sodium exchange, 1700, 1703, 1705, 1706
**Nephrectomy**
ammonia metabolism after, 378–379
**Nephritis**
aminonucleoside and sodium excretion, 990*–991*
glomerular, and hyperlipemia, 186–191
and hepatic cholesterol metabolism, 1434–1440
and hyperlipemia, 191, 1717–1723
hypoalbuminemia, 191
and nephrosis, differential diagnosis, 191
urinary urate excretion and zoxazolamine, 997*
**Nephrosis**
serum lipids and lipoproteins, 986*
and transcortin cortisol binding, 1293
**Nervous system**
autonomic, 713
and exercise in cardiac failure, 1055*
and lipid metabolism, 989*, 1007*
and venoconstriction in heart failure, 1056*
and venous pressure, 1055*
central
adaptability in hypotension, 1016*
and ammonia in hepatic coma, 381
involvement in influenza, 233–234
sensitivity to endotoxin, 1124–1125
disorders, and neuraminic acid, 1763–1769
and muscle atrophy, 873–880
parasympathetic and intestinal smooth muscle, 2119–2130
**Neuraminic acid**
acetyl and glycolyl derivatives, 755, 759
cerebrospinal concentration in neurologic diseases, 1756–1757
structure, 755
ventricular fluid concentration in hydrocephalus, 1762
**Niacin,** 907
**Nickel,** urine concentration, 1452–1462
**Nicotinamide,** and uric acid synthesis, 1019*
after thiadiazoles, 908–910, 913–914
**Nicotine,** antidiuretic responses in aldosteronism, 999*
**Nicotinic acid**
and aortic atherosclerosis, 1330
cholesterol-lowering effect of anoretic properties, 1328–1333
**Nitrogen**
balance, 1245
and salicylates, 1003*
collagen, in dystrophy and neurogenic atrophy, 875
and erythrocyte radioiodine binding, 280–286
excretion, after methionine, 2216–2223
fecal excretion, 1153, 1242
in dipyrrylmethene compounds, 1070–1073
fraction in expired gas, 1193
isotopic, and urea metabolism, 1617–1625
metabolism
in adrenal insufficiency, 682–687, 694
and dietary intake, 894–895, 1137–1143, 1147
kinetic analysis, 892–901
San Pietro-Rittenberg model, 893–897
and methionine metabolism in protein depletion, 1241–1250
noncollagen, in kwashiorkor, 1026*
potassium chloride ratio, 1142

**Nitrogen** (*cont'd*)
urinary excretion, 694, 1137–1143, 1147, 1153, 1624
extraction from RS-1 solids, 1522
subfractions of ultrafiltrable fractions, 1932–1933
after thiadiazole, 1019*
**Nitrogen mustard**
and hematodepression, 988*
toxicity, 1055*
**Nitrophenylphosphatase,** serum acid, platelet as source, 148–153
**Noradrenaline.** *See* Norepinephrine
**Norepinephrine**
and adrenal blood flow, 1279–1282
and venous outputs after endotoxin, 1121
in aortic regurgitation, 1564–1570
and arterial system, 1030*
and atropine, 922
brain stem concentration, and ethanol, 1008*
and cardiac output, 922–924
catabolites, identification, 709
G suit and pulmonary vascular pressures, 924
hemodynamic responses, 1566–1570
in hemorrhagic shock, 678
and hypertension, in hypoxia, 1007*
in influenza and pulmonary complications, 223, 226
and left atrial pressure, 1007*
metabolism, 33–35, 707–773
in pheochromocytoma, 31–37, 1939–1940
plasma concentration, 13–37, 1935–1940
and nonesterified fatty acids, 989*, 1007*
and pulmonary diffusing capacity, 922–924
and sodium exchange time, 1700–1706
urinary excretion, 708, 710
**Normetadrenaline,** urinary excretion, 708, 710–711
**Normetanephrine,** in pheochromocytoma, 35, 37

O

**Obesity,** and ventilation, 502–506, 1341–1347
**Oleic acid**
in breast milk, 447, 449
and epididymal fat uptake, 1032*
**Orinase®.** *See* Tolbutamide
**Ornithine,** urinary excretion, 1038*
**Orotic acid,** synthesis, 798–808
**Orthoaminobenzoate,** and 5-hydroxyindoleacetic urinary excretion, 935–937
**Orthophosphate,** adenosine triphophatase and salicylates, 1002*
**Osteoporosis**
calcium binding, 1006*
clotting defects, 1006*
in Cushing's syndrome, 1046*
and hyperglobulinemia, 1006*
**Oxalic acid,** synthesis, hyperoxaluria, 1001*
**Oxaloacetic acid**
glutamic transaminase, serum concentration in myocardial infarction, 2111, 2116
in tricarboxylic acid cycle, 414
**Oxalosuccinate,** in tricarboxylic acid cycle, 414
**Oxygen**
arterial concentration
in congestive heart failure, 561–570
after head injury, 1000*
in Valsalva maneuver, 1916–1921
arteriovenous difference, 559–570
and Arfonad®, 557–578
and bath temperature, 1128
cerebral, 1016*; and eating, 2155
and chest irradiation, 587–592
and dextran hypervolemia, 122–125
and digitalis, 574–575, 577–578
in forearm, postexercise, 1129–1133
in high cardiac output, 2146, 2147
in hyperthyroidism, 1319
and hypervolemia, 120–125
and glucose, 120–121
and methoxamine, 1045*
in normal resting man, 1033*
regional, in polyostotic fibrous dysplasia, 1023*
and strophanthidin, 307–308
and vasodilatation, 562–570
consumption, 122–125, 561–570
and atropine, 922–924
cerebral, and eating, 2155
in emphysema, 498
and epinephrine, 922–924
of erythrocytes after triiodothyronine, 789–796
and exercise, 922–924, 1318–1325
and glucose, 120–121
and heparin, 1034*
and high cardiac output, 2146–2152
in hyperhemorrhea, 1007*
in lipemia, 1033*
myocardial, 310, 1033*, 1034*
and norepinephrine, 922–924
in obesity, 502–506, 1342
after partial cardiopulmonary by-pass, 1057*
and pulmonary diffusing capacity, 922–924, 927–928, 1187
and respiratory muscles in emphysema, 494–498
and strophanthidin, 307–308, 310
in thyrotoxicosis, 1318–1325
and triiodothyronine, 277
intake
and blood shunts, 1917–1921
and cardiac output, 1033*
forearm and temperature, after anaerobic work, 1126–1133
and hemorrhage, 235, 530, 533
and pulmonary artery occlusion, 1190, 1195–1197
and respiratory center response time, 1036*
and salicylates, 1003*
therapy in influenza complications, 235
and ventilation in emphysema, 1340
mixed venous concentration, 235, 530, 562–570
tension, 502–506
and iron uptake by reticulocytes, 171
ventricular, and chest irradiation, 587–592
**Oxyhemoglobin,** and pulmonary function, 1342
in influenza complications, 230
**Oxytetracycline**
and ammonia concentrations, in gastric secretions, 1271–1272, 1275
and gastric secretion in uremia, 1272–1273
plasma protein binding, 1956–1958, 1961
serum concentration, 1952–1961
urinary excretion, 1954–1956, 1961
and urea synthesis, 1621
**Oxytocin,** and sodium transport by toad bladder, 1020*

P

**Paget's disease,** serum alkaline phosphatase, 635, 637
**Palmitic acid**
in breast milk, and dietary intake, 447, 449
and epididymal fat uptake, 1032*
and fat metabolism, after growth hormone, 993*
serum albumin-binding of radiolabeled, 1720–1723
**Pancreas**
disease, and lysolecithin concentration, 1006*
extract, and diurnal serum lipid variations, 1019*
**Panhypopituitarism,** lipid concentrations, 1054*
**Pantothenic acid,** deficiency, 1421–1425
**Para-aminobenzoic acid,** in tuberculosis, 1357–1538, 1369–1370
**Para-aminohippurate clearance**
in adrenal cortical insufficiency, 686
and central nervous system fluids, 1032*
and glomerular filtration rate, 733, 734
and electrolyte excretion, 1736–1744
in hypertension, 985*
on low protein diets, 742
and mannitol diuresis, 735
in pituitary insufficiency, 885–890
and sodium excretion by diseased kidneys, 991*
and urinary excretion, 733
magnesium, 986*, 1736–1744
urea, 743
**Para-aminophenol,** and zoxazolamine, 997*
**Paraphenylenediamine,** and serum ceruloplasmin, 1673–1675
**Parathyroid**
and calcium, 999*
adrenal depletion, 1018*
reabsorption, 994*
and citrate excretion, 1018*
and phosphate metabolism, 1034*

and renal concentrating ability, 1214–1220
**Penicillin**
blood clearance, 1509–1518
and staphylococcal resistance, 1018*
in streptococcal pharyngitis, 1944
**Pentoses,** metabolism of radiolabeled, 407–412
**Pharyngitis,** and antistreptococcal diphosphopyridine nucleotidase, 1944–1946
**Phenobarbital**
dialysance in artificial kidney, 1040*
and serum isoniazid concentration, 1357
**Phenolic steroids.** *See* Estrogens
**Phenolphthalein,** synovial tissue release, 454
**Phenylalanine,** hepatic metabolism, 2189–2196
**Phenylbutazone,** analogs, 1313
**Phenylhydrazine** in iron deficiency, 1611
**Phenylpyruvate,** liver metabolism, 2192–2196
**Pheochromocytoma**
norepinephrine, 31–37
and epinephrine, after infusions, 1939–1940
**Phosphatase**
acid, 639, 640
akaline, 1023*, 1027*, 1044*, 1992
in bone disease, 632, 634–635
in carcinoma, 635–640
in cholangiolitic cirrhosis, 634
and cyanide, 639, 643
and fluoride, 639, 643
in polyostotic fibrous dysplasia, 1023*
and growth hormone, 1044*
in glucose degradation to lactate, 1574, 1575
in hepatobiliary disease, 632–634
**Phosphate**
and acetazolamide, 771–776
dialysance, in artificial kidney, 1040*
erythrocytes, 1054*
metabolism, 795, 796
after storage, 1043*
fractions, in kwashiorkor, 1026*
ionic strength, variation, 347–356
loss, in pulmonary emphysema, 2225, 2226
metabolism tests, in hyperparathyroidism, 1034*
and sodium exchange, 2225–2226
tubular reabsorption, 1035*
in hypercalcemia, 1021*
and vitamin D-resistant rickets, 1004*
urine excretion, 1153
and bicarbonate diuresis, 772–773
after lactate, 1735
$pK_3'$ values, 347–356
and potassium depletion, 1137–1143, 1147
**Phosphatidylethanolamine,** lipid fractions, 1053*
**6-Phosphogluconic dehydrogenase**
in erythrocyte metabolism, 795, 796
in glucose degradation to lactate, 1574, 1575
in hemoglobinuria, 1009*
in leukocytes, 2234–2237
**Phospholipids**
of aortic wall, 1016*
blood concentration, in viral hepatitis, 858, 861
after coconut oil, 1549–1550, 1552
constituents, 490–493
after corn oil, 1549, 1552
and dietary intake, 1019*, 1389–1391
diurnal variations, 1392
erythrocyte, 1032*
age, and surface area, 1054*
extraction from urinary RS-1 solids, 1522
of lipoprotein, alpha and beta ratios, 1016*
plasma concentration, 1032*, 1546
**Phosphorus**
and acetylated growth hormone, 1044*
after adrenalectomy, 1018*
deprivation, and vitamin D-resistant rickets, 1004*
and growth hormone, 1044*
metabolism
in adrenal cortical insufficiency, 682–686, 691–695
and dietary intake, 894–895
after parathyroidectomy, 1018*
serum content. *See* Serum, phosphorus
urinary excretion
and acidosis, 42–46
subfractions of ultrafiltrable fraction, 1932–1933
**Physostigmine,** and acetylcholine esterase, 704
**Phosphotungstic acid,** and vitamin $B_{12}$ binding, 1905–1913
**Pitressin®.** *See* Vasopressin
**Pituitary gland**
and adrenocorticotropic hormone, 291–297, 2101–2110
and cortisone, 293
and stress, 293, 294
anterior
hormones as antigens, 1004*
and iron absorption after hypophysectomy, 1042*
and neurohypophyseal insufficiency, coexistence of, 882–890
growth hormone, 14–20
and alloxan-diabetic hypophysectomized rats, 1038*
inhibition, 1044*
and insulin, 1038*
and iron absorption after hypophysectomy, 1042*
and plasma fatty acids, 484–487, 993*
species specificity, 1004*
and subcutaneous fat, 1032*
and sulfate uptake, 1038*
and hypoadrenal state, 296
lipemia-producing fraction from hog, 1038*
posterior insufficiency, 885–890
tumor, adrenocorticotropic hormone secreting, 1028*
**Placenta**
estrogen metabolite production and chorionic gonadotropin, human, 1049*
hydrogen equilibrium, 975–976
**Plasma**
in acidosis, respiratory, 774, 939–944
adrenal vein, aldosterone secretion, 1284–1285
and adrenocorticotropic hormone, 14–20, 302–304, 486, 1700–1706
albumin metabolism, 1676–1681
kinetic analysis, 69–87
in alkalosis, 774
respiratory, 2197–2201
ammonium, 1035*
after ammonium chloride, 194–198
antihemophilic factor, 1924–1926
anti-$Rh_0$ (D) reaction with erythrocytes, 279–289
antithrombin activity
and one stage prothrombin time, 1103
and thrombolytic state, 1108
bicarbonate, 1664–1666
and hydrogen ion secretion, 25
and reabsorption, 940–944, 1042*
in renal disease, 40–42, 44, 50–51
in respiratory acidosis, 939–944
blood-bank, steroid binding capacity, 388
calcium concentration
and serum, 1006*
after sulfate, 1407–1410
carbon dioxide concentration, 194–198, 772–776, 939–944, 957, 1539–1542, 1664–1666, 2177, 2178
after ammonium chloride, 194–198
in cholera, 1880, 1885
and 1,4-diene corticosteroids, 684, 685, 687, 696
and electrolyte exchanges, 957
and left atrial stretch receptors, 1050*
and mortality in rats, 951
in respiratory acidosis, 949–959
after sodium bicarbonate, 1885, 1889
and sodium exchange, 1700–1706
and sulfate infusion, 1407–1410
tension, 773–774, 939–944, 951, 957, 1664, 2197
carotene, in neomycin malabsorption syndrome, 1014*
catechol amines, 33
in idiopathic high cardiac output state, 2146
and cerebrospinal fluid sodium exchange, 1698–1706
chloride, 952, 1539–1542
and acid-base, 2177, 2178
and erythrocyte estrone concentration, 613–617
and sulfate infusion, 1407–1410
after rubidium, 1539
cholesterol, 1252, 1337, 1546, 1718–1720
and bile acid synthesis, 1334–1338
and dietary intake, 1019*, 1043*, 1389–1391, 1436
diurnal variations, 1019*, 1392
in hyperlipemia, 855, 1718–1723
and hypotensive therapy, 1013*
in nephrosis, 1434–1440
and nicotinic acid, 1329–1330

**Plasma** (*cont'd*)
after rabbit antirat kidney serum, 1439
secretion through intestinal mucosa, 1337
in viral hepatitis, 858, 861
in zincuria, 1460
clearance
cortisol, 299–304
estrone, 621–622
and inulin-urate, 1304
potassium in pituitary insufficiency, 884
radioiodine and thyrotropic hormone effect, 334–341
radioiron, 1018*
clot lysis, 1089
after electroshock, 814, 819
coagulation, 1044*
in hemorrhagic shock, 55–56
in hyperglobulinemia, 1006*
cord blood, histamine concentration, 600–601, 603
corticosteroid, 998*
and adrenocorticotropic hormone, 302–304
binding, 384–391, 998*
cortisol, 302–304, 385, 995*, 998*
cord blood, 1050*
and hypoglycemia, 1001*
in hypopituitarism, 1025*
metabolites, 2244–2250
neonatal, 1050*
creatinine concentration, 44
diodrast concentrations, 988*
electrolytes
in cholera, 1880–1881
after rubidium, 1539
after sodium cycle resin, 1053*
epinephrine, 817–821, 1007*
after infusion, intravenous, 1935–1940
in pheochromocytoma, 1939–1940
in schizophrenia, 1937–1941
and erythrocytes, estrone, *in vitro* studies, 611–617
euglobulin fractions, 817–821
fatty acids, 1544–1553
nonesterified, 275–277, 484–487, 989*, 1007*, 1032*, 1047*
fibrinolytic activity, 1099
and acetylcholine, 817–821
after electroshock therapy, 814–821
and epsilon amino caproic acid, 819–821
in hemorrhagic shock, 57–58
in hyperplasminemia, 1005*
after streptokinase, 1090
glucose, and triiodothyronine, 277
hemoglobin, 474–483, 653–658
and plasma pool outflow, 1479–1482
histamine concentration, 597, 599
hormone destruction, 14–20
17-hydroxycorticosteroids, after tetrahydrocortisone, 301
5-hydroxytryptamine, 597, 600
iodoalbumin metabolism in myxedema, 91–100
iron, 997*
and aconitase, 1608, 1610
after citrate loading, 1614–1615
deficiency, 1018*
and iron exchange in man, 393
and lead-poisoned reticulocytes, 173, 180
in sideroachrestic anemia, 998*
and ischemia, 817–821
lactate
after eating, 1037*, 2156, 2157
in high cardiac output, 2146
after strophanthidin, 310, 315
lipid, 1550
and deoxyribonucleic acids, 1039*
and diet, 448, 856–859, 1019*, 1384–1392, 1546–1550
diurnal variations, 1019*, 1384–1392
fractions, 1053*, 1547
and glucose, 986*–987*
in lipemia, 1033*, 1544–1553
after rabbit antirat kidney serum, 1439
and starvation, 856–861
and triiodothyropropionic acid, 1054*
lipoprotein lipase concentration, after heparin, 1746–1754
loss, in hemorrhagic shock, 62, 64–65
magnesium
and glomerular filtration rate, 1741
after lactate, 1734–1737
and reabsorption, 1741–1744
mothers and newborn infants, transcortin-cortisol binding, 1291
and mucosubstances of urine RS-1 solids, 1530–1536
in myelocytic leukemia, 1904–1913
norepinephrine, 1007*
after infusion, intravenous, 1935–1940
in pheochromocytoma, 31–37, 1939–1940
in schizophrenia, 1937–1941
osmolality, 2–6, 518–519, 743, 887, 1407–1410, 1730, 1885, 1976
pH, 169, 476–477, 771–776, 1664, 1743–1744
in hypercalcemia, 1052*
and ionic strength, 1052*
after sodium cycle carboxylic acid, resin, 1053*
and urine titratable acid, 353–357
phosphate, in hypercalcemia, 1052*
phospholipids, 1032*
after rabbit antirat kidney serum, 1439
plasmin, 1087–1088
plasminogen, 1093
platelet-poor, acid nitrophenylphosphatase activity, 149, 152, 153
potassium, 849, 1053*
and acid-base balance, 2176–2186
after bicarbonate, 1886
in cholera, 1886
and desoxycorticosterone acetate, 845
and dietary intake, 952
peritubular, in chicken, 22–29
in respiratory acidosis, 25–26, 952, 955, 958–959
after rubidium, 1538–1542
after sodium bicarbonate, 1053*
sodium correlation, 2176–2187
and sulfate infusion, 1407–1410
proteins, 988*
binding of corticosteroids, 384–391
binding of estrogens, 1290
binding of hemoglobin, 483, 653, 657
and dehydration in cholera, 1881, 1885
methionine incorporation into, 1243–1250
myoglobin binding, 1020*
perchloric and phosphotungstic acid precipitable, 1905–1913
in protein depletion, 1243–1250
tetracycline analogues, 1956–1958, 1961
after thyroid stimulating hormone, 334
vitamin $B_{12}$ binding, 1904–1913
prothrombin time, 1103, 1632, 1635
and pyrogen, 817–821
renal flow, 884–890
and alcohol, 837, 840
in congestive heart failure, 571–573
in hypercalcemia, 1052*
and intrathoracic pressure, 836–841
salicylate concentration after infusions, 1303–1305
sodium, 1730
and cerebrospinal fluid exchange, 1698–1706
in hypercalcemia, 1052*
potassium correlation, 2176–2187
in respiratory acidosis, 952
after rubidium, 1539
after sodium infusion, 1883–1885
and sulfate infusion, 1407–1410
variations, individual and species, 1703
after water, 1885
and solute diuresis, 743
and streptokinase, 14–20, 1013*, 1099, 1106–1107, 1632, 1635
and plasminogen activation, 1090, 1099
tetrahydrocortisol glucuronide, 995*
thrombolytic activity
and clot plasminogen concentration, 1090–1091
and epsilon amino caproic acid, 1092
and myocardial infarction, 1111–1118
thromboplastin component, in hemophilia, 1924–1926
thyroxine half-life and thyroxine-binding, 1683–1687
transcortin binding, 384–391
tyrosine concentration, 36
umbilical cord blood, cortisol binding, 998*
urea, 1730
on low protein diet, 741–742
and urea space measurement, 1625
uremic, ionic composition, 1052*
uric acid
dietary intake, 1891
after purines in gout, 1893–1894
-urine ratios, 2–12
in osmotic diuresis, 1726–1731
volume
and body composition, 1065
in congestive heart failure, 560

and estrone distribution, 612
height and weight relation, 1069–1071, 1075–1076
in obesity, 502, 503
in pneumonia complicating influenza, 228
and pressure breathing, 840
after thyroid hormone, 94, 100

**Plasmin**
and chloroform-induced esterase, 984*
clot dissolution, 1086–1094
and reformation, 1633
and fibrinolytic system, 812–813, 818, 821, 1630–1641
inhibitor neutralization *in vivo*, 1630–1631
plasma concentration, 1087–1088
prothrombin activity during hemorrhagic shock, 56, 58
p-toluene L-arginine methyl ester, 984*
purified human, and insulin, 18–19
streptokinase-activated, 1088, 1099–1100, 1632–1641
and polypeptide hormones, 14–20
thromboembolic disease, 1096–1118
and thrombolytic mechanisms, 1094
and urokinase, 813, 1089

**Platelets**
acid nitrophenylphosphatase source, 148–153
and erythrocyte volume in healthy men, 1074
globulin coating, 159
in hemorrhagic shock, 54, 55, 58, 64
histamine, 597
after irradiation, in leukemia, 1048*
lifespan, 985*
after freezing with glycerin-plasma solutions, 995*–996*
microelectrophoresis and dextran, 155–159
phospholipids, 1032*
serotonin concentration
after 5-hydroxytryptophan, 717
in infancy and childhood, 597–600
storage, 985*
and streptokinase therapy, 1101
transfusion of fresh and lyophilized, 1689–1696

**Pneumonia**
*See also* Influenza; Viruses
bacterial, 202, 203, 210, 214, 217–220, 223, 229–230, 233–236, 239, 250, 256, 257, 264
secondary, 233, 234, 257
diffuse abacterial, and antecedent heart disease, 258
pneumonococcal, 240
and muscular dystrophy, 241
primary influenza virus, 214, 220–222, 223, 234, 236, 256–257
and rheumatic heart disease, 262
staphylococcal, 234, 237, 239
virus, 214, 220–222, 234, 236

**Poisoning**
carbon tetrachloride, 1034*
lead, porphyrin synthesis, 1184

**Poliomyelitis**, viruses, and transferrin, 1024*

**Porphyria**, and fecal mesobilifuscin, 1184

**Posture**
and blood flow, 1199
in congestive heart failure study, 659–667
and pulmonary diffusing capacity, 923, 925–930
and transpulmonary pressure, 660

**Potassium**
and acetylcholinesterase, 702–706
and acid-base balance, 1538–1542, 2176–2187
and calcium excretion, 1407
cation-carrier complex, in transport process, 29
chloride, 1539–1542
cyanide, and myoglobin iron uptake, 1602, 1604
deficiency, 846–852, 1141, 1149–1164
and ammonium excretion, 1139–1140, 1156
and blood pH, 1144, 1150, 1157
and creatinine excretion, 1137–1143, 1147
and fecal loss, 1147
and lactic dehydrogenase, 1027*
and pyelonephritis, 1056*
and renal conservation, 1134–1147
and sodium metabolism, 851–852, 1164
and sulfate infusion, 1407–1410
and vasopressin, 846
and desoxycorticosterone, 987*, 1149–1164
in erythrocyte, 792–796
fractions, and refrigeration, 1581, 1584–1585
exchangeable, 1542
and acid-base disturbances, 2176–2187
in respiratory acidosis, 949–959
and sodium, 987*, 1142, 1158–1159
excretion, 1135–1147, 1153
after acetazolamide, 986*
in acidosis, 42–47, 952–954
after aldosterone, 1965–1967
after ammonium chloride, 194–198
in chicken, 21–29
in cholera, 1880, 1883
after exercise, 2–6, 8–12
fecal, 1139–1140, 1153, 1180, 1183
after lactate, 1735, 1738
and low protein diet, 741–742
after mersalyl, 26–27
and positive pressure breathing, 840
after renal artery and ureter obstruction, 991*
after SU-4885, 2102–2110
and vasodilatation, in congestive heart failure, 571–573
iodide, 792–796
and hypocholesterolemia, 1332
insulin-induced movement, 1057*
loss, 1142, 1147
and desoxycorticosterone acetate, 987*
and failing heart, 313
and SU-4885, 2102–2110
metabolism, 894–895
in adrenal cortical insufficiency, 684–687, 689, 695–700
and muscle
hyperpolarization, 1057*
in respiratory acidosis, 954–955, 958–959
perchlorate, and thyroid venous iodide concentration, 1036*
peritubular, 28
phosphate, $pK_2'$ of, 351–356
in pituitary insufficiency, 884
plasma. *See* Plasma
renal conservation and ionic intakes, 1134–1147
serum. *See* Serum, potassium
:sodium ratio, in saliva and spirolactone therapy, 1044*
transfer, 309–311, 1057*
across colon, 987*
from amniotic fluid to mother and fetus in hydramnios, 978
in erythrocytes, 705, 1579–1580
in paroxysmal nocturnal hemoglobinuria, 705
and refrigeration time, 1580–1581
tubular, 28

**Prednisolone**
and calcium metabolism, 682, 686, 691–693, 695
and creatinine clearance, 685, 697
and eosinophils, 681, 685, 688
and inulin clearance, 688, 689
metabolism, 681–700
in adrenal cortical insufficiency, 681–690
and nitrogen metabolism, 682–685, 691–700
and phosphorus metabolism, 682, 685–686, 691–693
and potassium metabolism, 684, 685, 687, 689, 695
and serum carbon dioxide concentration, 684, 685, 696
and sodium metabolism, 684–685, 690, 695–699, 1029*

**Prednisone**
and aldosterone excretion, 2101–2110
and eosinophils, 681, 685, 700
and 5-hydroxytryptophan excretion, 716
in influenza complications, 223, 226, 251, 253
and nitrogen metabolism, 682–687, 691–699
and potassium metabolism, 684–686, 695–696
and renal function, 688
and serum isoniazid concentration, 1357
and sodium excretion, 1029*
and urinary constituents after SU-4885, 2101–2110

**Pregnancy**
and corticosteroids, 301, 998*, 999*
at high altitude, and hyperventilation, 1010*
hyperadrenocorticism, 390
and influenza complications, 216, 217, 224, 251, 260, 264
plasma cortisol clearance, 299–304
sodium exchange, 666–668
transcortin binding, 386–391
water exchange, 971–980

**Pregnane-3,11,20-trione,** corticosteroid binding, 385
**Pressure**
*See also* Hypertension; Hypotension
arterial, 120–125, 777, 1319, 1567–1570, 2146
after albumin, 922–924
after aldosterone, 1965–1967
in aortic insufficiency, 1567–1570
and bath temperature, 1128
and body position, 660
in congestive heart failure, 561–570, 575, 663
and consciousness loss, prediction, 1016*
and dextran, 122–125
direct and mathematical measurement, 782–783
and eating, 2155
and elasticity and viscosity of vessel wall, 1030*
and epinephrine, 1000*, 1001*, 1937
and ethanolamine, 1013*
after G suit inflation, 922–924
and head injury, 1000*
and hemorrhage, 525–536
after hexamethonium, 1001*
and high cardiac output, 2146
in hyperthyroidism, 1319
and hypervolemia, 120–125
in hypoxia, 1007*
and isoproterenol, 342–345, 995*
in lung, gas-free excised, 458
and methoxamine, 1045*
in mitral valve disease, 1045*
and myocardium status, 1033*
and norepinephrine, 1568, 1937
after partial cardiopulmonary bypass, 1057*
and positive pressure breathing, 840
and pulmonary arterial occlusion, 1012*, 1199
and serum nonesterified fatty acid concentration, 989*
and strophanthidin, 307–308
and vasodepressor, 1016*
and vasodilatation, 561–570
and veno-arterial perfusion, 984*–985*
atrial, 120–125, 130–131, 561–570, 995*, 1000*, 1001*
in hemorrhage and reinfusion, 534
in hyperthyroidism, 1319
in hypoxia, 1007*
in lung, gas-free excised, 458
in mitral valve disease, 1045*
and respiratory rate and depth, 998*
septal defect closure, 1047*
as vascular congestion index, 460
breathing and renal function, 835–841
carbon dioxide, in pulmonary complications of influenza, 230
carotid, 1000*
cuff, 814
and fibrinolytic activity, 815–816
and glomerular filtration rate, 734
diastolic, 120, 130, 561, 1020*, 1045*, 1128
esophageal, 112
and body position, 666
and chest irradiation, 587–592
interruption of flow, 1263–1270
and isoproterenol, 344
peristaltic, 110–116
in pneumothorax, 1341, 1346
and pulmonary resistance, 1265
and pulmonary vascular pressure, 998*
and ventilation, 1346–1347
and exercise. *See* Exercise
forearm, and isoproterenol, 344
gastric, 400
intracardiac
after Arfonad®, 557–578
after digitalis, 574–575, 577–578
and Starling's law, 575
intracranial
neuraminic acid and ventricular fluid, 1763
and sodium exchange, 1705
intrapleural, 666, 1265, 1341, 1346–1347
intrathoracic, 836–841
mouth, 112, 1263–1270, 1916
perfusion, and juxtaglomerular cell granulation, 605–610
pulmonary artery, 665, 998*, 1047*, 1196, 1265, 1916
in aortic insufficiency, 1567, 1569–1570
and chest irradiation, 587–592
and dextran, 122–125
and elastin, 1009*–1010*
in gas-free excised lung, 458
and hemorrhage, 525–536
in hyaline membrane disease, 2168–2175
in hyperpnea, 1191–1193
in hyperthyroidism, 1319
with hypervolemia, 120–125
in hypoxia, 1007*
in mitral stenosis, 1191–1195
in rheumatic heart disease, 1191–1193
and strophanthidin, 307–308
pulse, 777, 1209
and bath temperature, 1128
cardiac catheterization models, 778–781
and cardiac output in hyperhemorrhea, 1007*
and epinephrine infusion, 1937
on inspiration, 998*
and nonesterified fatty acid concentration, 989*
after norepinephrine, 1566, 1569–1570, 1937
after partial cardiopulmonary by-pass, 1057*
and strophanthidin, 307–308
and thyroxine-binding, 1683–1687
and swallowing, 112, 401–402
systolic, 120, 1012*
after atrial septal defect closure, 1047*
cardiac catheterization model, 778–781
in pyelonephritis, 1228–1239
tracheal-esophageal, 587–592
during Valsalva maneuver, 1916
vena caval, inferior, 1285
venous, 1055*, 1279–1282
in influenza complications, 227, 228
ventricular, 130, 561–570, 575, 587–592, 1012*, 1045*, 1204–1212
vestibular, 402
volume through cardiac cycle, 1204–1206
wedge
hepatic, 1021*
pulmonary, 562–570, 998*, 1007*, 1033*, 1047*
**Primaquine,** and hematological recovery, 1017*
**Priscoline®.** *See* Tolazoline
**Probenecid**
in gout, 997*
and salicylate uricosuria, 1308–1309, 1313
and serum isoniazid concentration, 1357
and urinary magnesium excretion, 986*, 1736–1744
**Prochlorperazine,** and colonic serotonin response, 2126, 2127
**Proconvertin,** in hemophilia, 1924–1926
**Progesterone**
albumin binding, 390
in congenital galactosemia, 1030*
corticosteroid binding, 385
and galactose induced cataracts, 1030*
in lymphocytic neoplasms, 993*
transcortin binding, 385, 391
**Progoitrin,** antithyroid activity, 1465–1474
**Properdin system,** and staphylococcal bacteremia, 985*–986*
**Prostate**
and acid phosphatase activity, 149, 152, 153
sialic acid in secretions, 758–760
**Protein**
acid mucopolysaccharide ratio in thrombocytes, 1063
in amyloidosis, 993*
blood coagulation in hemophilias, 1924–1926
calcium binding, 1021*
cerebrospinal, sodium ratio to total, 1759–1767
C-reactive, 993*
and diodrast binding, 988*
dysproteinemia, 1013*
fraction
and bilirubin binding, 827–829
composition in edema, 1037*
in double albumin, 1412–1419
gamma globulin in urine, 2159–2167
subfractionation of urinary, 1390, 1520–1536
vitamin $B_{12}$ binding in leukemia, 2135–2143
in glomerular nephritis, 186–191
intake, 1001*
and energy expenditure, 1017*
and glomerular filtration rate, 731–732
and metabolic pool turnover, 899–901
and nitrogen balance, 895, 1242
and uric acid excretion, 744, 895
and urine flow, 741–742, 744
and water clearance, 742, 747

and weight, 895, 1242
and iron transfer to reticulocytes, 161–183
and liver function, 319, 322, 1992
myoglobin binding, 1020*
in nephritis, 186–191, 987*
plasma. *See* Plasma
serum. *See* Serum
and streptokinase therapy, 1101
synthesis, 1241–1250
and pyridine nucleotides, 317–324
and renal acid excretion, 1162
and tricarboxylic acid cycle, 414
thyroxine-binding, 636, 639, 988*–989*
familial abnormality, 1683–1687
**Proteinuria**
after ethylenediaminetetraacetate, 1462
in influenza complications, 230
tetracycline binding, 1495
**Prothrombin**
and antithrombin clotting time, 1103
in hemophilia, 1924–1926
plasma labile factors, 56, 58, 59, 62, 64
and streptokinase, 1099, 1102, 1632, 1635
**Protoporphyrin,** and myoglobin iron uptake, 1600–1604
**Pulmonary artery**
blood flow. *See* Blood flow, pulmonary
congestion, 1015*
and norepinephrine, 1564–1570
distention, and lung inflation at birth, 456–462
embolism, 1112
and streptokinase, 1099, 1116
and thrombolytic therapy, 1115–1116
narrowing, and chest irradiation, 591
in obesity, 501
occlusion, and diffusing capacity, 1190, 1195–1197
pressure. *See* Pressure, pulmonary
**Pulmonary syndrome,** and influenza virus, 213–264
differentiation studies, 256–258
**Purine**
intake and uric acid excretion, 1891
metabolism, and nucleic acids, 1401–1402
methemoglobin reduction in erythrocyte, 1555–1562
and renal function, in gout, 1893–1894
**Purpura,** hyperglobulinemic, 1058*
**Pyelonephritis**
and alcohol, 519
and bacterial species, 1009*, 1228–1239
and glomerular filtration rates, 517–518
and potassium depletion, 1056*
and sodium excretion, 990*–991*
and ureteral obstruction, 1009*
urine/plasma osmolal ratio, 519
**Pyrazinamide,** with isoniazid in tuberculosis, 1370
**Pyridine nucleotides,** metabolic pathways, 1558
and protein synthesis, 317–324
**Pyridoxine** and isoniazid, 1357, 1369–1370
**Pyrimidine**
metabolism in man, 798–808
synthesis in pernicious anemia, 1044*
**Pyrophosphate**
metabolism in connective tissue, 452
**Pyrrole,** metabolism, 1015*
**Pyruvate**
arterial concentration after strophanthidin, 310, 315
blood concentration in idiopathic high cardiac output state, 2146
cerebral concentration and eating, 1037*, 2155, 2156
2:3 diphosphoglycerate conversion to, 1578
in hyperhemorrhea, 1007*
in influenza complications, 230
in kwashiorkor, 1026*
and lactate, 1026*
and glucose, 1574, 1575
myocardial extraction, 310

R

**Red cell.** *See* Erythrocyte
**Resorcinol,** in subfractions of ultrafiltrable fraction, 1931–1933
**Respiration**
and cerebral blood flow, 1036*
energy cost of breathing, and ventilation, 1342–1347
and exercise, 1188
and head injury, 1000*
and hemorrhage, 532
in hyperpnea, 1188–1189
in influenza complications, 217, 221, 229–230, 235
and muscles in emphysema, 494–498
negative pressure, 1973–1979
in obesity, 502–506
pulmonary mechanics, 1268–1270
and ventricular pressure, 998*
**Respiratory quotient**
cerebral, and eating, 2155
and dietary intake, 895
and pulmonary diffusing capacity, 1187
**Respiratory rates**
in influenza, 218, 220
and pulmonary vascular pressures, 998*
after partial cardiopulmonary bypass, 1057*
after platelet transfusion, 1691
and serum nonesterified fatty acid concentration, 989*
and tidal volume, 502–506
**Respiratory tract**
cold air effects, 1053*–1054*
influenza involvement, 210, 213–214, 216–217, 234, 256
**Reticulocytes**
cobalt uptake, 178–179
glucose-6-phosphate dehydrogenase deficiency, racial factor, 2259–2260
glycolytic rate, 1576–1579
iron uptake, 161–183, 393, 1002*
and chymotrypsin, 175, 180
and ethylenediaminetetraacetic acid, 165–167, 169, 174, 180
and glucose, 174–175
and lead concentration, 172, 173
in liver slices, 177
after irradiation, in leukemia, 1048*
metabolism and maturation, 1582
phosphate partition, 1577
after primaquine, 1017*
**Rheumatic disease**
antibodies, 1944–1948
and cortisone, 599, 600
joint stiffness, 1056*
serum constituents, 1013*
fractionation, 1058*
and transcortin cortisol binding, 1293
**Rheumatoid factor**
isolation and characterization, 424–433
of hypogammaglobulinemia, 1058*
**Ribose**
intake, and uric acid excretion, 1891
metabolism, 407–412
methemoglobin reduction, in erythrocytes, 1559–1560
structural formulas, 407
**Ribose-5-phosphate**
in erythrocyte metabolism, 795, 796
in glucose degradation to lactate, 1574, 1575
**Riboside,** and methemoglobin reduction, 1557–1562
**Ribulose-5-phosphate,** in erythrocyte metabolism, 795, 796
**Rubidium,** electrolyte and acid-base balance, 1538–1542

S

**Salicylates**
and basal metabolic rate, 1003*
and bilirubin, 825
protein-binding, 829, 832
dialysance, in artificial kidney, 1040*
and hyperuricemia, 1310
and isoniazid, 1357–1358, 1369–1373
and oxidative phosphorylation, 1002*
and panmyelophthisis, 1182
and urate excretion, 1298–1314
after acetazolamide, 1307–1308
and probenecid, 1308–1309, 1313
and urine alkalinization, 1306–1307
**Saliva**
in duodenal ulcer, 1002*
potassium-sodium ratio and spirolactone therapy, 1044*
**Secobarbital** and isoniazid concentration, 1357
**Sedoheptulose-7-phosphate,** and erythrocytes, 1043*
**Semen,** sialic acid, 755–761
**Seminal vesicle,** sialic acid, 758–760
**Serotonin**
benzyl analog, 2126, 2129
in biliary tract obstruction, 934–937

**Serotonin** (*cont'd*)
brain stem concentration, and ethanol, 1008*
and cholinergic nervous system, 2123–2124
in hepatic cirrhosis, 934–937
intestinal responses, 2119–2129
metabolism in liver disease, 715–719, 1008*
platelet concentration, after 5-hydroxytryptophan, 716–719
in rheumatoid arthritis, 1059
**Serum**
acid nitrophenylphosphatase, 148–153
acid phosphatase, 639, 640
albumin
double peak, 1412–1419
after glomerulonephritis, 988*
half-life in analbuminemia, 867
and hyperlipemia, in acute glomerular nephritis, 187
alkaline phosphatase, 682, 692
and acetylated growth hormone, 1044*
in bone disease, 632, 634–635
in carcinoma, 635–636, 639, 640
in hepatobiliary disease, 632–634
mobility zones, 630–643
anti-beef growth hormone, 1004*
antibiotics, clearance, 1487–1518
antibodies, 984*, 1004*, 1632
Candida reacting, 992*
after glomerulonephritis, 987*–988*
to hog intrinsic factor, 1022*
in hypoparathyroidism, 1079
in influenza, 206–209, 219–220, 231
macroglobulin, 431
and rheumatoid factor precipitin curves, 430–431
in streptococcal disease, 1943–1948
streptokinase, 987*–988*, 1632
antigen-antibody precipitate, and esterase activity, 984*
antiricketic activity and calcium metabolism, 1078–1083
and vitamin D, 1004*, 1079–1082
bicarbonate, 230
and ammonium excretion, 956–957
bilirubin
in erythroblastosis, 825–826
and sulfobromophthalein retention, 994*, 1990–1994
calcium, 1018*, 1407–1410
in adrenal cortical insufficiency, after steroids, 682, 683, 692
in hypercalcemia, 1052*, 1080
in hyperglobulinemia, 1006*
and milk-alkali syndrome, 1080
nonprotein-bound fraction, 1021*
in nontropical sprue, 1080
and parathyroid, 994*, 999*, 1018*, 1079–1080, 1215–1220
and renal concentrating ability, 1214–1220
and vitamin D, 1078–1083
carbon dioxide, 1144
in adrenal insufficiency, 684, 685, 687, 696
in influenza, 230, 236
in potassium depletion, 1150
ceruloplasmin, 1676–1681
chloramphenicol clearance, 1498–1507
chloride, 230, 1539–1542, 1965–1967
and acid-base balance, 1538–1542, 2177–2178
and adrenal insufficiency, 684, 686, 687
after ammonium chloride, 194–198
and blood urea concentration, 750–751
and calcium excretion after sulfate, 1407–1410
in cholera, 1880
after desoxycorticosterone, 1158–1159
in diarrhea, 1883
after 1,4-diene steroids, 684, 686, 687
and dietary intake, 46
and extracellular fluid volume, 1158–1159, 1162
and glomerular filtration rate, 465, 468, 733–734
in influenza, 230
and ionic movements, 437, 1139
and low protein diet, 744–745
and methionine, 2215–2223
in potassium depletion, 1141, 1144, 1150
in respiratory acidosis, 949–959
and urine osmolality, 733–734
chloroform-induced esterase, 984*
cholesterol, 1016*, 1039*, 1255–1260
and androsterone, 1010*, 1011*
and basal metabolic rate, 1055*
and breast milk fatty acids, 448
and dietary intake, 1019*, 1389–1391
diurnal variations, 1392
and double albumin, 1413
in glomerular nephritis, 186–191
and glucose, 986*–987*
in hyperlipemia, 855, 1718–1723
and hypotensive therapy, 1013*
and triiodothyronine, 277
citrate, 1018*
cold agglutinins, 231
demethylchlortetracycline, 1952–1961
diphosphopyridine nucleotidase, inhibition, 1942–1948
electrolytes, 230
and aldosterone excretion, 1444
after ammonium chloride, 194–198
and methionine, 2215–2223
freezing point depression, 1588–1593, 1597
gamma globulin, 553–556
immunological studies, 579–585
in lupus erythematosus, 327
in urine, 2159–2167
globulin, 987*, 993*
in edema fluid, 1037*
phosphatase, 632–643
and thyroxine binding, 1683–1687
glutamic acid, 369–371
after erythromycin, 1513
and pH, 1419
glutamic oxaloacetic transaminase, 230–231
and liver function, 1992, 1994
hexosamine, 993*
inulin: cerebrospinal fluid ratios, 1771–1772
isocitric and lactic dehydrogenases, in myocardial infarction, 2111–2118
lecithin, 490–493
osmolality, 1000*
and antidiuretic hormone, 545–549
paraphenylenediamine oxidase activity, 1673
phospholipids, 1019*
and breast milk fatty acids, 448
and deoxyribonucleic acids, 1039*
diurnal variations, 1392
in essential hyperlipemia, 855
regulatory control, 1039*
after vanadium, 1253–1255
phosphorus, 682, 683, 692, 1018*
and growth hormone, 1044*
potassium, 230, 846–848, 850–852, 1886
after aldosterone, 1965–1967
after ammonium chloride, 194–198
and arterial pH, 2177–2178
after bicarbonate, 1886
and blood urea, 750–751
carbon dioxide tension, 1141, 1150, 2182
in carbon tetrachloride poisoning, 1034*
and glomerular filtration rate, 465, 468, 472, 733–734
in hypercalcemia, 1052*
in influenza complications, 230
and intrathoracic pressure, 836–841
and ionic movements, 437
and low protein diet, 744–745
and methionine, 2215–2223
after parathyroid extract, 1216
in potassium depletion, 1141
in respiratory acidosis, 25–26, 941–942, 952, 955, 958–959
after rubidium, 1539–1542
sodium correlation, 2176–2187
after sodium cycle resin, 1053*
in sprue, 1080
and strophanthidin, arteriovenous differences, 310–312
in virilizing adrenal hyperplasia, 1446
properdin, and bacteremia, 985*–986*
proteins, 1412–1419
antiricketic activity, 1081–1083
and calcium binding, 1021*
chlortetracycline binding, 1495
C-reactive, 993*
and in edema fluid, 1037*
in glomerulonephritis, 187, 987*
and hyperlipemia, 187
and streptokinase therapy, 1101
and thyroxine-binding, 988*–989*, 1683–1687
prothrombin, in hemophilia, 1924–1926
pyruvate, 230
rabbit antirat kidney, and hypercholesteremia, 1434–1440
rheumatoid factor isolation, 426–433
sialic acid, 1026*

sodium, 195–198, 230, 548, 955, 958–959, 999*, 1219, 1965–1967
and adrenocorticotropic hormone, 999*
in aldosteronism, 999*
after ammonium chloride, 194–198
and blood urea, 750–751
in carbon tetrachloride poisoning, 1034*
and in cerebrospinal fluid, 1698–1706
in dilution syndrome, 1015*
and glomerular filtration rate, 465, 468, 470, 472, 733–734
in hyponatremia and edema, 1015*
and ionic movements, 24, 437
and low protein diet, 741–742, 744–745, 748
and methionine, 2216
in potassium depletion, 1141, 1144, 1150
and urine osmolality, 733–734, 1730
in virilizing adrenal hyperplasia, 1446
sulfation factor and insulin, 1038*–1039*
tetracycline, 1488–1489, 1952–1955
urea nitrogen, 1620
uric acid, 895, 908
vitamin $B_{12}$ binding in leukemia, 1026*, 2135–2143
vitamin D transport, 1078–1083

**Shock**
anaphylactoid, and vasculitis, 1045*
cardiac performance and veno-arterial shunt, 985*
of head injury, and circulation, 1000*
hemorrhagic, 673–680
and endotoxin, 677, 1008*
"hypercoagulability," 62, 64–65
intravascular clotting, 53–65
irreversible, 1008*
leukopenic response, 676–677

**Sialic acid**
of isolated rheumatoid factor, 429–430, 433
and reticulocytes, iron uptake, 176
serum concentration, 1026*
in serum and genital tract, 755–761
of urine subfractionations, 1930–1933
RS-1 solids, 1522

**Silver,** urine concentration, 1452–1462

**Sitosterol,** and serum lipid concentration, 1054*

**Skeleton**
*See also* Bone
polyostotic fibrous dysplasia, 1023*

**Skin**
mucopolysaccharide concentrations in pretibial myxedema, 945–947
temperature after anaerobic work, 1130–1133

**Sleep**
and blood glucose in diabetes, 2229–2233

**Sodium**
absorption in diabetes, 1225–1227
and acid-base balance, 1053*, 2215–2223
after rubidium, 1538–1542
and adrenocorticotropic hormone, 1700–1706
and aldosterone, 999*, 1964–1970
bicarbonate, 366, 704, 771–776, 1664
and alkalosis, 771–776, 1053*, 1664
and ammonia excretion, 370
and carbon dioxide tension, 726
frog and mammalian, 726
glutamic acid dehydrogenase, 369–370
and respiratory acidosis, 940–944, 955, 958–959
and salicylate, 1303, 1308, 1312
transport to distal tubule, 775, 776
and urinary magnesium excretion, 986*
and water loss in cholera, 1885
bone concentration, 955, 958–959
cerebrospinal, in neurological diseases, 1763
chloride, 195–198, 351–356, 415–418, 704, 843–752, 986*, 1664, 1964–1970
in dilution syndrome, 1015*
and electrolyte exchanges, 957
and erythrocyte osmotic activity, 1588–1597
hypertonic, infusion, 546–549
and plasma bicarbonate concentration, 2197–2198
and pulmonary diffusing capacity, 926, 927
and uptake of fluorescent-labeled lupus, 327
urea and urine concentration, 743
and chlorothiazide, 1700–1706
citrate, and malic acid excretion, 415–418
concentration, nondialyzable, 1765
and cortisone, 1700–1706, 1965–1970
depletion, 196–198
and desoxycorticosterone, 851–852, 987*, 1029*, 1163, 1700–1706, 1964–1970
exchange, 27, 771–776, 949–959, 1664, 1700–1706
kinetic models, 961–970
mathematical analysis, 968–970
for phosphate, 2224–2228
for potassium, 2180
excretion, 42–46, 351–356, 741–742, 986*, 990*, 991*, 1153, 1883–1885, 1965–1967
after ammonium chloride, 194–198
in cholera, 1880
in diarrhea, 1883
after exercise, 2–6, 8–12
and 9α-fluoroprednisolone, 1029*
in hydropenia, 4, 9, 12
in hypercalcemia, 1052*
after lactate, 1735
and potassium depletion, 1133–1147
and spirolactone therapy, 1044*
and vasodilatation, 571–573
after water, 1885
and heart, after strophanthidin, 310–312, 314
hydroxide, 373–382, 415–418
in hypertension, 985*
intake, 894–895, 1139–1140, 1147, 1538–1542, 1883–1885
and aldosterone excretion, 1442, 2102
and anion-cation balance, 1149
and potassium, 1135, 1147
and urinary electrolyte and steroid excretion, 2101–2110
intracellular, 954–955
in potassium depletion, 1158–1159
iodide in atherosclerosis, 540
loss, 688
and glomerulotubular imbalance, 690
in pulmonary emphysema, 2224–2228
metabolism, 894–895
in adrenal cortical insufficiency, 684–690, 695–699
orthoaminobenzoate, 935
plasma. *See* Plasma, sodium
potassium ratio, 999*, 1044*, 1142, 1158–1159
reabsorption, 27, 851–852, 985*, 1163
in loop of Henle, 1219
renal function, 1139, 1147
and antidiuretic hormone release, 1001*
and intrathoracic pressure, 836–841
and steroid hormones, 690, 699, 1029*
retention, 1029*, 1964–1970
in adrenal · insufficiency, 1964–1970
and 9α-fluorohydrocortisone, 1966–1967
and SU-4885, 2101–2110
and vasopressin, 999*, 1969–1970
serum. *See* Serum, sodium
sulfate, 351–356
and calcium excretion, 1407
and electrolyte excretion, in chicken, 23
taurocholate, 1055*
transport
from amniotic fluid to mother and fetus, 964, 978
and electrochemical potential gradient, 435–441
in erythrocytes, 1579–1581
into intracellular volumes, 1162
into medullary interstitial fluid, 748
by proximal tubule, 1029*
by toad bladder, 1020*

**Somatotropin.** *See* Pituitary, growth hormone

**Sphingomyelin**
erythrocyte and plasma exchange, 1032*
lipid fractions, 1053*
of lipoproteins, 1016*
serum concentration, 490–493
in hepatic and pancreatic diseases, 1006*

**Spinal cord**
inulin space, 1772
transection and adrenal responses to endotoxin, 1120, 1125

**Spleen**
copper concentration and age, 1675
granulocyte flight into capillaries in hemorrhagic shock, 679, 680

**Spleen** (*cont'd*)
and hemostatic breakdown of hemorrhagic shock, 61–65
and siderocyte iron recycling, 998*
toxicity, of mustard treated homogenates, 1055*
water and electrolyte concentration, 752
**Sprue,** nontropical, and vitamin D, 1080–1082
**Staphylococcus**
drug resistance, 1018*
and influenza complications, 231–233, 237, 239, 259–260, 270
and polymorphonuclear leukocytes, 996*
properdin and complement titers, 986*
**Stearic acid,** in breast milk, 449
**Stercobilin**
fecal excretion, 1167, 1170–1174
formation patterns, in dyserythropoiesis, 1014*
**Steroids**
*See also* specific compounds
adrenal cortical
and urinary concentrating mechanism, 843–852, 1029*
and water clearance, 890
in adrenal insufficiency, 671–700
in influenza complications, 223, 226, 235
and joint stiffness, 1056*
**Stilbestrol,** and transcortin, 1292
**Stomach.** *See* Gastrointestinal tract
**Stool.** *See* Feces
**Streptococcus**
serum antibodies, 1943–1948
and systolic pressure, 1231–1239
**Streptokinase**
after antigen-antibody precipitate, 984*
in streptococcal disease, 1945–1948
and fibrinolytic system, 1088–1094, 1630–1641
and thrombolytic state maintenance, 1096–1118
**Streptolysin O,** serum antibody titers, 1943–1948
**Streptomycin**
blood clearance, 1356, 1509–1518
and isoniazid, against tubercle bacilli, 1349–1356, 1370
microbiologic assay test, 1362
and para-aminosalicylic acid, 1382
reaction manifestation, 1370
**Stress**
emotional
and ethanol addiction, 1009*
and fibrinolytic activity, 817, 821
in newborn, 1050*
pituitary responsiveness
and adrenocorticotropic hormone, 293, 297, 1050*
species differences, 296
and serum nonesterified fatty acid concentration, 989*
**Strophanthidin,** in congestive heart failure, 306–315
**Succinic acid**
in carbon tetrachloride poisoning, 1034*
in malic acid excretion in kidney, 419
and myoglobin iron uptake, 1603, 1604
and reticulocyte iron uptake, 172
in tricarboxylic acid cycle, 414, 422
**Succinic dehydrogenase,** in juvenile dystrophy and neurogenic atrophy, 876, 877
**Succinylcholine,** and fibrinolytic activity, 815
**Succinylsulfathiazole,** and urea synthesis, 1621
**Sucrose**
biliary excretion, postinfusion, 1650
and blood osmotic activity, 1589–1590
extracellular space, variability measurement, 1644–1658
extrarenal losses, postinfusion, 1651, 1654
and sodium exchange, 1700–1706
**Sulfadiazine**
and plasma-cerebrospinal fluid exchange, 1032*
and protein-bound bilirubin displacement, 832
**Sulfanilamide,** in hemorrhagic shock, 1008*
**Sulfanilic acid,** and bilirubin concentration, 826, 832
**Sulfate**
in bile azopigments, 647
bilirubin, 645–651
and calcium, urinary excretion, 1404–1410
carbazole:orcinol ratio in acid mucopolysaccharides, 1061
cartilage uptake and growth hormone, 1038*–1039*
excretion and acid-base balance, 2222
intake and electrolyte excretion, 2215–2223
**Sulfisoxazole,** and bilirubin binding, 825–829, 832
**Sulfobromophthalein,** biliary excretion, 997*, 1426–1432
metabolites, 994*, 1015*
and hepatic dysfunction, 1989–1994
identification, 1981–1987
and ninhydrin, 1982–1983
retention, 994*, 1990, 1992
and thyroxine-binding, 1683–1687
vascular pathways after injection, 2202–2214
**SU-4885 (2-Methyl-1,2-*bis*[3-pyridyl]-1-propanone),** structural formula, 2101
**Sulfonamides,** in icteric serum, 825–826
**Sulfuric acid**
bilirubin treatment with, 650
metabolism, 1034*
and methionine, 1244, 1247, 2215–2223
**Swallowing,** 401–402, 405

T

**Taurine,** and methionine metabolism, 2223
**Temperature**
*See also* Fever; Hypothermia
airway, and pulmonary disease, 1054*
and cation transport, 1580
chloroform-induced esterase and plasminogen, 984*
and erythrocyte, 1580
antibody binding, 285–287, 289
and forearm after anaerobic work, 1126–1133
and hog intrinsic factor concentration, 103–108
and iron
myoglobin uptake, 1601
transfer to reticulocyte, 170–171
and joint stiffness, 1056*
and platelet acid nitrophenylphosphatase activity, 150, 153
and serum, antiricketic potency, 1081
and transcortin binding, 388
**Testes,** sialic acid isolation, 760
**Testosterone**
albumin binding, 390
and citrate excretion, 422
corticosteroid binding, 385
and iron absorption after hypophysectomy, 1042*
in lymphocytic neoplasms, 993*
**Tetracycline**
analogues, distribution and excretion, 1950–1961
blood clearance, 1487–1495
and isoniazid in tuberculosis, 1370
and staphylococcal resistance, 1018*
**Tetrahydrocortisol**
and cortisol metabolism pathway, 2238–2251
urinary excretion, after SU-4885, 2101–2109
**Tetrahydrocortisone**
glucuronidate and cortisol, 995*
urinary excretion, after SU-4885, 2101–2109
**Tetrahydrodesoxycorticosterone,** urinary excretion, after SU-4885, 2101–2109
**Tetrahydrodesoxycortisol,** urinary excretion, after SU-4885, 2101–2109
**Thiamine,** in hyperhemorrhea, 1007*
**Thorax**
caval constriction, and aldosterone secretion, 1284
compliance
and chest irradiation, 587–592
and hemorrhage, 526
and pulmonary resistance, 1267–1270
elastic resistance, in obesity, 505, 506
volume receptor areas, water clearance, 841
**Thrombocytes**
acid mucopolysaccharides, 1062–1064
in rheumatoid arthritis, 1059
**Thrombocytopenia,** platelet transfusion, 1689–1696
**Thrombocytosis**
in hemorrhagic shock, 62, 64–65
platelet survival, 985*
**Thromboembolic disease,** fibrinolytic activity, 1086–1118, 1628
**Thromboplastin**
antecedent, in hemophilia, 1924–1926

generation test, 55–58, 59, 1006*
and phosphatide, 1044*
**Thyroid gland**
antagonism by progoitrin, 1465–1474
and antiserum, 1004*
and glomerular filtration rate, 884
in hyperhemorrhea, 1007*
in hyperthyroidism, 334–341
prognosis, 1051*
and iodoalbumin metabolism, 88–100
and iron absorption after hypophysectomy, 1042*
and mucopolysaccharides, 989*
and muscle, extraocular and neck, 989*
and potassium perchlorate, 1036*
in pretibial myxedema, 946
radioiodine uptake and clearance, 1468–1473
and thyroxine-binding, 1683–1687
**Thyrotoxicosis**
blood flow, 1324–1325
hemodynamics
and exercise, 1318–1320
and heart disease, 1318, 1320–1321
and progoitrin, 1467, 1473–1474
**Thyrotropin**
and thyroid venous blood, 1036*
time factor in effects, 334–341
**Thyroxine**
binding capacity, 988*–989*
familial tendency, 1683–1687
cellular uptake in hyperthyroidism, 1035*
and erythrocyte metabolism, 792–796
and iron absorption after hypophysectomy, 1042*
and lipid concentration, after triiodothyropropionic acid, 1054*
metabolism, 1899–1902
**Tin,** urine concentration, 1452–1462
**Tissue**
adipose, 1026*, 2132
fatty acids, 1011*, 1022*, 1032*, 1718–1723
insulin response failure, 1004*
measurement of change in total, 1475–1478
phosphorylase activity, 1052*
peripheral, 2132
insulin responses, 1023*, 1050*
subcutaneous, 1026*
synovial, mycopolysaccharides metabolism, 451–455
temperature, and forearm oxygen uptake, 1126
**Tolbutamide,** hypoglycemia
nocturnal variations, 2230–2232
after pancreatectomy, 902–905
**Toxicity**
of chloramphenicol, 1507
chlortetracycline, in uremia, 1495
after 2-ethylamino-1,3,4 thiadiazole, 908
of nitrogen mustard, 1055*
of streptokinase, 1104, 1114–1115, 1638–1639
tetracycline, 1487, 1495
from vanadium, 1255–1256
**Transcortin**
binding and stability, 384–391
and corticosteroids, 387
and estrogens, 1290–1296
cortisol binding, 384–391, 1290
in children and in adult, 1295
**Transplantation,** marrow, 1048*
in leukemia, 1709–1716
**Tricarboxylic acid cycle,** and malic acid excretion, 414–423
**Triglyceride.** *See* Lipids
**Triiodothyronine**
and androsterone in myxedema, 1010*–1011*
cellular uptake, in hyperthyroidism, 1035*
and cholic acid excretion, 1012*
and erythrocyte metabolism, 788–796
metabolism, 948*
in pituitary insufficiency, 884–890
and plasma nonesterified fatty acid, 277
L-thyroxine deiodination to, 1899–1902
**3:5:3′ Triiodothyropropionic acid**
in hypercholesterolemia, 1054*
**Triolein,** radiolabeled
distribution in atherosclerosis, 539–543
in lipid fractions, 1053*
in malabsorption syndrome, 1014*
**Triphosphopyridine nucleotide**
in breast cancer, 1012*
and erythrocytes, 792–796
and erythrocyte glucose-6-phosphate dehydrogenase, 2235–2236
and isocitric and lactic dehydrogenase activity, 2114–2115
in leukocyte sonicate, 802
and protein synthesis, 319, 324
reduction, 1558
in glucose degradation to lactate, 1574, 1575
**Tritium**
amniotic fluid, fetus and mother, uptake, 963–980
cholic acid uptake and ester cholesterol, 1336–1337
**Trypsin**
inhibitor on streptokinase-activated plasminogen, 15, 19
pH
and myoglobin digestion, 1030*
and transcortin, 391
reticulocytes, 175, 180
**Tryptophan,** in alcoholics, 1008*–1009*
**Tuberculosis**
lesion resection, 1376–1382
sputum, bacteriologic studies, 1376–1382
streptomycin and isoniazid, combined therapy, 1349–1374
**Tumor**
ascites, antibody to, 996*
catecholamines, 33
chromaffin, epinephrine and norepinephrine secretion, 1939–1940
growth inhibition by thiadiazoles, 907, 914
secreting, assay for detection, 36–37
**Tyrosine**
anomalous albumin B, 1419
and chloroform-induced esterase, 984*
formation from phenylalanine, 2190–2191, 2193–2195

**U**

**Unesterified fatty acids.** *See* Fatty acids, nonesterified
**Urea**
clearance
in adrenal insufficiency, 1011*
in aldosteronism, 999*
and artificial kidney, 1040*
and cell permeability, 1020*
and exercise, 12
and glomerular filtration rate, 464–466, 733–734, 738, 740
in influenza complications, 230
and intrathoracic pressure, 836–841
and low protein diet, 741–748
and medullary hypertonicity, 470–471
and negative pressure breathing, 1974–1975
after nephrectomy, 750–754
after parathyroid extract, 1219
in pituitary insufficiency, 887–890
and renal concentrating mechanism, 2–6, 1726–1731
San Pietro-Rittenberg method, 898–901
and ureter and bladder perfusion, 747
and urine osmolality, 741–748
metabolism, 1617–1625
in uremia, 749–754, 1272–1275
**Uremia**
and acidosis, 47–51
anion and ion concentration, 1052*
and chloramphenicol, 1273, 1275, 1500–1502, 1507
gastric secretion
and antibiotics, 1271–1275
hypoacidity, 1271–1275
and urea toxicity, 749–754
and urine urea concentration, 471
**Uric acid**
excretion
and calorie intake, 895
in gout, 1778–1781, 1890–1897
and salicylate, 1298–1314
synthesis, 908–911, 1008*, 1019*
tubular reabsorption, 1893
and probenecid, 1313
**Uridine diphosphoglucose,** 452
**Uridine diphosphoglucuronic acid,** 451–452, 455
**Uridine triphosphate,** 452
**Urine**
in adrenal cortical insufficiency, 681–690
albumin and thyroid hormone, 96–100
aldosterone, 1442–1450, 1966–1967
alkaline, 1307–1308
after potassium, 24
amino acid patterns after arginine, 1038*
carbon dioxide tension, 1664
catecholamines, 33
chloramphenicol recovery, in liver disease, 1504–1505
concentration, 1452–1462

**Urine** (*cont'd*)
after aldosterone and cortisone, 1966–1967
after ammonium chloride, 194–198
antidiuretic hormone, 545
in congestive heart failure, 574–575
fetal, isotopes, 975–976
glucose, nocturnal variations, 2230–2232
after hypertonic sodium chloride, 546
norepinephrine, 37, 708
oxalate, after glycine ingestion, 1001*
and parathyroid, 1018*, 1215–1220
in potassium depletion, 1133–1147
in renal disease, 42–51, 1005*
after rubidium, 1540, 1542
after salicylate infusion, 1304–1305, 1311–1313
after sodium chloride infusion, 548
and sodium intake, 2101–2109
after stress in newborn, 1050*
and SU-4885, 2101–2109
sucrose, postinfusion, 1649–1656
after sugar infusion, 548
after sulfate, 1404–1410
and thyroxine-binding, 1683–1687
after urea infusion, 739–743
vanadium, and serum cholesterol, 1255–1256
in virilizing adrenal hyperplasia, 1442–1450
after water loading, 548
and cortisol, 848
and cortisone, 885, 889, 1965–1967
and desoxycorticosterone acetate, 844–852, 987*, 1142, 1147
excretion
ammonia, 195–198, 952–953, 1542
in anterior and posterior hypophysis failure, 886–890
bicarbonate, 42–45, 50–51, 771–776, 1153, 1664, 1885
bilirubin, 1183
calcium, 1021*, 1218, 1404–1410
of chloride, 42–46, 351–356, 465, 468, 846–848, 952–954, 1153, 1965–1967
citrate, 1018*, 1613–1615
copper, radiolabeled, in Wilson's disease, 1678
cortisol metabolites, 2238–2251
dehydroisoandrosterone, 358–364
electrolytes, 42–51, 194–198, 574–575, 681–700, 2101–2109
estrogen, 1683–1687
estrone, 622–625
5-hydroxyindoleacetic acid, 934–937
iron chelate in anemia, 1018*
17-ketosteroid, 357–364, 697, 699, 700, 1256, 1683–1687
of magnesium, 986*, 1733–1744
mesobilifuscin in parenchymal liver disease, 1183
nitrogen, 683, 692–693, 1620–1625
phosphate, 347–356, 1052*
phosphorus, 42–46, 1018*, 1932–1933
plasminogen activator after streptokinase, 1114
Porter-Silber chromogen, 1050*
of potassium, 26–27, 42–47, 465, 468, 472, 571–573, 733–735, 952–954, 999*, 1135, 1147, 1153, 1735, 1738, 1965–1967
ribose, 408, 410–412
of sodium, 27, 42–46, 194–198, 351–356, 571–573, 733–735, 952–954, 991*, 1029*, 1052*, 1139, 1446, 1735, 1965–1967
steroids, 2101–2109
sulfobromophthalein, 1993–1994
sulfur after methionine, 1244, 1247, 2215–2223
urate, 1300–1314
urea nitrogen, 1620
urobilinogen, 1183
flow, 886, 887, 889, 1405, 1974–1975
after alcohol, 518–519, 837, 840–841
and bicarbonate reabsorption, 1664, 2197–2201
in diabetes insipidus, 889
and filtration rate reduction, 463–472, 734–740, 1730
and hydration, 1978
in hydropenia, 2–6
after hypertonic sodium chloride, 546
and intrathoracic pressure, 836–841
after lactate, 1735
and low protein diet, 736, 744–745
and mannitol diuresis, 10, 735, 739, 844
in osmotic diuresis, 1726–1731
after sodium chloride infusion, 548
and sucrose space, 1651–1656
after sugar infusion, 548
after tetracycline analogues, 1955
tubular secretion, 1781
after urea, 736, 1000*
and vasodilatation, 571–573
and water clearance, 518, 548, 1973–1979
follicle stimulating hormone, 1683–1687
fractions
gamma globulin, 2159–2166
glucuronoside, 623–625
goitrin recovery, after progoitrin, 1468–1470
in hypertension, 985*
hypertonic, 518, 883–890, 1216
hypotonic, 890, 1216, 1220
ionic strength and phosphate, $pK_2'$, 347–356
and mersalyl, 26–27
metals, after intake, 1452–1462
and negative pressure breathing, 1974–1975
nondialyzable solids, subfractionation, 1927–1933
of RS-1, 1525–1536, 1930, 1933
osmolality
and antidiuretic hormone release, 1001*
and back diffusion of urea in bladder, 371
and changes in medullary urea, 746
after hormone therapy, 885
in hydropenia, 2–6
and hypotension, 466, 468
and intrathoracic pressure, 836–841
and low protein diet, 736, 742–748
in pituitary insufficiency, 885–890
in renal disease, 521, 522
after sodium, 1730
and urea concentrations, 735, 736, 741–748, 1730
pentose metabolites in, 408, 410–412
pH, 45, 353, 949–959, 1034*, 1743–1744
after ammonium chloride, 45, 194–198, 956
and anion intake, 1140
and anoxia of renal papillary tissue, 991*
in hypercalcemia, 1052*
after lactate, 1735, 1738
and metal excretion, 1458–1459
after methionine, 2215–2223
and phosphate ratio to glomerular filtrate, 353–357
after purines in gout, 1893–1894
in renal tubular acidosis, 1053*
and RS-1 solids, 1530–1536
and salicylate, 1303–1306
and sulfate infusion, 1407–1410
and ureter obstruction, 991*
in pituitary insufficiency, 885–890
-plasma ratios, in osmotic diuresis, 1726–1731
and adrenal steroids, 844–852
in pregnancy, 17-hydroxycorticosteroids excretion, 301
in respiratory acidosis, 939–944, 949–959
and streptokinase, 1103
**Urobilinogen,** excretion
in anemias, 1175–1185
mesobilifuscin ratio, 1176–1179, 1183–1184
and pyrrole metabolism, 1015*
**Uronic acid,** acid mucopolysaccharide concentration, 946
and fibrinolytic activity, 812–813, 819–820, 1089, 1106

V

**Vaccine,** influenza, 209–211
**Valine,** and protein synthesis, 321
**Valsalva maneuver,** arterial oxygen saturation changes, 1916–1921
**Vanadium**
and cholesterol synthesis, 1251
urine concentration, 1452–1462
after ethylenediaminetetraacetate, 1462
**Vascular system**
atherosclerotic, triglyceride dynamics, 539–543
cerebral, respiratory center response time, 1037*
lipoprotein lipase concentration, and heparin, 1746–1754
peripheral, 1007*
and streptokinase therapy, 1118

portal versus hepatic artery for sulfobromophthalein injection, 2202–2213
pulmonary, 590, 998*, 1567–1570
after atrial septal defect closure, 1047*
and chest irradiation, 587–592
and hemorrhage, 524–536
resistance
in aortic insufficiency, 1567, 1569–1570
after Arfonad®, 557–578
in congestive heart failure, 559
after digitalis, 574–575, 577–578
peripheral, 1007*
pulmonary, 590, 998*
renal, 571–573
systemic, 562–570
"small strain" theory, 1030*
splanchnic, circulation time, 1025*
viscosity, 1030*

**Vasoconstriction**, and inulin clearance, 655

**Vasodilatation**
cerebral, and respiratory center response time, 1036*
in cutaneous and subcutaneous tissues, and bath temperature, 1132
peripheral
in congestive heart failure, 557–576
in high cardiac output, 2151–2152
renal, and oxygen tension, 12

**Vasopressin**
in adrenal insufficiency, 1969–1970
in aldosteronism, 999*
and glomerular filtration rate, 734
in kidney disease, 517–518
and negative pressure breathing, 840
and renal insufficiency, 1005*
and sodium transport, 1699–1704, 1969
by toad bladder, 1020*
and urine, 844–847
after desoxycorticosterone, 845
flow, and intrathoracic pressure, 836–841
hypotonic after parathyroid extract, 1218
after low protein diet, 741
and water reabsorption, 852

**Vena cava**
inferior
and aldosterone secretion, 986*
and aortic shunts, 985*
potassium, 2102–2109
thoracic constriction and aldosterone secretion, 1279–1282
isocitric and lactic acid dehydrogenase activity, 2214–2217
sulfobromophthalein concentration, after hepatic and portal vein injection, 2208–2209

**Ventilation**
alveolar, 500–506
in hemorrhage, 527–532
in asthma, 1054*
after atropine, 922–924
and body position, 665–666, 923–924
and diffusing capacity for carbon monoxide, 921–930, 1186–1200
after epinephrine, 922–924
and exercise, 922–930, 1191–1193, 1198
in heart disease, 561–570, 1191–1195
in hemorrhage, 527–529
in hyperpnea, 1188–1189, 1192–1196, 1342–1343
and intrapleural pressure, 1346–1347
and isoproterenol 343–345
after norepinephrine 922–924
in obesity, 500–506, 1339–1347
in pneumothorax, 1341
in pulmonary emphysema, 495–497, 1339–1347
and pulmonary function, 534–536
and chest irradiation, 589, 591
and respiratory center response time, 1036*
and vasodilatation, 562–570

**Ventricle**
filling resistance and isoproterenol, 995*
function, 995*, 1204–1212
and capillary pressure, 1045*
and fiber length curve, 1021*
septal defect in pulmonic stenosis, 1012*
stroke work, 130–132, 1209, 1211
and dextran, 122–125
in high cardiac output, 2146–2152
in hyperthyroidism, 1319
and hypovolemia, 120
after norepinephrine, 1566, 1569–1570
and vasodilatation, 562–570
and veno-arterial perfusion, 984*–985*

**Viomycin**, and isoniazid in tuberculosis, 1370

**Virus**
adeno-, and transferrin, 1024*
in common cold, 762–768
and cortisone, 267–268
influenza A, 206–209, 213, 216, 260–261, 266–273
*See also* Influenza
influenza B, 1047*–1048*
isolation, 206–209, 213, 216, 260–261
methods, 266–273
poliomyelitis, type II, inhibition, 1047*
2060 and J. H., infectivity and interrelationships, 1014*

**Viscera**
and platelet, acid nitrophenylphosphatase activity, 150–151
resistance in obesity, 504
splanchnic, and exercised muscle, 1005*

**Vitamin**
$B_{12}$
binding, 102–108, 1015*–1016*, 1022*, 1026*, 1904–1913
in leukemic sera, 1026*, 2135–2142
enzymatic pattern of pyrimidine synthesis, 1044*
and hog intrinsic factor, 102–108, 1015*–1016*, 1022*
and phosphotungstic acid precipitate, 1907–1908
D, 1004*, 1079–1082

**W**

**Water**
balance, 999*
blood volume changes and cardiac function, 117–136
body, 195–198
and blood urea concentration, 750–751
and extracellular fluid, 884
and potassium, exchangeable, 2180
clearance, 518, 748, 836–841, 845–850, 999*
in hypercalcemia, 1052*
concentration
in muscle, in juvenile dystrophy and neurogenic atrophy, 875–880
and osmotic activity, 1592
renal, and low protein diet, 744–745
deprivation, 2–12, 463–472, 1000*
renal concentrating mechanism and exercise, 2–12
diuresis, 548, 844–847, 1700, 1973–1979
and alcohol, 837–841
and antidiuretic hormone release, 1001*
after Arfonad®, 557–578
and cortisone, 886–890
after digitalis, 574–575, 577–578
and medullary urea concentrations, 747
and triiodothyronine, 886–890
and urine-plasma carbon dioxide tension, 772, 776
excretion, 688
in cholera, 1879
and electrolyte excretion, 574–575
and exercise, 2–12
and intrathoracic pressure, 836–841
metabolism, 882, 1000*, 1137–1143, 1147
and potassium depletion, 1158–1159
reabsorption, 1–6, 11–12, 985*, 1005*
in osmotic diuresis, 1726–1731
and sodium exchange
kinetic models, 961–970
mathematical analysis, 968–970
between mother, fetus and amniotic fluid, 961–970
transfer, 978
myocardial after strophanthidin, 310
in urine subfractions of ultrafiltrable fraction, 1932–1933
and vasopressin, 846–847, 999*, 1000*

**Weight**
*See also* Obesity
in healthy men, 1066–1068
heterozygous carrier of gene, 1046*

**Weight** (*cont'd*)
after hormone therapy in pituitary insufficiency, 885–890
loss, 195–198
and caloric expenditure, 1017*
and potassium, exchangeable, 2180–2186
and protein-free diet, 1242
and pulmonary function, 501
and red cell and plasma volumes, 1069–1071
and sucrose space, 1651–1656
vanadium retention, 1255–1256

X

**Xanthine,** 1401
**Xanthosine,** and methemoglobin reduction, 1557–1562
D-**Xylose**
in malabsorption syndrome, 1014*
structural formula, 407
urinary excretion, 408, 410–412

Z

**Zinc**
mesobilifuscin concentration and recycling, 1170
urine concentration, 1452–1462
after ethylenediaminetetraacetate, 1462
**Zoxazolamine**
and tubular urate secretion, 1313
uricosuric response and aspirin, 997*

# THE JOURNAL

OF

# CLINICAL INVESTIGATION

VOLUME XXXVIII

1959

PUBLISHED BY

THE AMERICAN SOCIETY FOR CLINICAL INVESTIGATION

PHILIP K. BONDY, *Editor-in-Chief*

*Associate Editors*

FRANKLIN H. EPSTEIN

ALLAN V. N. GOODYER

**EDITORIAL COMMITTEE**

THOMAS P. ALMY

SOLOMON A. BERSON

GEORGE L. CURRAN

LEWIS DEXTER

I. S. EDELMAN

CLEMENT A. FINCH

ALFRED P. FISHMAN

ROBERT A. GOOD

JOHN B. HICKAM

ALEXANDER LEAF

ARNOLD S. RELMAN

I. HERBERT SCHEINBERG

JOHN V. TAGGART

RICHARD W. VILTER

KENNETH L. ZIERLER

# CONTENTS

## Number 1, January, 1959 (Part I)


Studies on the Renal Concentrating Mechanism. II. Effect of Small Acute Changes in Solute Excretion. Lawrence G. Raisz and Robert L. Scheer ..... 1

Studies on the Renal Concentrating Mechanism. III. Effect of Heavy Exercise. Lawrence G. Raisz, William Y. W. Au and Robert L. Scheer ..... 8

The Destruction of Glucagon, Adrenocorticotropin and Somatotropin by Human Blood Plasma. I. Arthur Mirsky, Gladys Perisutti and Neil C. Davis ..... 14

The Mechanism of Potassium Excretion in the Chicken. Jack Orloff and Douglas G. Davidson ..... 21

Studies on the Biogenesis and Metabolism of Norepinephrine in Patients with Pheochromocytoma. Albert Sjoerdsma, Lemuel C. Leeper, Luther L. Terry and Sidney Udenfriend ..... 31

On the Mechanism of Acidosis in Chronic Renal Disease. William B. Schwartz, Philip W. Hall, 3rd, Richard M. Hays and Arnold S. Relman ..... 39

The Nature and Mechanism of the Hemostatic Breakdown in the Course of Experimental Hemorrhagic Shock. Rinaldo Turpini and Mario Stefanini ..... 53

Studies of Iodoalbumin Metabolism. I. A Mathematical Approach to the Kinetics. Charles G. Lewallen, Mones Berman and Joseph E. Rall ..... 66

Studies of Iodoalbumin Metabolism. II. The Effects of Thyroid Hormone. Charles G. Lewallen, Joseph E. Rall and Mones Berman ..... 88

Mechanism of Intrinsic Factor Action in Everted Sacs of Rat Small Intestine. Victor Herbert ..... 102

The Characteristics and Similarity of Primary and Secondary Peristalsis in the Esophagus. Bertram Fleshler, Thomas R. Hendrix, Philip Kramer and Franz J. Ingelfinger 110

The Effect of Experimentally Induced Hypervolemia on Cardiac Function in Normal Subjects and Patients with Mitral Stenosis. Truman G. Schnable, Jr., Harold Eliasch, Bengt Thomasson and Lars Werkö ..... 117

Some Factors Affecting Indicator Dilution Curves in the Presence and Absence of Valvular Incompetence. J. I. E. Hoffman and George G. Rowe ..... 138

Platelets as a Source of Serum Acid Nitrophenylophosphatase. Marjorie B. Zucker and Jennie Borrelli ..... 148

Microelectrophoresis of Blood Platelets and the Effects of Dextran. S. William Ross and Richard V. Ebert ..... 155

Transfer of Iron from Serum Iron-Binding Protein to Human Reticulocytes. James H. Jandl, John K. Inman, Richard L. Simmons and David W. Allen ..... 161

Hyperlipemia in Early Stages of Acute Glomerular Nephritis. Walter Heymann and S. G. F. Wilson ..... 186

Sodium and Water Depletion and Ammonia Formation by the Kidneys. Roberto F. Santos 193


## Number 1, January, 1959 (Part II)


Studies on Influenza in the Pandemic of 1957–1958. I. An Epidemiologic, Clinical and Serologic Investigation of an Intrahospital Epidemic, With a Note on Vaccination Efficacy. Herbert L. Blumenfeld, Edwin D. Kilbourne, Donald B. Louria and David E. Rogers ..... 199

Studies on Influenza in the Pandemic of 1957—1958. II. Pulmonary Complications of Influenza. Donald B. Louria, Herbert L. Blumenfeld, John T. Ellis, Edwin D. Kilbourne and David E. Rogers ..... 213

Studies on Influenza in the Pandemic of 1957–1958. III. Isolation of Influenza A (Asian Strain) Viruses from Influenza Patients with Pulmonary Complications. Details of Virus Isolation and Characterization of Isolates, With Quantitative Comparison of Isolation Methods. Edwin D. Kilbourne ..... 266

Number 2, February, 1959

Plasma Nonesterified Fatty Acids in Hyperthyroid States. Clayton Rich, Edwin L. Bierman and Irving L. Schwartz ..... 275

Reaction of I-131 Trace Labeled Human Anti-$Rh_0$ (D) with Red Cells. S. P. Masouredis 279

Effects of Exogenous Adrenocorticotropic Hormone (ACTH) upon Pituitary ACTH Concentration after Prolonged Cortisone Treatment and Stress. Donald A. Holub, Julian I. Kitay and Joseph W. Jailer ..... 291

On the Rate of Hydrocortisone Clearance from Plasma in Pregnant Women and in Patients with Laennec's Cirrhosis. Nicholas P. Christy, Eleanor Z. Wallace, Wilfred E. L. Gordon and Joseph W. Jailer ..... 299

Myocardial Response to Acetyl Strophanthidin in Congestive Heart Failure: A Study of Electrolytes and Carbohydrate Substrates. Timothy J. Regan, Raymond C. Christensen, Takashi Wada, Frederick N. Talmers and Harper K. Hellems ..... 306

Studies on the Relationship between Glucose Oxidation and Intermediary Metabolism. III. The Influence of Pyridine Nucleotides on Protein Synthesis. Jean D. Wilson and Marvin D. Siperstein ..... 317

Studies on the Mechanism of the Lupus Erythematosus (L. E.) Phenomenon. Alan C. Aisenberg ..... 325

Early Effects of Thyrotropin on Protein-Bound $Iodine^{131}$ and Plasma $Iodide^{131}$. William P. Deiss, Patrick J. O'Shaughnessy and James O. Wynn ..... 334

Effects of Isoproterenol on Peripheral Venous Tone and Transmural Right Atrial Pressure in Man. John W. Eckstein and William K. Hamilton ..... 342

The Influence of Urinary Ionic Strength on Phosphate $pK_2'$ and the Determination of Titratable Acid. William B. Schwartz, Norman Bank and Robert W. P. Cutler ..... 347

Studies in Cushing's Syndrome. III. Urinary 17-Ketosteroids in Patients with Bilateral Adrenal Cortical Hyperplasia. Joseph W. Jailer, Raymond Vande Wiele, Nicholas P. Christy and Seymour Lieberman ..... 357

The Effect of the Administration of Sodium Bicarbonate and Ammonium Chloride on the Excretion and Production of Ammonia. The Absence of Alterations in the Activity of Renal Ammonia-Producing Enzymes in the Dog. Floyd C. Rector, Jr. and Jack Orloff ..... 366

The Role of pH Gradient in the Distribution of Ammonia between Blood and Cerebrospinal Fluid, Brain and Muscle. James R. Stabenau, Kenneth S. Warren and David P. Rall ..... 373

Transcortin: A Corticosteroid-Binding Protein of Plasma. W. Roy Slaunwhite, Jr. and Avery A. Sandberg ..... 384

Body Iron Exchange in Man. Clement A. Finch ..... 392

Esophageal Catheterization Studies. I. The Mechanism of Swallowing in Normal Subjects with Particular Reference to the Vestibule (Esophago-Gastric Sphincter). James H. Pert, Murray Davidson, Thomas P. Almy and Marvin H. Sleisenger ..... 397

The Metabolic Fate of $C^{14}$ Labeled Pentoses in Man. STANTON SEGAL AND JOSEPH B. FOLEY 407
The Excretion of *l*-Malic Acid in Relation to the Tricarboxylic Acid Cycle in the Kidney. P. VISHWAKARMA AND W. D. LOTSPEICH 414
Studies on the Isolation and Characterization of the "Rheumatoid Factor." H. G. KUNKEL, E. C. FRANKLIN AND H. J. MULLER-EBERHARD 424
The Electrical Potential Difference Generated by the Large Intestine: Its Relation to Electrolyte and Water Transfer. I. L. COOPERSTEIN AND STANLEY K. BROCKMAN 435
The Fatty Acids of Human Milk. II. Alterations produced by Manipulation of Caloric Balance and Exchange of Dietary Fats. W. INSULL, JR., J. HIRSCH, A. T. JAMES AND E. H. AHRENS, JR. 443
ANNOUNCEMENT OF MEETINGS 316

NUMBER 3, MARCH, 1959

Metabolism of Mucopolysaccharides in Connective Tissue. I. Studies of Enzymes Involved in Glucuronide Metabolism. ALFRED JAY BOLLET, JESSE F. GOODWIN AND AUDREY K. BROWN 451
The Inflationary Force Produced by Pulmonary Vascular Distention in Excised Lungs. The Possible Relation of this Force to that Needed to Inflate the Lungs at Birth. MARY ELLEN AVERY, N. ROBERT FRANK AND IRWIN GRIBETZ 456
The Effect of a Fall in Filtration Rate on Solute and Water Excretion in Hydropenic Man. MARVIN F. LEVITT, MARSHALL S. LEVY AND DEMETRA POLIMEROS 463
The Distribution of Extracorpuscular Hemoglobin in Circulating Plasma. WILLOUGHBY LATHEM AND WILLIAM E. WORLEY 474
Effect of Growth Hormone on Plasma Fatty Acids. M. S. RABEN AND C. H. HOLLENBERG 484
Correction 488
The Phospholipid Composition of Human Serum Lipoprotein Fractions Separated by Ultracentrifugation. GERALD B. PHILLIPS 489
The Oxygen Consumption and Efficiency of the Respiratory Muscles in Health and Emphysema. REUBEN M. CHERNIACK 494
Hypoventilation in Obesity. B. J. KAUFMAN, M. H. FERGUSON AND R. M. CHERNIACK 500
Studies of the Incorporation of $Fe^{59}$ Into Normal and Abnormal Hemoglobins. HELEN M. RANNEY AND PAUL KONO 508
Observations on the Concentrating and Diluting Mechanisms of the Diseased Kidney. NEAL S. BRICKER, RICHARD R. DEWEY, HERBERT LUBOWITZ, JAMES STOKES AND TOVE KIRKENSGAARD 516
The Effects of Hemorrhage on Pulmonary Circulation and Respiratory Gas Exchange. PAUL H. GERST, CHRISTEN RATTENBORG AND DUNCAN A. HOLADAY 524
Localization and Retention of $I^{131}$ from Fed Triolein in the Atherosclerotic Infiltration of Rabbit Aortas. MEYER FRIEDMAN, SANFORD O. BYERS, LELAND FELTON AND PAXTON CADY 539
The Effect of Changing Serum Osmolality on the Release of Antidiuretic Hormone in Certain Patients with Decompensated Cirrhosis of the Liver and Low Serum Osmolality. LAURENCE E. EARLEY AND CHARLES A. SANDERS 545
Studies on the Circulating Insulin Inhibitor Found in Some Diabetic Patients Exhibiting Chronic Insulin Resistance. JAMES B. FIELD 551
Cardiac, Hemodynamic and Renal Functions in Congestive Heart Failure During Induced Peripheral Vasodilation; Relationship to Starling's Law of the Heart in Man. BRUCE J. SOBOL, RICHARD H. KESSLER, BERTHA RADER AND LUDWIG W. EICHNA 557
Immunochemical Studies of Human Serum Gamma Globulins. SOLOMON J. ZAK AND ROBERT A. GOOD 579

The Effects of Chest Irradiation on Pulmonary Function. STANFORD K. SWEANY, WILLIAM T. MOSS AND FRANCIS J. HADDY ..... 587
ANNOUNCEMENT OF MEETINGS ..... 462

NUMBER 4, APRIL, 1959

Histamine and 5-Hydroxytryptamine in the Blood of Infants and Children. ROSS G. MITCHELL AND ROSEMARY CASS ..... 595
The Effect of High Perfusion Pressures on the Granulation of Juxtaglomerular Cells in an Isolated Kidney. LOUIS TOBIAN, ALICE TOMBOULIAN AND JEANNETTE JANECEK ..... 605
*In Vitro* Studies with 16-$C^{14}$-Estrone: Distribution between Plasma and Red Blood Cells of Man. PATRICIA E. WALL AND CLAUDE J. MIGEON ..... 611
Some Aspects of the Metabolism of 16-$C^{14}$-Estrone in Normal Individuals. CLAUDE J. MIGEON, PATRICIA E. WALL AND JEAN BERTRAND ..... 619
Zone Electrophoretic Studies of Serum Alkaline Phosphatase. I. N. ROSENBERG ..... 630
Studies of Bilirubin Sulfate and Other Nonglucuronide Conjugates of Bilirubin. KURT J. ISSELBACHER AND ELIZABETH A. MCCARTHY ..... 645
The Renal Excretion of Hemoglobin: Regulatory Mechanisms and the Differential Excretion of Free and Protein-Bound Hemoglobin. WILLOUGHBY LATHEM ..... 652
The Effect of Body Position Change on Lung Compliance in Normal Subjects and in Patients with Congestive Heart Failure. JOHN TURNER SHARP ..... 659
Studies on Carbohydrate Metabolism in Patients with Neoplastic Disease. II. Response to Insulin Administration. JONATHAN S. BISHOP AND PAUL A. MARKS ..... 668
The Granulocytopenic Response in Hemorrhagic Shock. F. B. SCHWEINBURG, F. G. SMIDDY AND J. FINE ..... 673
Metabolic Studies with a New Series of 1,4-Diene Steroids. I. Effects in Addisonian Subjects of Prednisone, Prednisolone, and the 1,2-Dehydro Analogues of Corticosterone, Desoxycorticosterone, 17-Hydroxy-11-Desoxycorticosterone, and 9α-Fluorocortisol. MAURICE M. PECHET, BLAIR BOWERS AND FREDERIC C. BARTTER ..... 681
Metabolic Studies with a New Series of 1,4-Diene Steroids. II. Effects in Normal Subjects of Prednisone, Prednisolone, and 9α-Fluoroprednisolone. MAURICE M. PECHET, BLAIR BOWERS AND FREDERIC C. BARTTER ..... 691
Potassium Transport in the Acetylcholinesterase-Deficient Erythrocytes of Paroxysmal Nocturnal Hemoglobinuria (PNH). JOSEPH V. AUDITORE, ROBERT C. HARTMANN AND EDWARD F. COLE ..... 702
Metabolism of Noradrenaline in the Human. MCC. GOODALL, N. KIRSHNER AND LAWRENCE ROSEN ..... 707
ANNOUNCEMENT OF MEETINGS ..... 610

NUMBER 5, MAY, 1959

Serotonin Metabolism in Liver Disease. FRANCIS J. BORGES, JEROME K. MERLIS AND SAMUEL P. BESSMAN ..... 715
Calculation of Intracellular pH from the Distribution of 5,5-Dimethyl-2,4-Oxazolidinedione (DMO). Application to Skeletal Muscle of the Dog. WILLIAM J. WADDELL AND THOMAS C. BUTLER ..... 720
Effects of Reduced Glomerular Filtration on Urine Concentration in the Presence of Antidiuretic Hormone. NORMAN G. LEVINSKY, DOUGLAS G. DAVIDSON AND ROBERT W. BERLINER ..... 730

The Role of Urea in the Urine Concentrating Mechanism. NORMAN G. LEVINSKY AND ROBERT W. BERLINER ..... 741
Toxicity of Urea and its Role in the Pathogenesis of Uremia. EVELYN FRANCES GROLLMAN AND ARTHUR GROLLMAN ..... 749
Sialic Acid in Human Semen and in the Male Genital Tract. LEONARD WARREN ..... 755
Transmission of the Common Cold to Volunteers Under Controlled Conditions. IV. Specific Immunity to the Common Cold. GEORGE GEE JACKSON AND HARRY F. DOWLING ..... 762
The Relation of Urinary $CO_2$ Tension to Bicarbonate Excretion. RICHARD M. PORTWOOD, DONALD W. SELDIN, FLOYD C. RECTOR, JR. AND ROBERT CADE ..... 770
A Practical Study of the Air Chamber Model of the Cardiovascular System. SIDNEY ROSTON AND LEONARD LEIGHT ..... 777
The Renal Clearances of Iodide and L-Diiodotyrosine Measured Simultaneously. WILLIAM E. LASSITER AND JOHN B. STANBURY ..... 784
The Effect of Triiodothyronine on the Oxidative Metabolism of Erythrocytes. I. Cellular Studies. THOMAS NECHELES AND ERNEST BEUTLER ..... 788
Pyrimidine Metabolism in Man. I. The Biosynthesis of Orotic Acid. LLOYD H. SMITH, JR. AND FAITH A. BAKER ..... 798
Studies on Enhanced Fibrinolytic Activity in Man. SOL SHERRY, ROBERT I. LINDEMEYER, ANTHONY P. FLETCHER AND NORMA ALKJAERSIG ..... 810
Studies in Kernicterus. I. The Protein Binding of Bilirubin. GERARD B. ODELL ..... 823
Effect of Altered Intrathoracic Pressure on Renal Hemodynamics, Electrolyte Excretion and Water Clearance. H. V. MURDAUGH, JR., H. O. SIEKER AND F. MANFREDI ..... 834
The Effects of Adrenal Steroids and Potassium Depletion on the Elaboration of an Osmotically Concentrated Urine. GERHARD GIEBISCH AND RODOLFO LOZANO ..... 843
Studies on a Case of Essential Hyperlipemia. Blood Lipids, with Special Reference to the Composition and Metabolism of the Serum Glycerides Before, During and After the Course of a Viral Hepatitis. LARS A. CARLSON AND BÖRJE OLHAGEN ..... 854
Comparative Studies on the Half-Life of $I^{131}$-Labeled Albumins and Nonradioactive Human Serum Albumin in a Case of Analbuminemia. HERMANN BENNHOLD AND EKKEHARD KALLEE ..... 863

NUMBER 6, JUNE, 1959

A Biochemical Study of Certain Skeletal Muscle Constitutents in Human Progressive Muscular Dystrophy. PAUL J. VIGNOS, JR. AND M. LEFKOWITZ ..... 873
Combined Anterior Pituitary and Neurohypophyseal Insufficiency. Studies of Body Fluid Spaces and Renal Function. M. MENCER MARTIN ..... 882
Studies of the Effect of Dietary Protein and Caloric Levels on the Kinetics of Nitrogen Metabolism Using $N^{15}$ L-Aspartic Acid. DONALD P. TSCHUDY, HABEEB BACCHUS, SHERMAN WEISSMAN, DONALD M. WATKIN, MARJORIA EUBANKS AND JULIUS WHITE ..... 892
Tolbutamide Hypoglycemia in Acutely Depancreatized Dogs. MARTIN KURTZ, CHARLES M. HOLTZMAN AND EDWARD MEILMAN ..... 902
Studies of the Uricogenic Effect of 2-Substituted Thiadiazoles in Man. IRWIN H. KRAKOFF AND M. EARL BALIS ..... 907
A Study of the Mechanism by Which Exercise Increases the Pulmonary Diffusing Capacity for Carbon Monoxide. JOSEPH C. ROSS, REGINA FRAYSER AND JOHN B. HICKAM ..... 916
*In Vivo* Studies of 5-Hydroxyindole Metabolism in Patients with Hepatic Cirrhosis and in Rats. ROBERT M. DONALDSON, JR., JULIAN ARABEHETY AND SEYMOUR J. GRAY ..... 933
The Kinetics of Bicarbonate Reabsorption during Acute Respiratory Acidosis. WILLIAM B. SCHWARTZ, ADRIEN FALBRIARD AND GUY LEMIEUX ..... 939

Mucopolysaccharide Content of Skin in Patients with Pretibial Myxedema. WILLIAM H. BEIERWALTES AND ALFRED JAY BOLLET ..... 945
Tissue and Renal Response to Chronic Respiratory Acidosis. NORMAN W. CARTER, DONALD W. SELDIN AND H. C. TENG ..... 949
The Role of the Monkey Fetus in the Exchange of the Water and Sodium of the Amniotic Fluid. EMANUEL A. FRIEDMAN, MARY JANE GRAY, DONALD L. HUTCHINSON AND ALBERT A. PLENTL ..... 961
The Role of the Fetus in the Water Exchange of the Amniotic Fluid of Normal and Hydramniotic Patients. DONALD L. HUTCHINSON, MARY JANE GRAY, ALBERT A. PLENTL, HERMOGENES ALVAREZ, ROBERTO CALDEYRO-BARCIA, BRUNO KAPLAN AND JOHN LIND ..... 971
Proceedings of the Fifty-First Annual Meeting of the American Society for Clinical Investigation Held in Atlantic City, N. J., May 4, 1959 ..... 981

NUMBER 7, JULY, 1959

The Acid Mucopolysaccharide and 5-Hydroxytryptamine Content of Human Thrombocytes in Rheumatoid Arthritic and Nonarthritic Individuals. GRACE P. KERBY AND S. M. TAYLOR ..... 1059
Red Cell, Plasma and Blood Volume in Healthy Men Measured by Radiochromium ($Cr^{51}$) Cell Tagging and Hematocrit: Influence of Age, Somatotype and Habits of Physical Activity on the Variance After Regression of Volumes to Height and Weight Combined. R. WENNESLAND, ELLEN BROWN, J. HOPPER, JR., J. L. HODGES, JR., O. E. GUTTENTAG, K. G. SCOTT, I. N. TUCKER AND B. BRADLEY ..... 1065
Studies of Antiricketic Activity in Sera From Patients With Disorders of Calcium Metabolism and Preliminary Observations on the Mode of Transport of Vitamin D in Human Serum. WILLIAM C. THOMAS, JR., H. GEMMELL MORGAN, THOMAS B. CONNOR, LILLIAN HADDOCK, CHARLES E. BILLS AND JOHN E. HOWARD ..... 1078
The Mechanism of Clot Dissolution by Plasmin. NORMA ALKJAERSIG, ANTHONY P. FLETCHER AND SOL SHERRY ..... 1086
The Maintenance of a Sustained Thrombolytic State in Man. I. Induction and Effects. ANTHONY P. FLETCHER, NORMA ALKJAERSIG AND SOL SHERRY ..... 1096
The Maintenance of a Sustained Thrombolytic State in Man. II. Clinical Observations on Patients With Myocardial Infarction and Other Thromboembolic Disorders. ANTHONY P. FLETCHER, SOL SHERRY, NORMA ALKJAERSIG, FOTIOS E. SMYRNIOTIS AND SIDNEY JICK 1111
The Differential Response of the Adrenal Cortex and Medulla to Bacterial Endotoxin. RICHARD H. EGDAHL ..... 1120
Relationship Between a Range of Tissue Temperature and Local Oxygen Uptake in the Human Forearm. III. Changes Observed After Anaerobic Work, in the Posterexercise Period. DAVID I. ABRAMSON, SAMUEL TUCK, JR., YVONNE BELL, CAROLYN BURNETT AND HABIB REJAL ..... 1126
Experimental Potassium Depletion in Normal Human Subjects. I. Relation of Ionic Intakes to the Renal Conservation of Potassium. RUSSELL D. SQUIRES AND EDWARD J. HUTH .. 1134
Experimental Potassium Depletion in Normal Human Subjects. II. Renal and Hormonal Factors in the Development of Extracellular Alkalosis During Depletion. E. J. HUTH, R. D. SQUIRES AND J. R. ELKINTON ..... 1149
Studies of the Dipyrrylmethene ("Fuscin") Pigments. I. The Anabolic Significance of the Fecal Mesobilifuscin. A. SIGRID GILBERTSEN, PAUL T. LOWRY, VIOLET HAWKINSON AND C. J. WATSON ..... 1166

Studies of the Dipyrrylmethene ("Fuscin") Pigments. II. The Contrasting Ratios and Significance of the Fecal Urobilinogen and Mesobilifuscin in Certain Anemias. A. SIGRID GILBERTSEN, VIOLET HAWKINSON AND C. J. WATSON ..... 1175
The Effect of Changes in Ventilation and Pulmonary Blood Flow on the Diffusing Capacity of the Lung. G. M. TURINO, M. BRANDFONBRENER AND A. P. FISHMAN ..... 1186
Left Ventricular Function at Rest and During Exercise. CARLETON B. CHAPMAN, ORLAND BAKER AND JERE H. MITCHELL ..... 1202
Changes in Renal Concentrating Ability Produced by Parathyroid Extract. FRANKLIN H. EPSTEIN, DAVID BECK, FRANK A. CARONE, HOWARD LEVITIN AND ANDRZEJ MANITIUS .. 1214
Variability in Absorption of Insulin-$I^{131}$ in Normal and Diabetic Subjects after Subcutaneous and Intramuscular Injection. EDWARD W. MOORE, MARVIN L. MITCHELL AND THOMAS C. CHALMERS ..... 1222
Hematogenous Pyelonephritis in Rats. IV. Relationship of Bacterial Species to the Pathogenesis and Sequelae of Chronic Pyelonephritis. ALVIN P. SHAPIRO, ABRAHAM I. BRAUDE AND JENNIE SIEMIENSKI ..... 1228
The Effect of Protein Depletion on the Distribution of Protein Synthesis in the Dog. J. S. GARROW ..... 1241
Effect of Cholesterol Synthesis Inhibition in Normocholesteremic Young Men. GEORGE L. CURRAN, DANIEL L. AZARNOFF AND ROBERT E. BOLINGER ..... 1251
Estimation of Pulmonary Resistance by Repetitive Interruption of Airflow. JOHN A. CLEMENTS, JOHN T. SHARP, RUDOLPH P. JOHNSON AND JAMES O. ELAM ..... 1262

NUMBER 8, AUGUST, 1959

Ammonia as a Source of Gastric Hypoacidity in Patients with Uremia. CHARLES S. LIEBER AND ANDRÉ LEFÈVRE ..... 1271
Evidence that a Humoral Agent Stimulates the Adrenal Cortex to Secrete Aldosterone in Experimental Secondary Hyperaldosteronism. NICHOLAS A. YANKOPOULOS, JAMES O. DAVIS, BERNARD KLIMAN AND RALPH E. PETERSON ..... 1278
Transcortin: A Corticosteroid-Binding Protein of Plasma. II. Levels in Various Conditions and the Effects of Estrogens. AVERY A. SANDBERG AND W. ROY SLAUNWHITE, JR. ..... 1290
A Study of the Paradoxical Effects of Salicylate in Low, Intermediate and High Dosage on the Renal Mechanisms for Excretion of Urate in Man. T'SAI FAN YÜ AND ALEXANDER B. GUTMAN ..... 1298
A Correlation of Clinical and Hemodynamic Studies in Patients with Hyperthyroidism with and without Congestive Heart Failure. JOHN S. GRAETTINGER, JOSEPH J. MUENSTER, LOUIS A. SELVERSTONE AND JAMES A. CAMPBELL ..... 1316
Evaluation of Nicotinic Acid as an Hypocholesteremic and Anti-Atherogenic Substance. MEYER FRIEDMAN AND SANFORD O. BYERS ..... 1328
The Relation of Plasma and Biliary Cholesterol to Bile Acid Synthesis in Man. R. S. ROSENFELD AND LEON HELLMAN ..... 1334
The Efficiency of Ventilation during Voluntary Hyperpnea: Studies in Normal Subjects and in Dyspneic Patients with Either Chronic Pulmonary Emphysema or Obesity. H. W. FRITTS, JR., J. FILLER, A. P. FISHMAN AND A. COURNAND ..... 1339
Combined Drug Treatment of Tuberculosis. I. Prevention of Emergence of Mutant Populations of Tubercle Bacilli Resistant to Both Streptomycin and Isoniazid *In Vitro*. MAURICE L. COHN, GARDNER MIDDLEBROOK AND WILLIAM F. RUSSELL, JR. ..... 1349
Combined Drug Treatment of Tuberculosis. II. Studies of Antimicrobially-Active Isoniazid and Streptomycin Serum Levels in Adult Tuberculous Patients. WILLIAM MANDEL, ANGELINE D. HEATON, WILLIAM F. RUSSELL, JR. AND GARDNER MIDDLEBROOK ..... 1356

Combined Drug Treatment of Tuberculosis. III. Clinical Application of the Principles of Appropriate and Adequate Chemotherapy to the Treatment of Pulmonary Tuberculosis. WILLIAM F. RUSSELL, JR., IRVING KASS, ANGELINE D. HEATON, SIDNEY H. DRESSLER AND GARDNER MIDDLEBROOK ..... 1366
Combined Drug Treatment of Tuberculosis. IV. Bacteriologic Studies on the Sputum and Resected Pulmonary Lesions of Tuberculous Patients. ANGELINE D. HEATON, WILLIAM F. RUSSELL, JR., JOHN DENST AND GARDNER MIDDLEBROOK ..... 1376
Dietary Fats and the Diurnal Serum Triglyceride Levels in Man. PETER F. KUO AND JOHN C. CARSON ..... 1384
The Effect of 6-Mercaptopurine on Primary and Secondary Immune Responses. ROBERT SCHWARTZ, ANNA EISNER AND WILLIAM DAMESHEK ..... 1394
Ion Association. III. The Effect of Sulfate Infusion on Calcium Excretion. MACKENZIE WALSER AND ANN A. BROWDER ..... 1404
Observations on Double Albumin: A Genetically Transmitted Serum Protein Anomaly. DAVID P. EARLE, MARTIN P. HUTT, KARL SCHMID AND DAVID GITLIN ..... 1412
Human Pantothenic Acid Deficiency Produced by Omega-Methyl Pantothenic Acid. ROBERT E. HODGES, WILLIAM B. BEAN, MARGARET A. OHLSON AND ROBERTA BLEILER ..... 1421
The Biliary Excretion of Sulfobromophthalein Sodium (BSP) in the Rat as a Conjugate of Glycine and Glutamic Acid. BURTON COMBES ..... 1426
Hepatic Metabolism of Cholesterol in Experimental Nephrosis in Rats. RAY H. ROSENMAN, WILLIAM BREALL, SANFORD O. BYERS AND DAVID D. RABIN ..... 1434
Aldosterone Excretion in Virilizing Adrenal Hyperplasia. ROBERT M. BLIZZARD, GRANT W. LIDDLE, CLAUDE J. MIGEON AND LAWSON WILKINS ..... 1442
Normal Concentrations of Some Trace Metals in Human Urine: Changes Produced by Ethylenediaminetetraacetate. H. MITCHELL PERRY, JR. AND ELIZABETH F. PERRY ..... 1452

NUMBER 9, SEPTEMBER, 1959

Antithyroid Activity Elicited by the Ingestion of Pure Progoitrin, a Naturally Occurring Thioglycoside of the Turnip Family. MONTE A. GREER AND J. M. DEENEY ..... 1465
Measurement of Change in Total Body Fat. LAURENCE H. KYLE, EDWARD J. WERDEIN, JOHN J. CANARY AND BERNICE PACHUTA ..... 1475
Studies on Hemoglobin Metabolism. I. The Kinetic Properties of the Plasma Hemoglobin Pool in Normal Man. LARS GARBY AND WARD D. NOYES ..... 1479
Studies on Hemoglobin Metabolism. II. Pathways of Hemoglobin Iron Metabolism in Normal Man. LARS GARBY AND WARD D. NOYES ..... 1484
Persistence of Antibiotics in Blood of Patients with Acute Renal Failure. I. Tetracycline and Chloretetracycline. CALVIN M. KUNIN, SEARLE B. REES, JOHN P. MERRILL AND MAXWELL FINLAND ..... 1487
Persistence of Antibiotics in Blood of Patients with Acute Renal Failure. II. Chloramphenicol and its Metabolic Products in the Blood of Patients with Severe Renal Disease or Hepatic Cirrhosis. CALVIN M. KUNIN, ANTHONY J. GLAZKO AND MAXWELL FINLAND ..... 1498
Persistence of Antibiotics in Blood of Patients with Acute Renal Failure. III. Penicillin, Streptomycin, Erythromycin and Kanamycin. CALVIN M. KUNIN AND MAXWELL FINLAND ..... 1509
Total Nondialyzable solids (TNDS) in Human Urine. III. A Method for Subfractionation of RS-1 Solids. J. S. KING, JR., J. M. LITTLE, W. H. BOYCE AND C. ARTOM ..... 1520
Total Nondialyzable Solids (TNDS) in Human Urine. IV. Electrophoretic Properties of RS-1 Subfraction. WILLIAM H. BOYCE AND J. STANTON KING, JR. ..... 1525

Electrolyte and Acid-Base Balance during Acute Loading with Rubidium Chloride. ANNE T. LAMBIE, ARNOLD S. RELMAN AND WILLIAM B. SCHWARTZ ..... 1538
The Fatty Acid Patterns of Plasma Lipids During Alimentary Lipemia. V. P. DOLE, A. T. JAMES, J. P. W. WEBB, M. A. RIZACK AND M. F. STURMAN ..... 1544
The Reduction of Methemoglobin in Human Erythrocytes Incubated with Purine Nucleosides. ERNST R. JAFFÉ ..... 1555
Norepinephrine Induced Pulmonary Congestion in Patients with Aortic Valve Regurgitation. TIMOTHY J. REGAN, VALENTINO DEFAZIO, KENAN BINAK AND HARPER K. HELLEMS ..... 1564
Alterations in Metabolic Energetics and Cation Transport During Aging of Red Cells. RALPH E. BERNSTEIN ..... 1572
A Study of the Osmotic Behavior of the Human Erythrocyte. FRANKLIN T. WILLIAMS, CHRISTOPHER C. FORDHAM, III, WALTER HOLLANDER, JR. AND LOUIS G. WELT ..... 1587
Incorporation of Radioiron into Myoglobin in an *In Vitro* System. GERALD T. PERKOFF, HERBERT C. SCHWARTZ AND FRANK H. TYLER ..... 1599
Iron Enzymes in Iron Deficiency. VI. Aconitase Activity and Citrate Metabolism. ERNEST BEUTLER ..... 1605
Urea Metabolism in Man. MACKENZIE WALSER AND LEONARD J. BODENLOS ..... 1617
The Lysis of Artificially Induced Intravascular Clots in Man by Intravenous Infusions of Streptokinase. ALAN J. JOHNSON AND W. ROSS MCCARTY ..... 1627
The Variability of Extracellular Fuid Space (Sucrose) in Man During a 24 Hour Period. Richard E. Peterson, James J. O'Toole and Walter M. Kirkendall, With an Appendix: An Examination of a Sequence of Randomized Errors by the Monte Carlo Method. OSCAR KEMPTHORNE ..... 1644
A Study of Subjects with Erythrocyte Glucose-6-Phosphate Dehydrogenase Deficiency: Investigation of Platelet Enzymes. BRACHA RAMOT, ARYEH SZEINBERG, AVINOAM ADAM, CHAIM SHEBA AND DORA GAFNI ..... 1659

NUMBER 10, OCTOBER, 1959 (PART I)

Characteristics of Renal Bicarbonate Reabsorption in Man. DONALD W. SELDIN, RICHARD M. PORTWOOD, FLOYD C. RECTOR, JR. AND ROBERT CADE ..... 1663
Observations on Ceruloplasmin in Wilson's Disease. ANDREW SASS-KORTSAK, MORRIS CHERNIAK, DOUGLAS W. GEIGER AND ROBERT J. SLATER ..... 1672
Familial Increase in the Thyroxine-Binding Sites in Serum Alpha Globulin. WILLIAM H. BEIERWALTES AND JACOB ROBBINS ..... 1683
Effectiveness of Transfusions of Fresh and Lyophilized Platelets in Controlling Bleeding due to Thrombocytopenia. DUDLEY P. JACKSON, DALE K. SORENSEN, EUGENE P. CRONKITE, VICTOR P. BOND AND THEODORE M. FLIEDNER ..... 1689
Factors Influencing the Exchange of Sodium between Plasma and Cerebrospinal Fluid. ROBERT A. FISHMAN ..... 1698
Supralethal Whole Body Irradiation and Isologous Marrow Transplantation in Man. E. DONNALL THOMAS, HARRY L. LOCHTE, JR., JOE H. CANNON, OTTO D. SAHLER AND JOSEPH W. FERREBEE ..... 1709
Mechanisms of Hyperlipemia in Experimental Nephrosis. JUDITH SAFFRAN AND NORMAN KALANT ..... 1717
Studies on the Renal Concentrating Mechanism. IV. Osmotic Diuresis. LAWRENCE G. RAISZ, WILLIAM Y. W. AU AND ROBERT L. SCHEER ..... 1725
Studies of the Renal Excretion of Magnesium in Man. EARL S. BARKER, J. RUSSELL ELKINTON AND JOHN K. CLARK ..... 1733

The Removal of Lipoprotein Lipase from the Blood by the Normal and Diseased Liver. WILLIAM E. CONNOR AND JOHN W. ECKSTEIN ..... 1746
The Neuraminic Acid Content of Cerebrospinal Fuid as Affected by Neurological Diseases. L. LAHUT UZMAN, EDGAR A. BERING, JR. AND CHARLES E. MORRIS ..... 1756
The Distribution of Intravenously-Injected Inulin in the Fluids of the Nervous System of the Dog and Rat. ASHTON B. MORRISON ..... 1769
Tubular Secretion of Urate in Man. ALEXANDER B. GUTMAN, T'SAI FAN YÜ AND LAWRENCE BERGER ..... 1778

NUMBER 10, OCTOBER, 1959 (PART II)

Introduction. PHILIP K. BONDY ..... 1783
History of the American Society for Clinical Investigation, 1909–1959. ELLEN R. BRAINARD 1784
I. Origins ..... 1784
II. Formative Years, 1909–1929 ..... 1804
III. Conflict and Compromise, 1930–1945 ..... 1812
IV. The Tempering of Traditions, 1946–1959 ..... 1819
Constitution of the American Society for Clinical Investigation ..... 1838
Officers of the Society from its Organization to the Present Time ..... 1840
Roster of the American Society for Clinical Investigation
I. Active Members ..... 1841
II. Emeritus Members ..... 1850
III. Deceased Members ..... 1864
History of the Journal of Clinical Investigation, 1924–1959
I. Personnel and Policies. ELLEN R. BRAINARD ..... 1865
II. Scientific Contents. PHILIP K. BONDY ..... 1873
Roster of Editorial Staffs of the Journal of Clinical Investigation from 1924 to the Present Time 1878

NUMBER 11, NOVEMBER, 1959

Water and Electrolyte Studies in Cholera. RAYMOND H. WATTEN, FRANCIS M. MORGAN, YACHAI NA SONGKHLA, BUNAM VANIKIATI AND ROBERT A. PHILLIPS ..... 1879
The Renal Excretion of Uric Acid in Patients with Gout and in Nongouty Subjects. C. A. NUGENT AND F. H. TYLER ..... 1890
Metabolism of L-Thyroxine by Human Tissue Slices. EDWIN C. ALBRIGHT AND FRANK C. LARSON ..... 1899
The Plasma Vitamin $B_{12}$ Binding Substance: I. Its Detection in the Seromucoid Fraction of Plasma from Normal Subjects and Patients with Chronic Myelocytic Leukemia. I. BERNARD WEINSTEIN, SHERMAN M. WEISSMAN AND DONALD M. WATKIN ..... 1904
The Demonstration of Pulmonary Arteriovenous Shunts in Normal Human Subjects, and Their Increase in Certain Disease States. ANTHONY D. JOSE AND WILLIAM R. MILNOR 1915
Application of Continuous Flow Electrophoresis to the Study of the Blood Coagulation Proteins. II. The Hemophilias (A and B). JESSICA H. LEWIS AND WILLIAM R. MERCHANT ..... 1924
Total Nondialyzable Solids (TNDS) in Human Urine. V. Subfractionation of the Ultrafiltrate (UF-O) Fraction. J. STANTON KING, JR. AND WILLIAM H. BOYCE ..... 1927
Plasma Concentrations of Epinephrine and Norepinephrine during Intravenous Infusions in Man. GERALD COHEN, BERNARD HOLLAND, JOANNE SHA AND MARCEL GOLDENBERG 1935

Serum Inhibition of Streptococcal Diphosphopyridine Nucleotidase in Uncomplicated Streptococcal Pharyngitis and in Rheumatic Fever. GERON C. BERNHARD AND GENE H. STOLLERMAN ..... 1942
Distribution and Excretion of Four Tetracycline Analogues in Normal Young Men. CALVIN M. KUNIN, A. C. DORNBUSH AND MAXWELL FINLAND ..... 1950
Adjustment to Aldosterone or Desoxycorticosterone Acetate Induced Sodium Retention in Patients with Addison's Disease. J. THOMAS AUGUST AND DON H. NELSON ..... 1964
Negative Pressure Respiration, Water Diuresis and Natriuresis in Normotensive, Hypertensive and Prehydrated Normotensive Subjects. WILLIAM H. HULET AND HOMER W. SMITH .. 1972
Identification of Metabolites of Sulfobromophthalein. G. M. GRODSKY, J. V. CARBONE AND R. FANSKA ..... 1981
Effect of Hepatic Dysfunction on Circulating Levels of Sulfobromophthalein and its Metabolites. JOHN V. CARBONE, GEROLD M. GRODSKY AND VIRGINIA HJELTE ..... 1989
Quantitative Aspects of the Reaction between Insulin and Insulin-Binding Antibody. SOLOMON A. BERSON AND ROSALYN S. YALOW ..... 1996
Species-Specificity of Human Anti-Beef, Pork Insulin Serum. SOLOMON A. BERSON AND ROSALYN S. YALOW ..... 2017
Nitrogen Clearance Rates of Right and Left Lungs in Different Positions. GLEN A. LILLINGTON, WARD S. FOWLER, R. DREW MILLER AND H. FREDERIC HELMHOLZ, JR. ..... 2026
An Experimental Evaluation of the Indicator Dilution Technique for the Measurement of Mitral Regurgitation. ROBERT H. EICH, INGOLF STAIB AND DANIEL ENERSON ..... 2035
Chronic Progressive Myopathy with Myoglobinuria: Demonstration of a Glycogenolytic Defect in the Muscle. RUDI SCHMID AND ROBERT MAHLER ..... 2044
The Reaction of the Lupus Erythematosus (L. E.) Cell Factor with Deoxyribonucleoprotein of the Cell Nucleus. HALSTED HOLMAN AND HELMUTH R. DEICHER ..... 2059
The Measurement of Pulmonary Diffusing Capacity for Carbon Monoxide by a Rebreathing Method. BENJAMIN M. LEWIS, TAI-HON LIN, FRANCES E. NOE AND ERNEST J. HAYFORD-WELSING ..... 2073
Velocity of Blood Flow and Stroke Volume Obtained from the Pressure Pulse. WILLIAM B. JONES, LLOYD L. HEFNER, W. H. BANCROFT, JR. AND WILLEM KLIP ..... 2087
Fluorescent Antiglobulin Studies in Leukopenic and Related Disorders. PAUL CALABRESI, EARL A. EDWARDS AND ROBERT F. SCHILLING ..... 2091

NUMBER 12, DECEMBER, 1959

Inhibition of Aldosterone Secretion and Modification of Electrolyte Excretion in Man by a Chemical Inhibitor of 11-$\beta$ Hydroxylation. WILLIAM S. COPPAGE, JR., DONALD ISLAND, MAUREEN SMITH AND GRANT W. LIDDLE ..... 2101
Studies on Isocitric and Lactic Dehydrogenases in Experimental Myocardial Infarction. PAUL E. STRANDJORD, KENNETH E. THOMAS AND LAURENS P. WHITE ..... 2111
Studies of Colon Contractility in Dogs. I. Description of Method and Effect of Parasympathomimetic Agents and Serotonin. MARVIN H. SLEISENGER, DAVID H. LAW, FREDERICK W. SMITH, JAMES H. PERT AND CHARLES M. LEWIS ..... 2119
The Effect of Insulin on Nonesterified Fatty Acid Release from the Human Leg. E. H. ESTES, JR., M. D. BOGDONOFF, S. J. FRIEDBERG, W. R. HARLAN, JR. AND D. L. TROUT ..... 2131
Electrophoretic Studies of the Vitamin $B_{12}$-Binding Protein of Normal and Chronic Myelogenous Leukemia Serum. AARON MILLER AND JOHN F. SULLIVAN ..... 2135
The Idiopathic High Cardiac Output State. RICHARD GORLIN, NORMAN BRACHFELD, JOHN D. TURNER, JOSEPH V. MESSER AND EDUARDO SALAZAR ..... 2144

A Study in Man of Cerebral Blood Flow and Cerebral Glucose, Lactate and Pyruvate Metabolism Before and After Eating. GEORGE G. ROWE, GEORGE M. MAXWELL, CESAR A. CASTILLO, D. J. FREEMAN AND CHARLES W. CRUMPTON ..... 2154
Physicochemical and Immunologic Studies of Gamma Globulins of Normal Human Urine. E. C. FRANKLIN ..... 2159
Static Volume-Pressure Relations of Excised Lungs of Infants with Hayline Membrane Disease, Newborn and Stillborn Infants. IRWIN GRIBETZ, N. R. FRANK AND MARY ELLEN AVERY 2168
Interrelations of Plasma Potassium Concentration, Plasma Sodium Concentration, Arterial pH and Total Exchangeable Potassium. J. LEIBMAN AND I. S. EDELMAN ..... 2176
Hepatic Metabolism of Phenylalanine during Development. FRANCIS T. KENNEY AND NORMAN KRETCHMER ..... 2189
Renal Reabsorption of Bicarbonate During Acute Respiratory Alkalosis. WILLIAM B. SCHWARTZ, GUY LEMIEUX AND ADRIEN FALBRIARD ..... 2197
Studies Concerning Functional Differences Between Liver Regions Supplied by the Hepatic Artery and by the Portal Vein. RALPH W. BRAUER, OTTO S. SHILL AND JOHN S. KREBS 2202
The Relation of Sulfur Metabolism to Acid-Base Balance and Electrolyte Excretion: The Effects of DL-Methionine in Normal Man. JACOB LEMANN, JR. AND ARNOLD S. RELMAN 2215
Pulmonary Transcapillary Exchange of $Na^{24}$ and $P^{32}$-Labeled Phosphate in Pulmonary Emphysema. M. A. ROTHSCHILD, A. L. DAVIS, M. ORATZ AND S. S. SCHREIBER ..... 2224
Metabolic Patterns During Physiologic Sleep: I. Blood Glucose Regulation During Sleep in Normal and Diabetic Subjects. EUGENE D. ROBIN, DAVID M. TRAVIS, DESMOND G. JULIAN AND BURIS R. BOSHELL ..... 2229
A Study of Subjects with Erythrocyte Glucose-6-Phosphate Dehydrogenase Deficiency. II. Investigation of Leukocyte Enzymes. BRACHA RAMOT, SHARON FISHER, ARYEH SZEINBERG, AVINOAM ADAM, CHAIM SHEBA AND DORA GAFNI ..... 2234
Cortisol Metabolism in Man: Observations of Pathways, Pool Sizes of Metabolites and Rates of Formation of Metabolites. NORMAN I. GOLD, LOUIS L. SMITH AND FRANCIS D. MOORE 2238
Erythrocyte Glucose-6-Phosphate Dehydrogenase Deficiency: Evidence of Differences Between Negroes and Caucasians with Respect to this Genetically Determined Trait. PAUL A. MARKS AND RUTH T. GROSS ..... 2253
Author Index to Volume XXXVIII ..... 2263
Subject Index to Volume XXXVIII ..... 2284